HHS Public Access
Author manuscript
Author Manuscript

Nature. Author manuscript; available in PMC 2016 July 09.
Published in final edited form as:
Nature. 2015 July 9; 523(7559): 177–182. doi:10.1038/nature14581.

Glypican1 identifies cancer exosomes and facilitates early
detection of cancer
Sonia A. Melo1,#,*, Linda B. Luecke1,*, Christoph Kahlert1,*, Agustin F. Fernandez2, Seth T.
Gammon3, Judith Kaye1, Valerie S. LeBleu1, Elizabeth A. Mittendorf4, Juergen Weitz5, Nuh
Rahbari5, Christoph Reissfelder5, Christian Pilarsky5, Mario F. Fraga2,6, David PiwnicaWorms3, and Raghu Kalluri1,§

Author Manuscript

1Department

of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson
Cancer Center, Houston, TX 77054, USA

2Cancer

Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), HUCA, Universidad
de Oviedo, Oviedo, Spain

3Department

of Cancer Systems Imaging, The University of Texas M.D. Anderson Cancer Center,
Houston, TX 77054, USA

4Department

of Surgical Oncology, The University of Texas MD Anderson Cancer Center,
Houston, TX 77030, USA
5Department

of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl
Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany

Author Manuscript

6Department

of Immunology and Oncology, National Center for Biotechnology, CNB-CSIC,
Cantoblanco, 28049 Madrid, Spain

Summary
Exosomes are lipid bilayer-enclosed extracellular vesicles (EVs) that contain proteins and nucleic
acids. They are secreted by all cells and circulate in the blood. Specific detection and isolation of
cancer cell-derived exosomes in circulation is currently lacking. Using mass spectrometry
analyses, we identified a cell surface proteoglycan, glypican-1 (GPC1), specifically enriched on
cancer cell-derived exosomes. GPC1+ circulating exosomes (crExos) were monitored and isolated

Author Manuscript

Reprints and permissions information is available at www.nature.com/reprints.
§

Correspondence and requests for materials should be addressed to rkalluri@mdanderson.org.
#Current address: Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal Institute of Pathology and
Molecular Immunology of the University of Porto (IPATIMUP), 4200 Porto, Portugal
*These authors contributed equally to this work
Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
The authors declare no competing financial interests.
Author contribution: S.A.M. conceptually designed and carried out most of the experiments, generated the data and the figures, and
wrote the manuscript; L.B.L. carried out most of the experiments; C.K. performed sequencing of primary tumors, performed most of
the statistical analysis of the manuscript and support in manuscript writing; A.F.F. optimized, performed and analyzed the UPLC-MS
data; S.T.G. performed mouse MRI and analyzed the data; J.K. GEMMs breeding, bleeding, euthanasia and material collection; V.S.L.
GEMMs breeding, bleeding, euthanasia, material collection and support in manuscript editing; E.A.M. provided breast cancer patient
samples and patient history; J.W., N.R., C.R. and C.P. collected and provided serum samples and patient history for analysis; M.F.F.
optimized, performed and analyzed the UPLC-MS data; D.P.W. mouse MRI interpretation and provided support in data interpretation
and analysis; R.K. conceived the idea, conceptually designed the study, supervised the project and wrote the manuscript.

Melo et al.

Page 2

Author Manuscript

using flow cytometry from the serum of cancer patients and mice with cancer. GPC1+ crExos were
detected in the serum of patients with pancreas cancer with absolute specificity and sensitivity,
distinguishing healthy subjects and patients with a benign pancreas disease from patients with
early and late stage pancreas cancer. Levels of GPC1+ crExos correlate with tumor burden and
survival in patients pre- and post-surgical tumor resection. GPC1+ crExos from patients and from
mice with spontaneous pancreas tumors driven by oncogenic KRAS contained RNA with specific
KRAS mutation, and it emerges as a reliable biomarker for the detection of PanIN lesions despite
negative signal by MRI in mice. GPC1+ crExos may serve as a potential non-invasive diagnostic
and screening tool to detect early stages of pancreas cancer to facilitate possible curative surgical
therapy.

Introduction
Author Manuscript
Author Manuscript

Exosomes are secreted membrane enclosed vesicles (extracellular vesicles or EVs) of a size
range of 50 to 150 nm diameter1. Formed during the inward budding of late endosomes, they
develop into intracellular multivesicular endosomes (MVEs)2. During this process, nucleic
acids and proteins are encapsulated into exosomes3–6. Exosomes are released into the
extracellular space and enter the circulation7,8. Various cell types such as immune cells8,
platelets9 or endothelial cells10, release exosomes into the blood stream. Several exosomesenriched proteins have been described and include members of the tetraspanin family (CD9,
CD63 and CD81), members of the endosomal sorting complexes required for transport
(ESCRT; TSG101, Alix) and heat shock proteins (Hsp60, Hsp70, Hsp90)11. Epithelial tumor
cells secrete exosomes carrying the epithelial cell adhesion molecule (EpCAM)12–14.
Melanoma-derived exosomes contain the tumor-associated antigen Mart-1 and tyrosinaserelated protein-2 (TYRP2)15–17. Exosomes from gastric, breast and pancreas cancer carry
members of the human epidermal growth factor receptor (HER) family18–20. None of these
markers are however specific to cancer-derived exosomes. Identification and isolation of
cancer specific exosomes in body fluids would aid in the detection and monitoring of cancer
and enable specific identification of DNA, RNA and protein content without contamination
from non-cancer exosomes. Such possibility could enable the early monitoring of cancer and
aid therapy decision.

GPC1 is a cancer exosomes specific protein

Author Manuscript

EVs from cancer cells (MDA-MB-231, triple negative human metastatic breast carcinoma),
fibroblasts (HDF, human dermal fibroblasts; NIH/3T3, mouse embryonic fibroblasts) and
non-tumorigenic epithelial cells (MCF10A, human mammary epithelial cells; E10, mouse
lung epithelial cells) were isolated using established ultracentrifugation methods21,22, and
called exosomes based on the following observations. NanoSight® nanoparticle tracking
analysis and transmission electron microscopy (TEM) revealed a range of 105±5 nm and
112±4 nm in diameter, respectively (Extended Data Fig. 1a,b)23. Presence of CD9 on
exosomes was shown by immunogold and TEM (Extended Data Fig. 1c) and of flotillin1
and CD81 by immunoblot (Extended Data Fig. 1d, Extended Data Fig. 8)23. The exosomes
proteome was evaluated using ultra performance liquid chromatography – mass
spectrometry (UPLC-MS) (Extended Data Table 1)24. Proteins were identified in exosomes

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 3

Author Manuscript
Author Manuscript

derived from different cell types (HDF, NIH/3T3, E10, MCF10A and MDA-MB-231),
including the exosomes markers such as TSG101, CD9 and CD63 (total number of proteins
identified in exosomes from different cell types were: HDF: 261, NIH/3T3: 171, E10: 232,
MCF10A: 214 and MDA-MB-231: 242; Extended Data Table 2). Bioinformatic analyses
revealed 48 proteins (25 cytoplasmic, 7 nuclear, 5 transmembrane, 1 membrane-anchored
and 7 secreted) as exclusively present in the cancer cell-derived exosomes (MDA-MB-231;
Fig. 1a, Extended Data Table 1). Glypican-1 (GPC1) is a membrane anchored protein
reported previously as overexpressed in a variety of cancers, including breast and pancreas
cancer25,26,27. GPC1 transcripts and protein levels were elevated in several breast and
pancreas cancer cell lines compared to non-tumorigenic cells (Extended Data Fig. 1e,f &
Extended Data Fig. 8). Therefore, in this study we focused on probing the utility of GPC1 as
marker of cancer exosomes. In contrast to exosomes derived from non-tumorigenic cell
lines, GPC1 protein was only detected in cancer cell-derived exosomes by immunoblot
(Extended Data Fig. 1g & Extended Data Fig. 8). Additionally, GPC1+ exosomes were
detected by immunogold TEM in cancer exosomes (T3M4 pancreas cancer line) but not in
non-cancer exosomes (HMLE; Fig. 1b).
We performed FACS analysis of exosomes coupled to aldehyde/sulphate beads to detect
GPC1 protein on their surface (Fig. 1c). Immunogold and TEM identified cancer exosomes
at the surface of beads with GPC1 expression while non-tumorigenic exosomes did not
exhibit GPC1 expression (Fig. 1d). Exosomes purified using sucrose gradients or
ultracentrifugation from cell lines showed GPC1 expression specifically when derived from
cancer cell lines (Fig. 1c, e–f; Extended Data Fig. 1h & Extended Data Fig. 8).

Author Manuscript

To determine whether GPC1+ exosomes could be isolated from the blood of tumor-bearing
mice, we implanted MDA-MB-231 human breast cancer cells in the mammary fat pads of
nude mice. The mice were bled prior to cancer cell inoculation, and repeatedly again when
tumors reached an average volume of 300, 550, 1000 and 1350 mm3, and circulating
exosomes (crExos) were isolated and assessed for the presence of GPC1 (Fig. 2a). The
relative percentage of GPC1+ crExos increased proportionally with tumor growth and
correlated with tumor burden (Fig. 2b–c; r=0.98, P=0.004). To further confirm the cancer
cell origin of GPC1+ crExos, we engineered MDA-MB-231 cells to stably express CD63GFP fusion protein. CD63 is an established exosomal marker22 and exosomes from these
cells (MDA-MB-231-CD63GFP) in culture were uniformly positive for GFP (Fig. 2d).
crExos were also collected from mice with orthotopic MDA-MB-231-CD63GFP tumors
(~1500 mm3 in size), and a subpopulation of the crExos were GFP+ (Fig. 2e). GPC1
expression was exclusively detected in the GFP+ crExos fraction but not in the GFP− crExos
(Fig. 2f).

Author Manuscript

GPC1+ circulating exosomes as a biomarker
Exosomes derived from cancer cell lines and circulating cancer cell-derived exosomes from
tumor-bearing mice were almost exclusively positive for GPC1 (Fig. 1e and Fig. 2f). Next,
we isolated crExos from patients with breast cancer (n=32), pancreatic ductal
adenocarcinoma (PDAC, n=190) and healthy donors (n=100) (Patient data is shown in
Extended Data Table 3). TEM of crExos isolated from the serum revealed a lipid bilayer and

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 4

Author Manuscript
Author Manuscript

CD9 positivity (Extended Data Fig. 2a–b). crExos isolated using sucrose gradient also
showed expression of exosomes marker, flotillin1 (Extended Data Fig. 2c & Extended Data
Fig. 8)23,22. The relative concentration of crExos was significantly higher in the sera of
cancer patients compared to healthy individuals (Extended Data Fig. 2d), and the average
size of PDAC crExos was significantly smaller compared to all other crExos (Extended Data
Fig. 2e). Analyses of sera from healthy individuals revealed baseline positivity for GPC1 in
crExos, ranging from 0.3 to 4.7% (average of 2.3%; Fig. 3a). We observed that 24 out of 32
(75% of patients) breast cancer patients demonstrated crExos GPC1+ level higher that
healthy individuals (P<0.0001; Fig. 3a). Any specific correlation between the level of
GPC1+ crExos and breast cancer subtypes was not appreciated in this patient cohort
(Luminal A, Luminal B or Triple Negative subtypes; Extended Data Fig. 2f), albeit group
size may be too small to conclusively probe such correlation. In contrast, all 190 PDAC
crExos revealed levels of GPC1+ crExos higher than levels noted in serum of healthy
individuals (P<0.0001; Fig. 3a, Extended Data Fig. 7a–b). These results indicated a strong
correlation between GPC1+ crExos and cancer, particularly for PDAC in this analysis. These
results encouraged us to perform further analyses to potentially inform on the utility of
GPC1+ crExos as a detection and monitoring tool for PDAC.

GPC1+ crExos contain oncogenic KrasG12D

Author Manuscript

Exosomes contain DNA and RNA28. KRAS is a frequently mutated gene in pancreas cancer
and mutant transcripts have been found in circulation3,29,30. Primary tumor samples of 47
patients with PDAC were sequenced to assess oncogenic KRAS status. Sixteen PDAC
tumors contained wild-type KRAS allele, 14 revealed KRASG12Dmutation, 11 with
KRASG12Vallele, 5 with KRASG12R allele and 1 with KRASG12V/C mutation (Fig. 3b).
Sufficient amount of corresponding serum was available from 10 patients with KrasG12D
mutations and 5 with KrasG12V mutation. GPC1+ crExos and GCP1− crExos from the same
patient were subjected to immunogold TEM to confirm specific GPC1 expression (Fig. 3c).
All 15 GPC1+ crExos with tumor validated oncogenic Kras mutation revealed identical
mutation by qPCR analysis of exosomal mRNA using specific primers (Fig. 3d). Wild-type
Kras mRNA was found both in GPC1+ and GPC1− crExos, while mutant Kras transcript was
only detected in the GPC1+ crExos (Fig. 3d). These results provide further support for the
cancer cell origin of the GPC1+ crExos and highlight their potential utility identifying cancer
specific genetic defects.

GPC1+ crExos detect early stage pancreas cancer
Author Manuscript

Further analysis of sera from the discovery cohort of patients revealed that the levels of
GPC1+ crExos could distinguish patients with histologically validated pancreatic cancer
precursor lesions (PCPL, n=5; Extended Data Table 3) from healthy individuals and patients
with benign pancreatic disease (BPD, n=26; Extended Data Table 3, Extended Data Table 4,
Fig. 3e). Specifically, the levels of GPC1+ crExos in the PCPL group (intraductal papillary
mucinous neoplasm, IPMN n=5) was consistently higher than the levels of GPC1+ crExos in
the healthy donor group, as well as in the BPD group (which includes 18 patients with
pancreatitis and 8 with cystic adenomas; Fig. 3e). All patients in PCPL group presented with
specific clinical symptoms and exhibited a macroscopic mass imaging using MRI or CT.

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 5

Author Manuscript

The BPD group exhibited similar GPC1+ crExos levels (average 2.1% GPC1+ crExos) as
healthy individuals (Fig. 3e).

Author Manuscript

We compared the specificity and sensitivity of GPC1+ crExos detection levels to CA 19-9
levels, a circulating protein currently used as a tumor biomarker for patients with pancreatic
adenocarcinoma31. CA 19-9 levels were elevated in the serum of patients with PDAC when
compared to healthy donors, but CA 19-9 levels were also significantly elevated in the serum
of patients with BPD (P<0.0001; Extended Data Fig. 2g). Importantly, CA 19-9 serum levels
failed to distinguish patients with PCPL from healthy donors (Extended Data Fig. 2g). When
comparing patients with pancreatic cancer from stage I to stage IV, to healthy individuals
and patients with BPD, the receiver operating characteristic (ROC) curves show that GPC1+
crExos revealed a near perfect classifier with an AUC of 1.0 (95% CI: 0.988 – 1.0)
exhibiting a sensitivity of 100% (95% CI: 98.1–100%) and specificity of 100% (95% CI:
97.1–100%); with a positive predictive value of 100% (95% CI: 98.1–100%) and a negative
predictive value of 100% (95%: 86.8–100%; Fig. 3f and Extended Data Fig. 3a–f). In
contrast, CA 19–9 was inferior in distinguishing between patients with pancreas cancer and
healthy controls (AUC of 0.739, 95% CI: 70.2–82.6%, P<0.001; Fig. 3f and Extended Data
Fig. 3a–f). Of note, neither the concentration of exosomes nor the size of exosomes was a
valid parameter to stratify patients with pancreas cancer versus control (Fig. 3f and Extended
Data Fig. 3a–f). GPC1+ crExos showed a sensitivity and specificity of 100% in each stage of
pancreas cancer (carcinoma-in-situ, stage I as well as stages II–IV), supporting its utility as a
biomarker for all stages of pancreas cancer progression and its potential use for early
detection of pancreas cancer.

Author Manuscript

Next, the discovery findings were validated using an independent patient cohort, composed
of 6 patients with histologically validated BPD (chronic pancreatitis), 56 patients with
PDAC and 20 healthy individuals (Extended Data Table 3). GPC1+ crExos distinguished
patients with PDAC from healthy individuals and patients with BPD (Fig. 3g). The BPD
group exhibited similar GPC1+ crExos levels as healthy individuals (Fig. 3g). In complete
agreement with the discovery cohort, receiver operating characteristic (ROC) curves
indicated that GPC1+ crExos (from PDAC, BPD patients and healthy individuals) revealed a
near perfect classifier with an AUC of 1.0 (95% CI: 0.956 – 1.0) a sensitivity of 100% (95%
CI: 93.6–100%), a specificity of 100% (95% CI: 86.8–100%), a positive predictive value of
100% (95% CI: 93.6–100%), and a negative predictive value of 100% (95%: 86.3–100%;
Fig.3h, Extended Data Fig. 3g).

GPC1+ crExos inform pancreas cancer burden
Author Manuscript

GPC1+ crExos levels correlated with tumor burden in mice (Fig. 2b–c). We next sought to
evaluate whether GPC1+ crExos levels could inform on metastatic disease burden of patients
with PDAC (Extended Data Table 3). GPC1+ crExos of PDAC patients with distant
metastatic disease showed significantly higher levels of bead bound-GPC1+ crExos (average
58.5%) when compared to patients with metastatic disease restricted to lymph nodes
(average 50.5%) or no metastases (average 39.9%; Extended Data Fig. 4a). Further, we
evaluated GPC1+ crExos in serum of PDAC patients at pre- and post surgery stages (post
operative day 7; PDAC n=29, PCPL n=4 and BPD n=4; Fig. 4a). Twenty-eight out of 29

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 6

Author Manuscript

PDAC patients and all PCPL patients with longitudinal blood collections showed a
significant decrease in GPC1+ crExos levels following surgical resection (PDAC: P<0.0001;
PCPL: P<0.001; Fig. 4b). In contrast, CA 19-9 levels decreased in only 19 out of 29 PDAC
patients and in none of the PCPL patients (PDAC: P=0.003; PCPL: P=0.81; Extended Data
Fig. 4b). In 4 BPD patients, the levels of neither GPC1+ crExos nor CA 19-9 showed a
difference (Fig. 4b and Extended Data Fig. 4b).

Author Manuscript

To determine the prognostic relevance of GPC1+ crExos in this longitudinal study cohort
(Fig. 4a), patients were dichotomized into 2 groups. Group 1 was defined by a decrease of
GPC1+ crExos greater or equal (≥) to the median decrease in GPC1+ crExos, and group 2
was defined by a decrease of GPC1+ crExos less (<) than the median decrease of GPC1+
crExos. Group 1 presented with improved overall (26.2 months) and disease specific (27.7
months) survival when compared to group 2 (15.5 months for both overall and disease
specific), indicating that a greater decrease in GPC1+ crExos levels after surgery is
associated with increased survival (Fig. 4c–d). While a decrease in CA 19-9 levels is noted
when comparing pre- and post-resection blood draws, this decrease did not significantly
associate with overall and disease-specific survival (Fig. 4e–f and Extended Data Fig. 4b).
Using a Cox regression model for a multivariate test to include the decrease in GPC1+
crExos, median age, AJCC stage, tumor grade and CA 19-9 levels, only GPC1+ crExos
revealed to be an independent prognostic and predictive marker for disease-specific survival
(hazard ratio: 5.353, CI: 1.651–17.358, P=0.005; Extended Data Fig. 4c–d).

Author Manuscript

Next, we evaluated whether an ELISA for circulating GPC1 could function with the same
specificity and sensitivity as GPC1+ crExos. Serum samples of the validation cohort (20
healthy individuals, 6 BPD patients and 56 PDAC patients) were analyzed for circulating
GPC1. While GPC1 levels were significantly higher in the PDAC patients when compared to
BPD patients and healthy individuals, the sensitivity and specificity of the assay was lower
when compared to GPC1+ crExos. The GPC1 ELISA was similar to circulating CA 19-9
assay. Receiver operating characteristic curve (ROC) indicated that GPC1 circulating protein
shows an AUC of 0.781 (95% CI: 0.675–0.865) a sensitivity of 82.14% (95% CI: 69.6–
91.9%), a specificity of 75% (95% CI: 54.9–90.6%), a positive predictive value of 0.04
(95% CI: 0 – 17.4%), and a negative predictive value of 100% (95%: 94.2 – 100%; Extended
Data Fig. 4e–f).

GPC1+ crExos to detect early PanIN lesions

Author Manuscript

In light of the highly specific and sensitive detection of GPC1+ crExos in pancreas cancer,
we next evaluated time course of GPC1+ crExos appearance in the serum relative to
pancreas tumor burden. To this end, we employed a genetically engineered mouse model
(GEMM) for PDAC. The Ptf1acre/+; LSL-KrasG12D/+; Tgfbr2L/L mice (PKT mice)32 develop
PDAC with full penetrance that reliably recapitulates the clinical and histopathological
features of the human disease32,33. The PKT mice consistently progress from pancreatic
intraepithelial neoplasia (PanIN) at 4.5 weeks of age and die at 8 weeks of age due to
PDAC32,33 (Extended Data Fig. 5a). In a longitudinal study, we bled PKT and littermate
control mice repeatedly at 4, 5, 6, 7 and 8 weeks of age (n=7 PKT mice and n=6 control
mice; Fig. 5a). Three out of 7 PKT mice were euthanized by week 7 along with 4 out of 6

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 7

Author Manuscript
Author Manuscript

controls, while the remaining 3 PKT mice and 2 controls were euthanized at week 8. At 4
weeks of age PKT mice showed on average an 8.4% GPC1+ crExos, and this increased
proportionally with time (and tumor burden) and severity of disease (histopathology),
whereas control mice showed an average of 1.2% GPC1+ crExos and this level remained
constant with time (Fig. 5b). crExos sizes and concentration did not consistently correlate
with disease over time (Extended Data Fig. 5b,c). Magnetic resonance imaging (MRI), an
established imaging modality used for the evaluation of PDAC34, was performed at the same
time points when mice were bled to measure GPC1+ crExos (Fig. 5c). When evaluated as a
group, GPC1+ crExos levels appeared prior to MRI detectable pancreatic masses (Fig. 5c–d
and Extended Data Fig. 5d). GPC1+ crExos size and concentration minimally correlated
with pancreas cancer (Extended Data Fig. 5b–c), whereas GPC1+ crExos levels correlated
with tumor volume determined by MRI, and appeared to lead the growth of the tumor
(Pearson correlation test, r=0.67, P=0.0005, 95% CI: 0.3504–0.8462; Fig. 5c,d and Extended
Data Fig. 5d). Importantly, no elevation of GPC1+ crExos was noted in mice ceruleininduced acute pancreatitis, supporting GPC1+ crExos is elevation is pancreas cancer specific
(Extended Data Fig. 5e). ROC curve analysis for GPC1+ crExos showed an AUC of 1.0
(95% CI: 0.75–1.0) in PKT mice compared to healthy littermate control mice at all ages
evaluated (Fig. 5e and Extended Data Fig. 5f).

Author Manuscript

A cross-sectional study was also initiated to assay tumor burden and GPC1+ crExos in PKT
mice, as early as 16 and 20 days of age (Fig. 5f). Mice were imaged by MRI, bled and
euthanized at these early time points, when mice present with pre-PanIN to early PanIN
lesions (Fig. 5f, Extended Data Fig. 6a and Extended Data Table 5). GPC1+ crExos were
detected in all PKT mice (PKT: 8.3% average, control: 1.8% average; Fig. 5g and Extended
Data Table 5). Histological analysis of PKT mice confirmed pre-PanIN lesions in 4 out of 7
PKT mice, and despite no observed histological lesions in 3 out of 7 PKT mice, GPC1+
crExos predicted future pancreas cancer emergence (Extended Data Table 5). Moreover, we
did not observe pancreas-associated masses by MRI in 16 and 20 days old PKT mice. Both
histopathological score and age of PKT mice correlated with GPC1+ crExos levels (Fig. 5h–
i). Of note, in 4 out of 7 PKT mice with no observed histological lesions, downstream
signals for Kras activation, such as phosphorylated ERK (pERK), was detected in the
pancreas tissue (Fig. 5j and Extended Data Fig. 6a). We also observed exclusive detection of
mutant KrasG12D mRNA in GPC1+ crExos compared to GPC1− crExos (Extended Data Fig.
6b).

Discussion
Author Manuscript

Tumor-derived exosomes are enriched in GPC1, and GPC1+ crExos exclusively carry
mutant Kras mRNA. We show that GPC1+ crExos is a reliable biomarker for detection of
early pancreas cancer. GPC1+ crExos are a prognostic marker superior to CA 19-9, the
currently employed serum biomarker in pancreas cancer. GPC1+ crExos lead MR imaging as
they can be detected in circulation prior to MRI-detectable lesions in GEMM of pancreas
cancer.
Routine screening of the general population for a rare cancer such as PDAC using MRI or
CT would be prohibitively expensive and associated with a high false positive rate35. GPC1+

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 8

Author Manuscript

crExos detect possibility of pancreas cancer in 16-day-old mice with unremarkable pancreas
histology and negative MRI. These results suggest the utility of GPC1+ crExos as a detection
and monitoring tool for pancreas cancer, with an emphasis on its application in early
detection, a clinical challenge that remains to be addressed.

Author Manuscript

While oncogenic KRAS mutations are likely driver mutations for pancreas cancer and are
detected in early PanIN-1 lesions, it is still estimated that 15 to 20 years may lapse before
early PanIN lesions become metastatic PDAC36–38. While this could offer a window for
early detection of this disease, PDAC currently presents late with rather non-specific clinical
symptoms. Therefore, as many as 80% of patients present with regional and distant
metastasis at diagnosis39. Although our understanding of the molecular and genetic details
associated with the progression of non-malignant precursor lesions to PDAC is steadily
increasing, such knowledge has yet to translate into the development of biomarkers that do
not require invasive biopsies. Patients with pancreas cancer exhibit elevated serum levels of
CA 19-9, CEA, CA-50, SPan-1, peanut agglutinin, DU-PAN-2, a-fetoprotein, tissue
polypeptide antigen and pancreatic oncofetal antigen40. While each of these markers
exhibits some utility in tracking biopsy-diagnosed disease they are not tumor specific
because they are also elevated in patients with benign diseases of the pancreas. The lack of
specific serum-based biomarkers with high degree of sensitivity and specificity and
retroperitoneal position of the pancreas further challenges the early detection of pancreas
cancer41,42. Pancreatico-duodenectomy (Whipple procedure) can be curative for PDAC
patients if tumors are detected early with clear surgical margins43. Due to the late diagnosis
of pancreas cancer, only around 15% of patients present with surgically resectable tumors44.
Studies comparing stage of disease with outcome following surgery suggests that death rates
for PDAC would be reduced if the disease were diagnosed at an earlier stage45.

Author Manuscript

Specific isolation of exosomes from the serum of cancer patients remains a challenge due to
the lack of specific markers that can be used to identify and distinguish cancer exosomes
from exosomes produced by other cells. Genetic profiling studies on circulating DNA from
cancer patients are cofounded by the fact that the isolated DNA represents all cells of the
body, thus making mutation and genetic defects challenging46,47. We previously
demonstrated that the DNA in circulation is mainly contained in exosomes6. Therefore a
marker for cancer-derived exosomes will significantly increase the sensitivity of detection
for low frequency mutations in the circulation. Such mutations are frequently associated
with tumor complexity and therapy resistance and relapse, providing a highly specific and
sensitive non-invasive tool for genetic monitoring of a tumor. As a proof of concept GPC1+
crExos identified KRAs mutations with 100% correlation with KRAS mutations in the
tumor.

Author Manuscript

Our results provide evidence for GPC1 as a pan-specific marker of cancer exosomes. GPC1
is a cell surface proteoglycan that interacts with many proteins and has diverse functions48.
Many cancer cells overexpress glypican-1 with most abundant increase observed in pancreas
cancer cells lines and tissue25–27. Many studies have suggested a role of GPC1 as a positive
regulator of cancer progression using orthotopic and GEMMs of PDAC49,50. GPC1+ crExos
is an attractive candidate for detection and isolation of exosomes in circulation of cancer
patients for further genetic analysis of cancer specific alterations in DNA, microRNA, RNA

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 9

Author Manuscript

and proteins. Such opportunity offers an unprecedented opportunity for informative early
detection of pancreas cancer and help design potential curative surgical options.

Methods
Patient samples and tissue collection
The study was conducted according to the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) criteria. The studies using human samples were designed as
an explorative study. As there was no interventional approach in this study, a priori power
calculation was not applicable. Instead, the number of patients included was assessed based
on previous studies investigating the diagnostic relevance of circulating biologicals in
pancreatic cancer51.

Author Manuscript
Author Manuscript

Serum samples and tissue samples from patients with pancreas cancer, serum samples only
from patients with a benign pancreas disease and from healthy donors, who had no evidence
of acute or chronic or malignant disease and had no surgery within the past 12 months, were
received from the department of General, Visceral and Transplantation Surgery from the
University of Heidelberg and from the University Hospital of Dresden after approval by the
local institutional review board (Heidelberg: 323/2004, Dresden: EK357112012). The cases
were obtained under an IRB-exempt protocol of the MD Anderson Cancer Center (IRB no.
PA14-0154). Serum samples from patients with breast cancer were collected at the MD
Anderson Cancer Center after approval of the institutional review board (IRB no.
LAB10-0690). A written consent for the serum sampling and tumor sampling was obtained
pre-operatively from all patients and prior to serum collection from each healthy donor with
disclosure of planned analyses regarding potential prognostic markers. The patients included
in this study were all consecutive patients who underwent a surgical procedure at the
University Hospital of Heidelberg, Germany, at the University Hospital of Dresden,
Germany (pancreas disease) or at the MD Anderson Cancer Center (breast cancer). All
samples were randomly selected from larger cohorts and were analyzed in a blinded fashion.
Unblinding of clinical parameters and corresponding experimental data was performed only
after finishing all experiments. Inclusion criteria of patients were a minimum of 18 years of
age, histologically verified pancreas cancer (pancreatic ductal adenocarcinoma),
histologically verified benign pancreas disease or breast cancer in a resection specimen, and
a negative medical history for any other malignant disease. All blood samples were taken
before treatment. Inclusion criteria for healthy control donors were a negative medical
history for any malignant disease.

Author Manuscript

On the day of surgery, 10 ml serum separator tubes were used to collect blood samples
before surgical incision. The blood samples were then centrifuged at 2,500g for 10 min to
extract the serum, and the serum was stored at −80°C until analyzed. Likewise, blood
samples were collected on day 7 after surgery for 29 patients with an adenocarcinoma of the
pancreas (PDAC), 4 patients with chronic pancreatitis and 4 patients with an intraductal
papillary mucinous neoplasm (IPMN).

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 10

Patient characteristics and clinical specimens

Author Manuscript
Author Manuscript

The pancreatic discovery cohort from the University Hospital of Heidelberg included 190
patients with an adenocarcinoma of the pancreas (PDAC), 18 patients with pancreatitis, 8
patients with a benign serous cystadenoma and 5 patients with an intraductal papillary
mucinous neoplasm (IPMN). Patients were subjected to surgery between 2006 and 2012 at
the Department of General, Visceral, and Transplantation Surgery, University of Heidelberg.
Clinical information included age, gender, AJCC tumor stage, tumor size (pT), presence and
number of lymph node metastases (pN), tumor grade (G), and treatment with (neo-)/adjuvant
chemotherapy. The pancreatic cohort from the University Hospital of Dresden included 56
patients with an adenocarcinoma of the pancreas (PDAC), 6 patients with chronic
pancreatitis, and 20 healthy donors. Patients were subjected to surgery between 2007 and
2013 at the Department of Gastrointestinal, Thoracic and Vascular Surgery, University of
Dresden. Clinical information included age, gender, AJCC tumor stage, tumor size (pT),
presence and number of lymph node metastases (pN), tumor grade (G), and treatment with
(neo-)/adjuvant chemotherapy. The breast cancer cohort consisted of 32 women with breast
cancer. All breast cancer patients were treated at the MD Anderson Cancer Center, Houston,
Texas. Clinical information included age, gender, AJCC tumor stage, tumor size (pT),
presence and number of lymph node metastases (pN), tumor grade, and treatment with
(neo-)/adjuvant chemotherapy.
Animal Studies

Author Manuscript

Nude mice (nu/nu) (purchased from Jackson Laboratory) underwent breast pad injections
with 0.5 million MDA-MB-231 cells or MDA-MB-231-CD63GFP cells in 20 μl of PBS
injected per breast pad. Blood was collected retro-orbitally and exosomes were isolated prior
to injection and at tumor volumes of 300, 550, 1000 and 1350mm3. Mice were euthanized
when the tumor size reached 1500 mm3 or when severe disease symptoms were present.

Author Manuscript

The disease progression and genotyping for the Ptf1acre/+; LSL-KrasG12D/+; Tgfbr2L/L
(PKT) and the Pdx1cre/+; LSL-KrasG12D/+; p53R172H/+ (KPC) mice was previously
described32,33,52. In the PKT longitudinal cohort, retro-orbital blood collections were
performed at 4, 5, 6, 7 and 8 weeks of age. Mice were euthanized at 8 weeks of age or
sooner if severe disease symptoms were noted. Histopathological analysis of mouse
pancreas specimen was performed following previously defined criteria4. Four C57BL/6
adult mice were subjected to repeated cerulean injection to induce acute pancreatitis (five
hourly repeated i.p. injections of 50 μg cerulein per kg of body weight) and euthanized 24
hrs after injection the last injection. Histological analyses of pancreas of mice was
performed according to Hingorani SR et al.52, and an histological score was attributed
according to the type of lesions detected: Score 1: PanIN1a, Score 2: PanIN1 a/b, Score 3:
PanIN2, Score 4: PanIN3, Score 5: Ductal adenocarcinoma. All mice were housed under
standard housing conditions at the MD Anderson Cancer Center (MDACC) animal facilities,
and all animal procedures were reviewed and approved by the MDACC institutional animal
care and use committee.

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 11

Cell lines

Author Manuscript
Author Manuscript

The following human cells lines were used: HMLE (American Type Culture Collection –
ATCC, Manassas, VA), BJ (ATCC), HDF (ATCC), HMEL (ATCC), MCF-7 (ATCC), MDAMB-231 (ATTC), Panc-1 (ATTC), SW480 (ATCC), HCT-116 (ATCC), MIA Paca2 (ATCC)
and T3M4 cells (Cell Bank, RIKEN BioResource Centre, Japan). The following murine
cells lines were used: NIH/3T3 (ATCC), E10 (ATCC), NMuMG (ATTC), 4T1 (ATTC) and
B16F10 cells (ATTC). HDF cells were cultured in DMEM supplemented with 20% (v/v)
fetal bovine serum (FBS), 100 U.ml−1 penicillin and 100 μg.ml−1 streptomycin. HMLE cells
and MCF10A cells were grown in DMEM/F12 supplemented with 5% (v/v) horse serum,
100 U.ml−1 penicillin, 100 μg.ml−1 streptomycin, 20 ng.ml−1 EGF, 0.5 mg.ml−1
hydrocortisone, 100 ng.ml−1 cholera toxin and 10 μg.ml−1 insulin. HMEL, MCF-7, MDAMB-231, HCT-116, SW480, 4T1, NIH/3T3, E10, U87 and B16F10 cells were maintained in
DMEM supplemented with 10% (v/v) FBS, 100 U.ml−1 penicillin and 100 μg.ml−1
streptomycin. Panc-1, MIA Paca2 and T3M4 cells were cultured in RPMI-1640
supplemented with 10% (v/v) FBS, 100 U.ml−1 penicillin and 100 μg.ml−1 streptomycin.
NMuMG cells were grown in DMEM supplemented with 10% (v/v) FBS, 100 U.ml−1
penicillin, 100 μg.ml−1 streptomycin and 10 μg.ml−1 insulin. All cell lines were kept in a
humidifying atmosphere at 5% CO2 at 37°C. MDA-MB-231-CD63GFP cells were
engineered by transfection with a plasmid encoding a CD63-GFP fusion protein expressed
under the control of a CMV promoter (p-CMV6-CD63-GFP from Origene, RG217238).
Transfections were performed using Lipofectamine 2000 reagent (Invitrogen).
Exosomes isolation from cells

Author Manuscript
Author Manuscript

Exosomes were obtained from supernatant of cells as previously described with some
modifications6. Briefly, cells were grown in T225 cm2 flasks in FBS-depleted of exosomes
RPMI media until they reached a confluency of 80–90%. Next, the media was collected and
centrifuged at 800g for 5 min, followed by a centrifugation step of 2,000g for 10 min to
discard cellular debris. Then, the media was filtered using a 0.2 μm pore filter (Syringe filter,
Cat. No. 6786-1302, GE Healthcare, UK). The collected media was then ultracentrifuged at
100,000g for 2 hrs at 4°C. The exosomes pellet was washed with 35 ml 1X PBS, followed
by a second step of ultracentrifugation at 100,000g for 2 hrs at 4°C. Afterwards, the
supernatant was discarded. Exosomes used for RNA extraction were resuspended in 500 μl
of Trizol; exosomes used for protein extraction were resuspended in 250 μl of lysis buffer
(8M Urea/2.5%SDS, 5 μg.ml−1 leupeptin, 1 μg.ml−1 pepstatin and 1mM
phenylmethylsulphonyl fluoride). Exosomes used for flow cytometry analysis (FACS),
transmission electron microscopy (TEM; see sections below) and immunogold staining were
resuspended in 100 μl 1X PBS. Ten microliters of these exosomes sample were used for
NanoSight LM10 (NanoSight Ltd., Minton Park, Amesbury, UK) analysis after dilution
1:100 in 1X PBS.
Exosomes isolation from human serum samples
As previously described, 250 μl of cell-free serum samples were thawed on ice6. Serum was
diluted in 11 ml 1X PBS and filtered through a 0.2 μm pore filter. Afterwards, the samples
were ultracentrifuged at 150,000g overnight at 4°C. Next, the exosomes pellet was washed

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 12

Author Manuscript

in 11 ml 1X PBS followed by a second step of ultracentrifugation at 150,000g at 4°C for 2
hrs. The supernatant was discarded and pelleted exosomes were resuspended in 500 μl of
Trizol for RNA analyses; or in 250 μl of lysis buffer (8M Urea/2.5%SDS, 5 μg.ml−1
leupeptin, 1 μg.ml−1 pepstatin and 1mM phenylmethylsulphonyl fluoride) for protein
analyses. Exosomes used for flow cytometry analysis (FACS), transmission electron
microscopy (TEM; see sections below) and immunogold staining were resuspended in 100
μl 1X PBS. Ten microliters of this exosomes sample were used for NanoSight LM10
(NanoSight Ltd., Minton Park, Amesbury, UK) analysis after Nano dilution 1:100 in 1X.
Immunogold Labeling and Electron Microscopy

Author Manuscript

Fixed specimens at an optimal concentration were placed onto a 400 mesh carbon/formvar
coated grids and allowed to absorb to the formvar for a minimum of 1 minute. For
immunogold staining the grids were placed into a blocking buffer for a block/
permeabilization step for 1 hr. Without rinsing, the grids were immediately placed into the
primary antibody at the appropriate dilution overnight at 4°C (1:300 anti-CD9 ab92726,
Abcam and anti-GPC1 PIPA528055, Thermo Scientific). As controls, some of the grids were
not exposed to the primary antibody. The following day, all the grids were rinsed with PBS
then floated on drops of the appropriate secondary antibody attached with 10 nm gold
particles (AURION, Hatfield, PA) for 2 hrs at room temperature. Grids were rinsed with
PBS and were placed in 2.5% Glutaraldehyde in 0.1M Phosphate buffer for 15 min. After
rinsing in PBS and distilled water the grids were allowed to dry and stained for contrast
using uranyl acetate. The samples were viewed with a Tecnai Bio Twin transmission electron
microscope (FEI, Hillsboro, OR) and images were taken with an AMT CCD Camera
(Advanced Microscopy Techniques, Danvers, MA).

Author Manuscript

Sucrose gradient
Sucrose density gradients were performed to purify exosomes. Exosomes were resuspended
in 2 ml of HEPES/sucrose stock solution (2.5M sucrose, 20mM HEPES/NaOH solution, pH
7.4). The exosomes suspension was overlaid with a linear sucrose gradient (2.0-0.25M
sucrose, 20mM HEPES/NaOH, pH 7.4) in a SW41 tube (Beckman). The gradients were
ultracentrifuged for 16 hrs at 210,000g at 4°C. Gradient fractions of 1 ml were collected
from top to bottom and densities of each fractions were evaluated using a refractometer.
Next, the exosomes pellets were washed in 1X PBS followed by a second step of
ultracentrifugation at 150,000g at 4°C for 2 hrs. Exosomes pellets were resuspended in
Laemmli buffer and/or PBS for further immunoblot and flow cytometry analysis.
Flow cytometry analysis of exosomes-bound beads

Author Manuscript

Exosomes were attached to 4 μm aldehyde/sulfate latex beads (Invitrogen, Carlsbad, CA,
USA) by mixing 30 μg exosomes in a 10 μl volume of beads for 15 min at room temperature
with continuous rotation. This suspension was diluted to 1 ml with 1X PBS and left for 30
min rotating at room temperature. The reaction was stopped with 100mM glycine and 2%
BSA in 1X PBS and left 30 min rotating at room temperature. Exosomes-bound beads were
washed 1 time in 1X PBS/2% BSA and centrifuge for 1 min at 10,000 rpm, blocked with
10% BSA with rotation at room temperature for 30 min, washed a second time in 1X
PBS/2% BSA and centrifuged for 1 min at 10,000 rpm, and incubated with anti-GPC1
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 13

Author Manuscript

(PIPA528055, Thermo-Scientific, 3 μl of antibody in 20 μl of 2%BSA/1X PBS) during 30
min rotating at 4°C. Beads were centrifuged for 1 min at 10,000 rpm, the supernatant was
discarded and beads were washed in 1X PBS/2% BSA and centrifuged for 1 min at 10,000
rpm. Alexa-488 or Alexa-594-tagged secondary antibodies (Life Technologies, NY 14072,
USA, 3 μl of antibody in 20 μl of 2%BSA/1X PBS) were used during 30 min with rotation at
4°C. Secondary antibody incubation alone was used as control and to gate the beads with
GPC1+ bound exos. The percent positive bead was calculated relative to the total number of
beads analyzed per sample (100,000 events). This percentage was therein referred to as the
percent beads with GPC1+ exosomes.
Ultra performance liquid chromatography – mass spectrometry (UPLC-MS)

Author Manuscript

Exosomes were mixed with 200 μl of methanol spiked with the Internal Standard
tryptophan-d5. After brief vortex mixing, the samples were incubated for 1 hr at −20°C.
After centrifugation at 16,000g for 15 min at 4°C, 190 μl of the supernatants was collected
and the solvent removed. The dried extracts were then reconstituted in 15 μl of methanol, of
which 10 μl were transferred to microtubes and derivatized. Chromatographic separation and
mass spectrometric detection conditions employed are summarized below:

Author Manuscript
Author Manuscript

System

SQD

Column type

UPLC BEH C18, 1.0 x 100 mm, 1.7 μm

Flow rate

0.14 ml/min

Solvent A

H2O + 10mM Ammonium Bicarbonate (+NH4OH until pH: 8.8)

Solvent B

ACN

(%B), time

2%, 0 min

(%B), time

8%, 6.5 min

(%B), time

20%, 10 min

(%B), time

30%, 11 min

(%B), time

99.9%, 12 min

(%B), time

2%, 14 min

Column temperature

40°C

Injection volume

1 μl

Ionisation

ES+

Source temperature

120°C

Nebulisation N2 flow

600 l / hour

Nebulisation N2 temperature

350°C

Cone N2 flow

10 l / hour

Capillary voltage

3.2 kV

Cone voltage

30 V

The mass range, 50 – 1000 m/z, was calibrated with cluster ions of sodium formate. An
appropriate test mixture of standard compounds was analyzed before and after the entire set
of randomized duplicated sample injections, in order to examine the retention time stability

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 14

Author Manuscript

and sensitivity of the LC/MS system throughout the course of the run. Data were processed
using the TargetLynx application manager for MassLynx 4.1 software (Waters Corp.,
Milford, USA). A set of predefined retention time, mass-to-charge ratio pairs, Rt-m/z,
corresponding to metabolites included in the analysis are fed into the program. Associated
extracted ion chromatograms (mass tolerance window = 0.05 Da) are then peak-detected and
noise-reduced in both the LC and MS domains such that only true metabolite related
features are processed by the software. A list of chromatographic peak areas is then
generated for each sample injection, using the Rt-m/z data pairs (retention time tolerance = 6
s) as identifiers. Normalization factors were calculated for each metabolite by dividing their
intensities in each sample by the recorded intensity of the internal standard in that same
sample. Visualization of disjoint and overlapping protein data sets was carried out by
drawing a VennDiagram of the 5 protein data sets using an R package53.

Author Manuscript

Cancer Antigen CA 19-9 Human and GPC1 ELISAs
Serum CA 19-9 and GPC1 protein levels in patients with pancreatic cancer, pancreatic
cancer precursor lesion, or benign pancreatic disease, and in healthy donors were assessed
using the Cancer Antigen CA 19-9 Human ELISA Kit (Abcam, ab108642) and the GPC1
Human ELISA kit (ABIN840422), according to the manufacturer’s directions.
Western blot analyses

Author Manuscript

Cells were lysed in RIPA buffer containing 5 μg.ml−1 leupeptin, 1 μg.ml−1 pepstatin and
1mM phenylmethylsulphonyl fluoride. Exosomes were lysed in 8M Urea/2.5% SDS
containing 5 μg.ml−1 leupeptin, 1 μg.ml−1 pepstatin and 1mM phenylmethylsulphonyl
fluoride. Sample loading was normalized according to Bradford relative protein
quantification and proteins separated following an electrophoretic gradient across
polyacrylamide gels. Wet electrophoretic transfer was used to transfer the proteins in the gel
onto PVDF membranes (ImmobilonP). The protein blot was blocked for 1hr at room
temperature with 5% non-fat dry milk in PBS/0,05% Tween and incubated overnight at 4°C
with the following primary antibodies: 1:300 anti-GPC1, PIPA528055 (Thermo-Scientific);
1:300 anti-β-Actin A3854 (Sigma-Aldrich); 1:300 anti-CD81 sc-166029 (Santa-Cruz); 1:300
anti-Flottilin1 sc-25506 (Santa-Cruz). Afterwards, HRP conjugated secondary antibodies
were incubated for 1 hr at room temperature. Washes after antibody incubations were done
on an orbital shaker, four times at 10 min intervals, with 1X PBS 0.05% Tween20. Blots
were developed with chemiluminescent reagents from Pierce.
RNA extraction of cells and exosomes

Author Manuscript

RNA of cells and exosomes was isolated using Trizol Plus RNA purification kit (Life
Technologies, 12183555) according to manufactures protocol. RNA was quantified using a
Nanodrop® ND-1000 (Thermo Fischer Scientific).
Quantitative real-time-PCR (qRT-PCR)
qRT-PCR was performed on DNase treated RNA using the SuperScript® III Platinum®
One-Step Quantitative RT-PCR System (Cat. no. 11732-088, Invitrogen, Life Technologies,
Grand Island, NY 14072 USA) according to the manufacturer’s directions on a 7300

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 15

Author Manuscript

Sequence Detector System (Applied Biosystems). 150 ng of RNA extracted from 2.5 × 108
exosomes was used as qPCR input. Primers for KRAS G12D mRNA and KRAS G12V
mRNA (both Sigma-Aldrich Corp. St. Louis, MO, USA) were designed as reported
previously54. Briefly, the altered base of KRAS G12D and KRAS G12V mutation was kept
at the 3′ end of the forward primer. An additional base mutation was included two positions
before the Kras mutation in order to increase the specificity of the amplification of the
mutant Kras allele. Forward primer sequences for KRAS G12D mRNA: F-5′ACTTGTGGTAGTTGGAGCAGA-3′. Forward primer sequences for KRAS G12V mRNA:
F-5′-ACTTGTGGTAGTTGGAGCAGT-3′. Forward primer sequences for KRAS wild-type
mRNA: F-5′-ACTTGTGGTAGTTGGAGCTGG-3′. Reverse primer for all KRAS: R-5′TTGGATCATATTCGTCCACAA-3′. GPC1 mRNA primer pairs (Cat. No. PPH06045A) and
18S mRNA primer pairs (Cat. No. QF00530467) were purchased as ready specific primer
pairs from Qiagen (Qiagen, Hilden, Germany). Threshold cycle55 (Ct) the fractional cycle
number at which the amount of amplified target reached a fixed threshold, was determined
and expression was measured using the 2−ΔCt formula, as previously reported56.

Author Manuscript

DNA extraction from human primary pancreatic cancer tumors and crExos

Author Manuscript

Immediately after resection, pancreatic tumor samples were snap-frozen in liquid nitrogen
and stored at −80°C until further processing. A 10 μm reference section of each sample was
cut and stained with hematoxylin and eosin by standard methods to evaluate the proportion
of tumor tissue and adjacent tumor stroma. Samples with a tumor stroma proportion > 30 %
were excluded into this study. DNA isolation was performed using a commercial DNA
Extraction Kit (DNeasy Blood & Tissue Kit, Cat. No. 69506, Qiagen, Germany) according
to the manufacturer’s protocol. The amount of DNA from tumor samples was quantified
using a Nanodrop® 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE
19810, USA).
Polymerase chain reaction (PCR) and Sanger Sequencing

Author Manuscript

PCR was performed in a 25 μl reaction tube consisting of 10 μl template DNA, 1 μM of each
primer, 2.5mM dNTP, 2.5 10 x PCR Buffer, 25mM Mg solution, 0.5 μl H2O and 2.5 μl Taq
Polymerase. Amplification was carried out in a T100 ThermoCycler (Bio-Rad) under
following conditions: 94°C for 1 min, 2 cycles of 94 °C for 10 s, 67°C for 30 s, 70 °C for 30
s; 2 cycles of 94 °C for 10 s, 64°C for 30 s, 70 °C for 30 s; 2 cycles of 94 °C for 10 s, 61°C
for 30 s, 70 °C for 30 s; 35 cycles of 94 °C for 10 s, 59°C for 30 s, 70 °C for 30 s; endless
4 °C. KRAS amplicon were generated using the following primers: forward 5′AAGGCCTGCTGAAAATGACTG-3′, 5′-AGAATGGTCCTGCACCAGTAA-3′. PCR
products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany).
Subsequently, sequencing reaction was performed using BigDye terminator kit (v3.1, Life
Technologies, USA) according to the manufacturer’s instructions. Sequencing products were
separated on an ABI 3730 automated sequencer (Life Technologies, USA). KRAS mutation
status was evaluated using Finch TV (Geospiza, Inc., Seattle, WA 98119, USA).
MRI imaging
MRI studies were conducted using a 7T small animal MR system, the Biospec USR70/30
(Bruker Biospin MRI, Billerica, MA) is based on an actively-shielded 7T magnet with a 30Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 16

Author Manuscript

cm bore and cryo-refrigeration. The system is equipped with 6 cm inner-diameter gradients
that deliver a maximum gradient field of 950 mT/m. A 3.5 cm inner-diameter linear birdcage
coil transmits and receives the MR signal. For image acquisition, T2 weighted, respiratory
gated, multi-slice imaging will be performed with respiration held to under 25 breaths per
minute to minimize motion artifacts in the abdomen. For mice where fat signal might mask
the T2 weighted image the fat-suppression pulse module will be utilized. Acquisition
parameters were minimally modified from Schmid A et. Al.57. The RARE-T2 weighted
pulse sequence was modified to include an effective Te of 56 ms with a total TR of 2265 ms.
Between 18 and 20 coronal slices were acquired per mouse with a slice thickness of 0.75
mm and slice spacing of 1 mm. In plane, pixel sizes of 0.156 mm × 0.156 mm with a matrix
size of 256×192 (40 mm × 30 mm FOV) was chosen to minimize in plane partial volume
effects, maintain a FOV sufficient to cover the abdomen, while also providing sufficient
throughput for the experiment.

Author Manuscript

To measure tumor burden, the region of suspected lesions are drawn blinded on each slice
after images intensities were normalized. The volume is calculated by addition of delineated
region of interest in mm2 x 1 mm slice distance.
Statistical analysis

Author Manuscript
Author Manuscript

The GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA 92037 USA) and
MedCalc statistical software version 13.0 (MedCalc Software bvba, Acacialaan 22, 8400
Ostend, Belgium) were used for all calculations. Unpaired Student’s t-test was applied to
calculate expression differences of the qPCR results (dCt-values). Analysis of variance
(ANOVA) tests were performed to calculate differences of multiple serum factors in murine
and human serum samples. As a post-hoc test, a Tukey-Kramer test was applied for pairwise
comparison of subgroups when the ANOVA test was positive in case of equal variance.
Tamhane T2 test was applied for pairwise comparison of subgroups when the ANOVA test
was positive in case of unequal variances. A paired two-tailed Student’s t-test was applied to
assay differences in percent bead with GPC1+ crExos and CA 19-9 in the longitudinal cohort
between pre-operative and postoperative blood samples. Receiver operating characteristic
curves (ROC) were used to determine the sensitivity, specificity, positive and negative
predictive value and to compare area under the curves (AUC) of serum factors using the
Delong method58. The cut-off value was determined using the Youden-Index. Univariate
analysis using the log-rank test was conducted to visualize (Kaplan Meier curves) and assess
disease-specific survival (time from diagnosis to cancer-related death or last follow-up) in
the longitudinal cohort of patients with pancreatic cancer. A multivariate analysis using the
Cox proportional hazards regression model was performed to evaluate the effect of a
decrease of percent bead with GPC1+ crExos in addition to age (continuous variable), AJCC
tumor stage, and tumor grade (G) and CA 19-9 levels (U.ml−1). Correlation analysis
between murine tumor burden and percent bead with GPC1+ crExos was performed using
the Spearman correlation test. Figures were prepared by using GraphPad Prism (GraphPad
Software, La Jolla, CA 92037 USA) and MedCalc statistical software version 13.0
(MedCalc Software bvba, Acacialaan 22, 8400 Ostend, Belgium). All presented P values are
two-sided and P < 0.05 was considered to be statistically significant.

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 17

Author Manuscript

Extended Data

Author Manuscript
Author Manuscript
Extended Data Figure 1. Exosomes isolation

Author Manuscript

a, Exosomes concentration and size distribution by NanoSight® analysis of culture
supernatant from NIH/3T3, MCF10A, HDF, MDA-MB-231 and E10 cells. Size mode: 105
nanometers (nm; 3 technical replicates). b, Transmission electron microscopy (TEM)
micrograph of MDA-MB-231-derived exosomes. Upper right image shows a digitally
zoomed inset. c, TEM micrograph of MDA-MB-231-derived exosomes following
immunogold labeling for CD9. Gold particles are depicted as black dots. Upper right image
shows a digitally zoomed inset. d, Immunoblot of flotillin1 and CD81 in exosomal proteins
extracted from culture supernatant of E10, NIH/3T3, MDA-MB-231, MCF10A and HDF
cells. e, RT–qPCR measurement of GPC1 mRNA levels in HMEL, HDF, HMLE, MCF7,
MDA-MB-231, T3M4, Panc-1, MIA Paca2. Results are shown as mean ± standard
deviation; n=3, 3 biological replicates, with 3 technical replicates each. f, Immunoblot of
GPC1 in HMEL, HDF, HMLE, MCF7, MDA-MB-231, T3M4, Panc-1 and MIA Paca2 cell
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 18

Author Manuscript

lysates (upper panel). β-actin was used as a loading control (lower panel). g, Immunoblot of
GPC1 in exosomal protein lysates derived from the culture supernatant of 3 non-tumorigenic
cell lines (HDF, HMEL, HMLE) and 5 tumorigenic cell lines (MCF7, MDA-MB-231,
T3M4, Panc-1, MIA Paca2) (upper panel). Immunoblot of flotillin1 was used as loading
control (lower panel). h, Immunoblot of flotillin1 in exosomal protein lysates from the
culture supernatant of MDA-MB-231 and T3M4 following sucrose gradient purification.
The protein content is assayed in each of the density layers listed.

Author Manuscript
Author Manuscript

Extended Data Figure 2. NanoSight® analysis in human serum samples

Author Manuscript

a, Transmission electron microscopy (TEM) micrograph of cancer patient serum-derived
exosomes. Upper right image shows a digitally zoomed inset. b, TEM micrograph of cancer
patient serum-derived exosomes following immunogold labeling for CD9. Gold particles are
depicted as black dots. Upper right image shows a digitally zoomed inset. c, Immunoblot of
flotillin1 of exosomal protein lysates from serum of cancer patient following exosomes
purification by sucrose gradient. The protein content is assayed in each of the density layers
listed. d, Exosomes concentration by NanoSight® analysis showing the number of exosomes
per 1 ml of serum derived from healthy donors (n=100), from breast cancer patients (n=32)
and from patients with a pancreatic ductal adenocarcinoma (PDAC, n=190). ANOVA, posthoc Tamhane T2, * P<0.05, **** P<0.0001; 3 technical replicates. e, Exosomes size
distribution by NanoSight® analysis showing the mode size of exosomes in 1 ml of serum
derived from healthy donors (n=100), from breast cancer patients (n=32) and from patients
with a pancreatic ductal adenocarcinoma (PDAC, n=190). ANOVA, post-hoc Tukey-Kramer

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 19

Author Manuscript

test, *** P<0.001; 3 technical replicates. f, Scatter dot plots depicting the percentage of
beads with GPC1+ bound exosomes purified from the serum of breast cancer patients. The
patients are subdivided into three subtypes: Luminal A, Luminal B and Triple Negative
breast cancer. g, Scatter plots depicting the serum CA 19-9 concentration (U/mL), evaluated
by ELISA, in healthy donors (n=100), patients with benign pancreas disease (BPD, n=26),
pancreas cancer precursor lesion (PCPL, n=5) and pancreatic ductal adenocarcinoma
(PDAC, n=190). Discovery cohort, ANOVA, post-hoc Tamhane T2 * P<0.05; ****
P<0.0001; 3 technical replicates. Data is presented as the mean ± standard deviation.

Author Manuscript
Author Manuscript
Author Manuscript

Extended Data Figure 3. Tumor stage-specific analysis

a, Table associated with receiver Operating Characteristic (ROC) curve analysis depicted in
Figure 1f. b–f, ROC curve analysis for percent GPC1+ crExos (red line), CA 19-9 serum

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 20

Author Manuscript

levels (blue scattered line), exosomes concentration (black line) and exosomes size
(scattered black line) in patients with carcinoma in situ (CIS) or stage I pancreatic cancer
(n=5) (a), stage IIa pancreatic cancer (n=18) (b), stage IIb pancreatic cancer (n=117) (c),
stage III pancreatic cancer (n=11) (d), and stage IV pancreas cancer (n=41) (e), compared to
control (healthy donors (n=100) and patients with a benign pancreatic disease (n=26), total
n=126). g, Table associated with ROC curve analysis depicted in Figure 1h. AUC: Area
under the curve, CI: confidence interval.

Author Manuscript
Author Manuscript
Extended Data Figure 4. Longitudinal human study

Author Manuscript

a, Scatter plots of percent beads with GPC1+ crExos by flow cytometry in patients with
pancreas cancer. Patients are divided based on metastatic disease (non-metastatic lesions,
lymph node metastases and distant metastases). ANOVA, post-hoc Tukey-Kramer test, *
P<0.05; 3 technical replicates. b, Scatter plots depicting serum CA 19-9 levels (U/ml) in
patients with benign pancreas disease (BPD) (n=4), cancer precursor lesion (PCPL) (n=4),
and pancreatic ductal adenocarcinoma (PDAC) (n=29) on the preoperative day and
postoperative day 7 in patients. Paired two-tailed Student’s t-test, ** P<0.01; 3 technical
replicates. c–d, Multivariate analysis (Cox proportional hazards regression model) of
prognostic parameters for overall (c) and disease-specific (d) survival of patients with
pancreas cancer in the longitudinal cohort (n=29). e, Scatter plots depicting serum GPC1

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 21

Author Manuscript

(ng/ml) levels by ELISA in patients with benign pancreas disease (BPD, n=6), pancreatic
ductal adenocarcinoma (PDAC, n=56) and healthy controls (n=20). ANOVA, post-hoc
Tukey-Kramer test, **** P<0.0001; 3 technical replicates. f, ROC curve for circulating
GPC1 protein (red line) in patients with pancreas cancer (n=56) vs. control (healthy donors
(n=20) and patients with a benign pancreatic disease (n=26), total n=6). AUC: Area under
the curve, CI: confidence interval.

Author Manuscript
Author Manuscript
Author Manuscript

Extended Data Figure 5. PDAC GEMM longitudinal study

a, Schematic diagram depicting the spontaneous development and progression of pancreatic
cancer in Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2L/L (PKT) mice and H&E of the pancreas at the
indicated time points showing healthy pancreas, PanIN lesions, and PDAC lesions. Scale
bars: 100 μm. b–c, Exosomes size (b) and concentration (c) assayed by NanoSight® analysis
from the serum of PKT mice (E: experimental, red) and control mice (C: control, blue) at 4,
5, 6,7 and 8 weeks of age. ANOVA, post-hoc Tukey-Kramer test, * P<0.05; 3 technical
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 22

Author Manuscript

replicates. d, Graph depicting the time wise progression of tumor volume measured by MRI
and the % beads with GPC1+ bound crExos in individual PKT mice (blue: tumor volume,
red: % GPC1+ crExos). e, Percent beads with GPC1+ crExos on beads from control mice
(n=3) and mice with cerulein-induced acute pancreatitis (n=4). Two-tailed Student’s t-test,
ns: not significant; 3 technical replicates. f, Results from ROC curves for percent beads with
GPC1+ bound crExos, exosomes concentration and exosomes size in 4, 5, 6 and 7 weeks old
PKT mice (n=7) vs. control (including age-matched littermate healthy control (n=6) and
mice with induced acute pancreatitis (n=4), n=10)). Data is presented as the mean ± standard
deviation.

Author Manuscript
Author Manuscript

Extended Data Figure 6. PDAC GEMM cross sectional studies

a, Representative micrographs of H&E stained pancreas from 16 days old control mice (left
panel) and PKT mice presenting with (right panel, encircled) and without (middle panel)
PanIN lesions. Scale bars: 100 μm. b, Ct values following qPCR analyses for oncogenic
KRASG12D, wild-type KRAS and 18S internal control RNA from exosomes of 44–48 days
old PKT mice serum segregated using FACS for GPC1+ bead bound exos (red) and GPC1−
bead bound exos (blue). Data is presented as the mean ± standard deviation.

Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 23

Author Manuscript
Author Manuscript
Author Manuscript

Extended Data Figure 7. Raw scatter dot plot depicting flow cytometry analyses of beads with
GPC1+ bound exosomes

a, Scatter plots and histogram of flow cytometry analyses of serum exosomes on beads of a
representative healthy control (left panels are secondary antibody only; right panels are
GPC1 antibody and secondary antibody). b, Scatter plots and histogram of flow cytometry
analysis of serum exosomes on beads of a representative pancreas cancer sample (left panels
are secondary antibody only; right panels are with GPC1 antibody and secondary antibody).

Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 24

Author Manuscript
Author Manuscript
Author Manuscript

Extended Data Figure 8.

Uncropped Western blots
Extended Data Table 1

List of the 48 proteins exclusive to MDA-MB-231
exosomes

Author Manuscript

Listing of the 48 proteins exclusively detected in exosomes from MDA-MB-231 cells
determined by ultra performance liquid chromatography – mass spectrometry (UPLC-MS)
and comparative analyses of exosomes derived from NIH/3T3, MCF 10A, HDF, E10 and
MDA-MB-231 cells. The proteins are grouped based on cellular location.
Protein Name

Gene ID

Cellular Location

ATP-binding cassette sub-family A member 6

ABCA6

Transmembrane

Tetraspanin-4

TSPAN4

Transmembrane

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 25

Author Manuscript

Protein Name

Gene ID

Cellular Location

SLIT and NTRK-like protein 4

SLITRK4

Transmembrane

Putative protocadherin beta-18

PCDHB18

Transmembrane

Myeloid cell surface antigen CD33

CD33

Transmembrane

Glypican-1

GPC1

Membrane anchored

Author Manuscript

Protein Name

Gene ID

Cellular Location

Histone H2A type 2-A

HIST1H2AA

Nucleus

Histone H2A type 1-A

HIST1H1AA

Nucleus

Histone H3.3

H3F3A

Nucleus

Histone H3.1

HIST1H3A

Nucleus

Zinc finger protein 37 homolog

ZFP37

Nucleus

Hypermethylated in cancer 2 protein

HIC2

Nucleus

Zinc finger protein 12

ZSCAN12

Nucleus

Protein Name

Gene

ID Cellular Location

Laminin subunit beta-1

LAMB1

Secreted

Tubulointerstitial nephritis antigen-like

TINAGL1

Secreted

Peroxiredoxin-4

PRDX4

Secreted

Collagen alpha-2(IV) chain

COL4A2

Secreted

Putative protein C3P1

C3P1

Secreted

Collagen alpha-1(II) chain

COL2A1

Secreted

Hemicentin-1

HMCN1

Secreted

Author Manuscript

Protein Name

Gene ID

Cellular Location

Putative rhophilin-2-like protein

RHPN2P1

Not specified

Ankyrin repeat domain-containing protein 62

ANKRD62

Not specified

Tripartite motif-containing protein 42

TRIM42

Not specified !

Author Manuscript

Protein Name

Gene ID

Cellular Location

Junction plakoglobin

JUP

Cytoplasm

Tubulin beta-2B chain

TUBB2B

Cytoplasm

Endoribonuclease Dicer

DICER1

Cytoplasm

E3 ubiquitin-protein ligase TRIM71

TRIM71

Cytoplasm

Katanin p60 ATPase-containing subunit A-like 2

KATNAL2

Cytoplasm

Protein S100-A6

S100A6

Cytoplasm

5′-nucleotidase domain-containing protein 3

NT5DC3

Cytoplasm

Valine--tRNA ligase

VARS

Cytoplasm

Kazrin

KAZN

Cytoplasm

ELAV-like protein 4

ELAVL4

Cytoplasm

RING finger protein 166

RNF166

Cytoplasm

FERM and PDZ domain-containing protein 1

FRMPD1

Cytoplasm

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 26

Author Manuscript
Author Manuscript

Protein Name

Gene ID

Cellular Location

78 kDa glucose-regulated protein

HSPA5

Cytoplasm

Trafficking protein particle complex subunit 6A

TRAPPC6A

Cytoplasm

Squalene monooxygenase

SQLE

Cytoplasm

Tumor susceptibility gene 101 protein

TSG101

Cytoplasm

Vacuolar protein sorting 28 homolog

VPS28

Cytoplasm

Prostaglandin F2 receptor negative regulator

PTGFRN

Cytoplasm

Isobutyryl-CoA dehydrogenase, mitochondrial

ACAD8

Cytoplasm

26S protease regulatory subunit 6B

PSMC4

Cytoplasm

Elongation factor 1-gamma

EEF1G

Cytoplasm

Titin

TTN

Cytoplasm

Tyrosine-protein phosphatase type 13

PTPN13

Cytoplasm

Triosephosphate isomerase

TPI1

Cytoplasm

Carboxypeptidase E

CPE

Cytoplasm

Extended Data Table 2

Exosomes proteins assayed by ultra performance liquid chromatography – mass
spectrometry (UPLC-MS) in indicated cell lines.
E10
prot_hit

Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

1

P04264

Keratin, type II
cytoskeletal 1 OS=Homo
sapiens GN=KRT1 PE=1
SV=6

2721

65999

68

30

57.8

8.15

2

P35527

Keratin, type I
cytoskeletal 9 OS=Homo
sapiens GN=KRT9 PE=1
SV=3

2381

62027

59

24

68.2

5.14

3

P13645

Keratin, type I
cytoskeletal 10
OS=Homo sapiens
GN=KRT10 PE=1 SV=6

2146

58792

66

29

57.9

5.13

4

P02768

Serum albumin
OS=Homo sapiens
GN=ALB PE=1 SV=2

2032

69321

104

9

13.5

5.92

5

P07996

Thrombospondin-1
OS=Homo sapiens
GN=THBS1 PE=1 SV=2

1823

129300

57

29

37.9

4.71

6

P02765

Alpha-2-HSglycoprotein OS=Homo
sapiens GN=AHSG
PE=1 SV=1

1784

39300

50

3

8.7

5.43

7

P01023

Alpha-2-macroglobulin
OS=Homo sapiens
GN=A2M PE=1 SV=3

1719

163188

62

8

7.5

6.03

8

P20742

Pregnancy zone protein
OS=Homo sapiens
GN=PZP PE=1 SV=4

1562

163760

48

4

2.5

5.97

9

P02751

Fibronectin OS=Homo
sapiens GN=FN1 PE=1
SV=4

1186

262460

37

26

17.6

5.46

10

P12111

Collagen alpha-3(VI)
chain OS=Homo sapiens
GN=COL6A3 PE=1
SV=5

1113

343457

51

39

20.2

6.26

11

P35908

Keratin, type II
cytoskeletal 2 epidermal
OS=Homo sapiens
GN=KRT2 PE=1 SV=2

1057

65393

35

21

48.4

8.07

12

P01024

Complement C3
OS=Homo sapiens
GN=C3 PE=1 SV=2

978

187030

43

18

14.7

6.02

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 27

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

13

P00734

Prothrombin OS=Homo
sapiens GN=F2 PE=1
SV=2

846

69992

21

6

8

5.64

14

P60709

Actin, cytoplasmic 1
OS=Homo sapiens
GN=ACTB PE=1 SV=1

820

41710

23

12

47.5

5.29

15

P08779

Keratin, type I
cytoskeletal 16
OS=Homo sapiens
GN=KRT16 PE=1 SV=4

762

51236

31

18

48

4.99

16

P19823

Inter-alpha-trypsin
inhibitor heavy chain H2
OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

708

106397

27

8

9.3

6.4

17

P02533

Keratin, type I
cytoskeletal 14
OS=Homo sapiens
GN=KRT14 PE=1 SV=4

579

51529

25

15

37.1

5.09

18

P0C0L4

Complement C4-A
OS=Homo sapiens
GN=C4A PE=1 SV=1

492

192650

20

9

5.6

6.65

19

P04259

Keratin, type II
cytoskeletal 6B
OS=Homo sapiens
GN=KRT6B PE=1 SV=5

446

60030

18

10

25.5

8.09

20

P12109

Collagen alpha-1(VI)
chain OS=Homo sapiens
GN=COL6A1 PE=1
SV=3

420

108462

11

7

11.3

5.26

21

P04406

Glyceraldehyde-3phosphate
dehydrogenase
OS=Homo sapiens
GN=GAPDH PE=1
SV=3

419

36030

12

6

28.4

8.57

22

Q07954

Prolow-density
lipoprotein receptorrelated protein 1
OS=Homo sapiens
GN=LRP1 PE=1 SV=2

419

504276

22

10

5.8

5.16

23

P02538

Keratin, type II
cytoskeletal 6A
OS=Homo sapiens
GN=KRT6A PE=1
SV=3

419

60008

18

10

27.1

8.09

24

P02788

Lactotransferrin
OS=Homo sapiens
GN=LTF PE=1 SV=6

416

78132

16

3

4.8

8.5

25

P68032

Actin, alpha cardiac
muscle 1 OS=Homo
sapiens GN=ACTC1
PE=1 SV=1

408

41992

13

6

26.8

5.23

26

P02771

Alpha-fetoprotein
OS=Homo sapiens
GN=AFP PE=1 SV=1

395

68633

9

3

5.6

5.48

27

Q08380

Galectin-3-binding
protein OS=Homo
sapiens GN=LGALS3BP
PE=1 SV=1

392

65289

15

10

26.7

5.13

28

P68363

Tubulin alpha-1B chain
OS=Homo sapiens
GN=TUBA1B PE=1
SV=1

364

50120

18

9

38.4

4.94

29

P13647

Keratin, type II
cytoskeletal 5 OS=Homo
sapiens GN=KRT5 PE=1
SV=3

360

62340

17

11

23.4

7.59

30

Q04695

Keratin, type I
cytoskeletal 17
OS=Homo sapiens
GN=KRT17 PE=1 SV=2

357

48076

20

10

32.6

4.97

31

Q9BYX7

Putative beta-actin-like
protein 3 OS=Homo
sapiens GN=POTEKP
PE=5 SV=1

347

41989

8

3

13.6

5.91

32

P06396

Gelsolin OS=Homo
sapiens GN=GSN PE=1
SV=1

340

85644

11

7

12.5

5.9

33

P04114

Apolipoprotein B-100
OS=Homo sapiens
GN=APOB PE=1 SV=2

327

515283

16

12

2.4

6.58

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 28

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

34

P03956

Interstitial collagenase
OS=Homo sapiens
GN=MMP1 PE=1 SV=3

318

53973

15

11

33.5

6.47

35

Q06033

Inter-alpha-trypsin
inhibitor heavy chain H3
OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

298

99787

10

5

5.1

5.49

36

P69905

Hemoglobin subunit
alpha OS=Homo sapiens
GN=HBA1 PE=1 SV=2

297

15248

13

3

33.1

8.72

37

P24821

Tenascin OS=Homo
sapiens GN=TNC PE=1
SV=3

292

240700

12

10

9.4

4.79

38

P07437

Tubulin beta chain
OS=Homo sapiens
GN=TUBB PE=1 SV=2

286

49639

12

7

34.2

4.78

39

P68371

Tubulin beta-2C chain
OS=Homo sapiens
GN=TUBB2C PE=1
SV=1

278

49799

10

7

27.4

4.79

40

P02774

Vitamin D-binding
protein OS=Homo
sapiens GN=GC PE=1
SV=1

273

52929

12

6

12

5.4

41

Q562R1

Beta-actin-like protein 2
OS=Homo sapiens
GN=ACTBL2 PE=1
SV=2

271

41976

8

3

16

5.39

42

P23142

Fibulin-1 OS=Homo
sapiens GN=FBLN1
PE=1 SV=4

269

77162

10

5

7.4

5.07

43

P13646

Keratin, type I
cytoskeletal 13
OS=Homo sapiens
GN=KRT13 PE=1 SV=4

256

49557

13

6

10.9

4.91

44

P02647

Apolipoprotein A–I
OS=Homo sapiens
GN=APOA1 PE=1
SV=1

255

30759

5

1

6

5.56

45

P14618

Pyruvate kinase
isozymes M1/M2
OS=Homo sapiens
GN=PKM2 PE=1 SV=4

228

57900

9

6

20.3

7.96

46

P04004

Vitronectin OS=Homo
sapiens GN=VTN PE=1
SV=1

215

54271

6

1

4.2

5.55

47

P19012

Keratin, type I
cytoskeletal 15
OS=Homo sapiens
GN=KRT15 PE=1 SV=3

210

49181

14

6

10.3

4.71

48

Q15582

Transforming growth
factor-beta-induced
protein ig-h3 OS=Homo
sapiens GN=TGFBI
PE=1 SV=1

196

74634

8

7

16.1

7.62

49

P36955

Pigment epitheliumderived factor OS=Homo
sapiens GN=SERPINF1
PE=1 SV=4

188

46283

7

3

12

5.97

50

Q99715

Collagen alpha-1(XII)
chain OS=Homo sapiens
GN=COL12A1 PE=1
SV=2

176

332941

8

5

4.9

5.38

51

P07900

Heat shock protein HSP
90-alpha OS=Homo
sapiens GN=HSP90AA1
PE=1 SV=5

175

84607

8

4

12.8

4.94

52

P02675

Fibrinogen beta chain
OS=Homo sapiens
GN=FGB PE=1 SV=2

174

55892

7

4

6.7

8.54

53

P02042

Hemoglobin subunit
delta OS=Homo sapiens
GN=HBD PE=1 SV=2

171

16045

9

2

12.9

7.85

54

P11717

Cation-independent
mannose-6-phosphate
receptor OS=Homo
sapiens GN=IGF2R
PE=1 SV=3

163

274199

5

2

0.8

5.64

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 29

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

55

P51884

Lumican OS=Homo
sapiens GN=LUM PE=1
SV=2

161

38405

9

3

12.4

6.16

56

P08697

Alpha-2-antiplasmin
OS=Homo sapiens
GN=SERPINF2 PE=1
SV=3

158

54531

2

1

2.2

5.87

57

P12259

Coagulation factor V
OS=Homo sapiens
GN=F5 PE=1 SV=4

153

251546

9

6

3.5

5.68

58

P08107

Heat shock 70 kDa
protein 1A/1B
OS=Homo sapiens
GN=HSPA1A PE=1
SV=5

147

70009

3

3

6.2

5.48

59

P17066

Heat shock 70 kDa
protein 6 OS=Homo
sapiens GN=HSPA6
PE=1 SV=2

147

70984

3

3

6.2

5.81

60

P19013

Keratin, type II
cytoskeletal 4 OS=Homo
sapiens GN=KRT4 PE=1
SV=4

146

57250

6

4

7.3

6.25

61

Q8TAA3

Proteasome subunit
alpha type-7-like
OS=Homo sapiens
GN=PSMA8 PE=1
SV=3

144

28512

4

3

19.5

9.07

62

Q5XKE5

Keratin, type II
cytoskeletal 79
OS=Homo sapiens
GN=KRT79 PE=1 SV=2

138

57800

7

3

6.9

6.75

63

P0C0S8

Histone H2A type 1
OS=Homo sapiens
GN=HIST1H2AG PE=1
SV=2

136

14083

3

2

21.5

10.9

64

Q99816

Tumor susceptibility
gene 101 protein
OS=Homo sapiens
GN=TSG101 PE=1
SV=2

135

43916

4

2

21.8

8.2

65

P23526

Adenosylhomocysteinase
OS=Homo sapiens
GN=AHCY PE=1 SV=4

134

47685

3

2

9.5

5.92

66

P00747

Plasminogen OS=Homo
sapiens GN=PLG PE=1
SV=2

132

90510

7

4

5.3

7.04

67

O95678

Keratin, type II
cytoskeletal 75
OS=Homo sapiens
GN=KRT75 PE=1 SV=2

132

59524

7

3

7.8

7.6

68

P13639

Elongation factor 2
OS=Homo sapiens
GN=EEF2 PE=1 SV=4

132

95277

6

4

10.3

6.41

69

Q9UBG0

C-type mannose receptor
2 OS=Homo sapiens
GN=MRC2 PE=1 SV=2

128

166568

2

2

1.6

5.54

70

Q15063

Periostin OS=Homo
sapiens GN=POSTN
PE=1 SV=2

127

93255

6

3

10.3

7.27

71

P62805

Histone H4 OS=Homo
sapiens GN=HIST1H4A
PE=1 SV=2

127

11360

5

4

38.8

11.36

72

P01008

Antithrombin-III
OS=Homo sapiens
GN=SERPINC1 PE=1
SV=1

126

52569

13

3

14.9

6.32

73

P19827

Inter-alpha-trypsin
inhibitor heavy chain H1
OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

124

101326

4

3

2.9

6.31

74

P11142

Heat shock cognate 71
kDa protein OS=Homo
sapiens GN=HSPA8
PE=1 SV=1

123

70854

4

4

7.6

5.37

75

P08729

Keratin, type II
cytoskeletal 7 OS=Homo
sapiens GN=KRT7 PE=1
SV=5

123

51354

4

2

5.1

5.4

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 30

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

76

P02794

Ferritin heavy chain
OS=Homo sapiens
GN=FTH1 PE=1 SV=2

122

21212

4

3

16.4

5.3

77

P05787

Keratin, type II
cytoskeletal 8 OS=Homo
sapiens GN=KRT8 PE=1
SV=7

122

53671

4

2

5.6

5.52

78

P01031

Complement C5
OS=Homo sapiens
GN=C5 PE=1 SV=4

122

188186

5

3

2.6

6.11

79

Q5VTE0

Putative elongation
factor 1-alpha-like 3
OS=Homo sapiens
GN=EEF1A1P5 PE=5
SV=1

121

50153

4

3

14.1

9.15

80

P05452

Tetranectin OS=Homo
sapiens GN=CLEC3B
PE=1 SV=3

121

22522

5

3

28.7

5.52

81

P49327

Fatty acid synthase
OS=Homo sapiens
GN=FASN PE=1 SV=3

119

273254

5

3

3.3

6.01

82

P07195

L-lactate dehydrogenase
B chain OS=Homo
sapiens GN=LDHB
PE=1 SV=2

118

36615

2

2

6.9

5.71

83

Q9H4B7

Tubulin beta-1 chain
OS=Homo sapiens
GN=TUBB1 PE=1
SV=1

112

50295

5

3

11.8

5.05

84

P15531

Nucleoside diphosphate
kinase A OS=Homo
sapiens GN=NME1
PE=1 SV=1

111

17138

1

1

11.2

5.83

85

Q7Z3Y8

Keratin, type I
cytoskeletal 27
OS=Homo sapiens
GN=KRT27 PE=1 SV=2

109

49792

7

2

7.6

4.98

86

P08238

Heat shock protein HSP
90-beta OS=Homo
sapiens GN=HSP90AB1
PE=1 SV=4

109

83212

4

2

6.2

4.97

87

P08123

Collagen alpha-2(I)
chain OS=Homo sapiens
GN=COL1A2 PE=1
SV=7

105

129235

2

2

2.3

9.08

88

Q86YZ3

Hornerin OS=Homo
sapiens GN=HRNR
PE=1 SV=2

101

282228

1

1

0.6

10.05

89

P02452

Collagen alpha-1(I)
chain OS=Homo sapiens
GN=COL1A1 PE=1
SV=5

99

138857

4

2

3

5.6

90

P04075

Fructose-bisphosphate
aldolase A OS=Homo
sapiens GN=ALDOA
PE=1 SV=2

98

39395

2

2

6.9

8.3

91

P02787

Serotransferrin
OS=Homo sapiens
GN=TF PE=1 SV=3

97

77014

4

2

1.7

6.81

92

P02748

Complement component
C9 OS=Homo sapiens
GN=C9 PE=1 SV=2

95

63133

3

2

3.8

5.43

93

Q8TEV9_REVERSED

Smith-Magenis
syndrome chromosomal
region candidate gene 8
protein OS=Homo
sapiens GN=SMCR8
PE=1 SV=2 REVERSED

91

104956

12

1

1.2

5.36

94

P02461

Collagen alpha-1(III)
chain OS=Homo sapiens
GN=COL3A1 PE=1
SV=4

90

138479

2

2

1.6

6.21

95

P00450

Ceruloplasmin
OS=Homo sapiens
GN=CP PE=1 SV=1

88

122128

3

3

2.9

5.44

96

P62979

Ubiquitin-40S ribosomal
protein S27a OS=Homo
sapiens GN=RPS27A
PE=1 SV=2

88

17953

4

3

19.9

9.68

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 31

Author Manuscript

E10

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

97

Q14697

Neutral alphaglucosidase AB
OS=Homo sapiens
GN=GANAB PE=1
SV=3

84

106807

2

2

3.9

5.74

98

Q08431

Lactadherin OS=Homo
sapiens GN=MFGE8
PE=1 SV=2

83

43095

2

1

3.9

8.47

99

A6NMY6

Putative annexin A2-like
protein OS=Homo
sapiens GN=ANXA2P2
PE=5 SV=2

82

38635

2

2

6.2

6.49

100

P07355

Annexin A2 OS=Homo
sapiens GN=ANXA2
PE=1 SV=2

82

38580

3

2

10.3

7.57

101

Q9BYX7_REVERSED

Putative beta-actin-like
protein 3 OS=Homo
sapiens GN=POTEKP
PE=5 SV=1 REVERSED

80

41989

4

1

3.5

5.92

102

Q8NI35

InaD-like protein
OS=Homo sapiens
GN=INADL PE=1 SV=3

79

196247

8

1

0.3

4.84

103

P15169

Carboxypeptidase N
catalytic chain
OS=Homo sapiens
GN=CPN1 PE=1 SV=1

79

52253

1

1

3.3

6.86

104

P28074

Proteasome subunit beta
type-5 OS=Homo
sapiens GN=PSMB5
PE=1 SV=3

79

28462

2

2

8.7

6.43

105

P49720

Proteasome subunit beta
type-3 OS=Homo
sapiens GN=PSMB3
PE=1 SV=2

78

22933

3

2

16.6

6.14

106

Q04756

Hepatocyte growth factor
activator OS=Homo
sapiens GN=HGFAC
PE=1 SV=1

77

70636

1

1

2.4

6.99

107

Q12931

Heat shock protein 75
kDa, mitochondrial
OS=Homo sapiens
GN=TRAP1 PE=1 SV=3

76

80060

1

1

2

8.3

108

P05121

Plasminogen activator
inhibitor 1 OS=Homo
sapiens GN=SERPINE1
PE=1 SV=1

76

45031

4

2

7

6.68

109

P20618

Proteasome subunit beta
type-1 OS=Homo
sapiens GN=PSMB1
PE=1 SV=2

74

26472

2

2

13.3

8.27

110

Q14624

Inter-alpha-trypsin
inhibitor heavy chain H4
OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

73

103293

4

1

1.9

6.51

111

Q5D862

Filaggrin-2 OS=Homo
sapiens GN=FLG2 PE=1
SV=1

72

247928

1

1

0.5

8.45

112

P06733

Alpha-enolase
OS=Homo sapiens
GN=ENO1 PE=1 SV=2

71

47139

3

2

10.1

7.01

113

P02790

Hemopexin OS=Homo
sapiens GN=HPX PE=1
SV=2

70

51643

7

1

5.4

6.55

114

P35442

Thrombospondin-2
OS=Homo sapiens
GN=THBS2 PE=1 SV=2

70

129908

4

2

3.2

4.62

115

P13929

Beta-enolase OS=Homo
sapiens GN=ENO3
PE=1 SV=4

69

46902

2

2

7.6

7.59

116

Q8WW52_REVERSED

Protein FAM151A
OS=Homo sapiens
GN=FAM151A PE=2
SV=2 - REVERSED

69

63987

2

1

1.4

6.2

117

P12110

Collagen alpha-2(VI)
chain OS=Homo sapiens
GN=COL6A2 PE=1
SV=4

69

108512

4

2

3.4

5.85

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 32

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

118

P04083

Annexin A1 OS=Homo
sapiens GN=ANXA1
PE=1 SV=2

68

38690

1

1

3.8

6.57

119

P01009

Alpha-1-antitrypsin
OS=Homo sapiens
GN=SERPINA1 PE=1
SV=3

68

46707

4

1

3.3

5.37

120

P22303

Acetylcholinesterase
OS=Homo sapiens
GN=ACHE PE=1 SV=1

67

67753

1

1

2.1

5.87

121

P55058

Phospholipid transfer
protein OS=Homo
sapiens GN=PLTP PE=1
SV=1

66

54705

1

1

2.2

6.53

122

P00488

Coagulation factor XIII
A chain OS=Homo
sapiens GN=F13A1
PE=1 SV=4

66

83215

1

1

2.2

5.75

123

Q03692

Collagen alpha-1(X)
chain OS=Homo sapiens
GN=COL10A1 PE=1
SV=2

66

66117

1

1

1.9

9.68

124

P05546

Heparin cofactor 2
OS=Homo sapiens
GN=SERPIND1 PE=1
SV=3

65

57034

2

1

2.4

6.41

125

P01266

Thyroglobulin
OS=Homo sapiens
GN=TG PE=1 SV=5

65

304594

3

3

0.8

5.4

126

P00338

L-lactate dehydrogenase
A chain OS=Homo
sapiens GN=LDHA
PE=1 SV=2

63

36665

2

1

8.1

8.44

127

O15111_REVERSED

Inhibitor of nuclear
factor kappa-B kinase
subunit alpha OS=Homo
sapiens GN=CHUK
PE=1 SV=2 REVERSED

63

84585

7

1

1.6

6.28

128

Q8NAV2_REVERSED

Uncharacterized protein
C8orf58 OS=Homo
sapiens GN=C8orf58
PE=2 SV=2 REVERSED

63

39636

3

1

4.1

8.54

129

P28070

Proteasome subunit beta
type-4 OS=Homo
sapiens GN=PSMB4
PE=1 SV=4

62

29185

2

2

7.2

5.72

130

P07686

Beta-hexosaminidase
subunit beta OS=Homo
sapiens GN=HEXB
PE=1 SV=3

61

63071

1

1

2.9

6.29

131

P05543

Thyroxine-binding
globulin OS=Homo
sapiens GN=SERPINA7
PE=1 SV=2

61

46295

2

1

2.4

5.87

132

Q9HDC9

Adipocyte plasma
membrane-associated
protein OS=Homo
sapiens GN=APMAP
PE=1 SV=2

60

46451

3

1

1.7

5.82

133

P25787

Proteasome subunit
alpha type-2 OS=Homo
sapiens GN=PSMA2
PE=1 SV=2

60

25882

1

1

6

6.92

134

P35125

Ubiquitin carboxylterminal hydrolase 6
OS=Homo sapiens
GN=USP6 PE=1 SV=2

60

158557

12

1

0.4

7.87

135

A6NIZ1

Ras-related protein
Rap-1b-like protein
OS=Homo sapiens PE=2
SV=1

59

20912

1

1

6.5

5.37

136

B9A064

Immunoglobulin
lambda-like polypeptide
5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

59

23049

2

1

3.7

9.08

137

Q99456

Keratin, type I
cytoskeletal 12
OS=Homo sapiens
GN=KRT12 PE=1 SV=1

58

53478

6

2

3.6

4.7

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 33

Author Manuscript

E10

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

138

Q86Y46

Keratin, type II
cytoskeletal 73
OS=Homo sapiens
GN=KRT73 PE=1 SV=1

58

58887

5

4

6.7

6.93

139

P20774

Mimecan OS=Homo
sapiens GN=OGN PE=1
SV=1

58

33901

2

2

9.7

5.46

140

Q9Y240

C-type lectin domain
family 11 member A
OS=Homo sapiens
GN=CLEC11A PE=1
SV=1

57

35672

1

1

5.3

5.06

141

P10909

Clusterin OS=Homo
sapiens GN=CLU PE=1
SV=1

57

52461

2

1

7.8

5.89

142

Q9NPY3_REVERSED

Complement component
C1q receptor OS=Homo
sapiens GN=CD93 PE=1
SV=3 - REVERSED

57

68515

2

1

1.1

5.27

143

P81605

Dermcidin OS=Homo
sapiens GN=DCD PE=1
SV=2

56

11277

2

2

22.7

6.08

144

P03973

Antileukoproteinase
OS=Homo sapiens
GN=SLPI PE=1 SV=2

55

14316

1

1

9.1

9.11

145

Q6YHK3

CD109 antigen
OS=Homo sapiens
GN=CD109 PE=1 SV=2

55

161587

2

2

1.8

5.59

146

P04180

Phosphatidylcholinesterol acyltransferase
OS=Homo sapiens
GN=LCAT PE=1 SV=1

55

49546

1

1

2.5

5.71

147

Q9BXJ4

Complement C1q tumor
necrosis factor-related
protein 3 OS=Homo
sapiens GN=C1QTNF3
PE=2 SV=1

55

26977

1

1

5.3

6.04

148

P16070

CD44 antigen OS=Homo
sapiens GN=CD44 PE=1
SV=3

53

81487

1

1

1.6

5.13

149

P02649

Apolipoprotein E
OS=Homo sapiens
GN=APOE PE=1 SV=1

53

36132

1

1

2.8

5.65

150

P29353_REVERSED

SHC-transforming
protein 1 OS=Homo
sapiens GN=SHC1 PE=1
SV=4 - REVERSED

51

62782

6

1

1.4

6.01

151

P35580

Myosin-10 OS=Homo
sapiens GN=MYH10
PE=1 SV=3

51

228858

2

2

1.2

5.44

152

P28066

Proteasome subunit
alpha type-5 OS=Homo
sapiens GN=PSMA5
PE=1 SV=3

50

26394

1

1

4.1

4.74

153

O95445

Apolipoprotein M
OS=Homo sapiens
GN=APOM PE=1 SV=2

49

21239

4

1

6.9

5.66

154

P04745

Alpha-amylase 1
OS=Homo sapiens
GN=AMY1A PE=1
SV=2

49

57731

1

1

2.3

6.47

155

Q13454

Tumor suppressor
candidate 3 OS=Homo
sapiens GN=TUSC3
PE=2 SV=1

49

39650

1

1

2

9.93

156

P49721

Proteasome subunit beta
type-2 OS=Homo
sapiens GN=PSMB2
PE=1 SV=1

49

22822

3

1

19.9

6.51

157

P32119

Peroxiredoxin-2
OS=Homo sapiens
GN=PRDX2 PE=1
SV=5

49

21878

1

1

9.1

5.66

158

Q6ZU45

Putative C-type lectin
domain-containing
protein NCRNA00083
OS=Homo sapiens
GN=NCRNA00083
PE=5 SV=1

49

25796

1

1

3.4

6.3

159

O43264_REVERSED

Centromere/kinetochore
protein zw10 homolog

49

88773

1

1

0.8

5.89

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 34

Author Manuscript

E10
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

OS=Homo sapiens
GN=ZW10 PE=1 SV=3
- REVERSED

Author Manuscript
Author Manuscript
Author Manuscript

160

Q9Y490

Talin-1 OS=Homo
sapiens GN=TLN1 PE=1
SV=3

48

269599

2

2

1

5.77

161

Q96CD0_REVERSED

F-box/LRR-repeat
protein 8 OS=Homo
sapiens GN=FBXL8
PE=1 SV=1 REVERSED

48

40490

11

1

1.9

7.03

162

P06702

Protein S100-A9
OS=Homo sapiens
GN=S100A9 PE=1
SV=1

47

13234

1

1

13.2

5.71

163

Q6P1X5_REVERSED

Transcription initiation
factor TFIID subunit 2
OS=Homo sapiens
GN=TAF2 PE=1 SV=3 REVERSED

47

136883

1

1

0.5

8.46

164

Q16853

Membrane primary
amine oxidase
OS=Homo sapiens
GN=AOC3 PE=1 SV=3

47

84568

1

1

1.2

6.05

165

P00558

Phosphoglycerate kinase
1 OS=Homo sapiens
GN=PGK1 PE=1 SV=3

47

44586

3

1

8.4

8.3

166

P02749

Beta-2-glycoprotein 1
OS=Homo sapiens
GN=APOH PE=1 SV=3

46

38273

1

1

2.6

8.34

167

A8MPT4

Glutathione S-transferase
theta-4 OS=Homo
sapiens GN=GSTT4
PE=3 SV=2

45

27941

2

1

2.5

6.25

168

Q8N6V9_REVERSED

Testis-expressed
sequence 9 protein
OS=Homo sapiens
GN=TEX9 PE=2 SV=1 REVERSED

45

44798

2

1

1.5

6.2

169

Q9Y2U8_REVERSED

Inner nuclear membrane
protein Man1 OS=Homo
sapiens GN=LEMD3
PE=1 SV=2 REVERSED

45

99935

2

1

0.7

7.31

170

P05154

Plasma serine protease
inhibitor OS=Homo
sapiens GN=SERPINA5
PE=1 SV=3

45

45646

2

1

1.5

9.3

171

Q8NDM7_REVERSED

WD repeat-containing
protein 96 OS=Homo
sapiens GN=WDR96
PE=2 SV=3 REVERSED

45

191861

1

1

0.5

5.71

172

Q6NXT2

Histone H3.3C
OS=Homo sapiens
GN=H3F3C PE=1 SV=3

44

15204

1

1

5.2

11.1

173

O95248

Myotubularin-related
protein 5 OS=Homo
sapiens GN=SBF1 PE=1
SV=3

44

208184

1

1

0.4

6.46

174

Q9UK61_REVERSED

Uncharacterized protein
C3orf63 OS=Homo
sapiens GN=C3orf63
PE=1 SV=3 REVERSED

44

188914

1

1

0.4

5.55

175

Q9Y6X9_REVERSED

MORC family CW-type
zinc finger protein 2
OS=Homo sapiens
GN=MORC2 PE=1
SV=2 - REVERSED

43

117750

2

1

1.6

8.6

176

P06746

DNA polymerase beta
OS=Homo sapiens
GN=POLB PE=1 SV=3

43

38154

1

1

1.8

9.01

177

Q92820

Gamma-glutamyl
hydrolase OS=Homo
sapiens GN=GGH PE=1
SV=2

43

35941

1

1

4.1

6.67

178

Q9TNN7

HLA class I
histocompatibility
antigen, Cw-5 alpha
chain OS=Homo sapiens
GN=HLA-C PE=2 SV=1

43

40886

1

1

3.6

7.11

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 35

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

179

Q12968_REVERSED

Nuclear factor of
activated T-cells,
cytoplasmic 3 OS=Homo
sapiens GN=NFATC3
PE=1 SV=1 REVERSED

41

115522

3

1

0.7

5.91

180

Q96M89

Coiled-coil domaincontaining protein 138
OS=Homo sapiens
GN=CCDC138 PE=1
SV=1

41

76171

2

1

2.3

8.75

181

Q9Y5E4_REVERSED

Protocadherin beta-5
OS=Homo sapiens
GN=PCDHB5 PE=1
SV=1 - REVERSED

41

86369

2

1

1

4.87

182

Q9NU02_REVERSED

Ankyrin repeat domaincontaining protein 5
OS=Homo sapiens
GN=ANKRD5 PE=2
SV=2 - REVERSED

41

86610

2

1

1.8

8.51

183

Q7Z5M8

Abhydrolase domaincontaining protein 12B
OS=Homo sapiens
GN=ABHD12B PE=2
SV=1

41

40750

4

1

1.7

8.57

184

Q15020_REVERSED

Squamous cell
carcinoma antigen
recognized by T-cells 3
OS=Homo sapiens
GN=SART3 PE=1 SV=1
- REVERSED

41

109865

4

1

0.6

5.45

185

P10643

Complement component
C7 OS=Homo sapiens
GN=C7 PE=1 SV=2

41

93457

2

1

2

6.09

186

P61769

Beta-2-microglobulin
OS=Homo sapiens
GN=B2M PE=1 SV=1

40

13706

1

1

8.4

6.06

187

Q9BY43

Charged multivesicular
body protein 4a
OS=Homo sapiens
GN=CHMP4A PE=1
SV=3

40

25083

2

1

6.3

4.65

188

O60312

Probable phospholipidtransporting ATPase VA
OS=Homo sapiens
GN=ATP10A PE=2
SV=2

40

167582

2

1

0.6

8.7

189

Q8NBM4

Ubiquitin-associated
domain-containing
protein 2 OS=Homo
sapiens GN=UBAC2
PE=2 SV=1

40

38938

2

1

2.3

9.21

190

Q99798

Aconitate hydratase,
mitochondrial OS=Homo
sapiens GN=ACO2
PE=1 SV=2

40

85372

1

1

1

7.36

191

Q14849

StAR-related lipid
transfer protein 3
OS=Homo sapiens
GN=STARD3 PE=1
SV=2

40

50471

1

1

1.6

8.52

192

Q8NFY9

Kelch repeat and BTB
domain-containing
protein 8 OS=Homo
sapiens GN=KBTBD8
PE=2 SV=2

39

68778

1

1

1.8

5.88

193

Q96K21

Zinc finger FYVE
domain-containing
protein 19 OS=Homo
sapiens GN=ZFYVE19
PE=1 SV=3

39

51514

1

1

1.7

5.57

194

P02760

Protein AMBP
OS=Homo sapiens
GN=AMBP PE=1 SV=1

39

38974

1

1

2

5.95

195

P53675_REVERSED

Clathrin heavy chain 2
OS=Homo sapiens
GN=CLTCL1 PE=1
SV=2 - REVERSED

39

186910

1

1

0.5

5.57

196

P0C869

Cytosolic phospholipase
A2 beta OS=Homo
sapiens GN=PLA2G4B
PE=1 SV=2

39

87922

2

1

1

5.64

197

Q8WUM4

Programmed cell death
6-interacting protein

39

95963

1

1

1.6

6.13

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 36

Author Manuscript

E10
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

OS=Homo sapiens
GN=PDCD6IP PE=1
SV=1

Author Manuscript
Author Manuscript
Author Manuscript

198

P05156

Complement factor I
OS=Homo sapiens
GN=CFI PE=1 SV=2

39

65707

1

1

1.2

7.72

199

P00736

Complement C1r
subcomponent
OS=Homo sapiens
GN=C1R PE=1 SV=2

39

80067

2

1

3.4

5.82

200

Q00535_REVERSED

Cyclin-dependent kinase
5 OS=Homo sapiens
GN=CDK5 PE=1 SV=3
- REVERSED

38

33283

1

1

3.1

7.9

201

Q9ULT0

Tetratricopeptide repeat
protein 7A OS=Homo
sapiens GN=TTC7A
PE=1 SV=3

38

96123

2

1

1.2

6.03

202

P25786

Proteasome subunit
alpha type-1 OS=Homo
sapiens GN=PSMA1
PE=1 SV=1

38

29537

1

1

4.6

6.15

203

Q9Y2C9_REVERSED

Toll-like receptor 6
OS=Homo sapiens
GN=TLR6 PE=2 SV=2 REVERSED

38

91820

1

1

1

6.83

204

Q14C86_REVERSED

GTPase-activating
protein and VPS9
domain-containing
protein 1 OS=Homo
sapiens GN=GAPVD1
PE=1 SV=2 REVERSED

38

164876

2

1

0.5

5.09

205

Q5T1B0

Axonemal dynein light
chain domain-containing
protein 1 OS=Homo
sapiens GN=AXDND1
PE=1 SV=1

38

117953

1

1

0.6

5.49

206

Q9P2G4_REVERSED

Uncharacterized protein
KIAA1383 OS=Homo
sapiens GN=KIAA1383
PE=1 SV=2 REVERSED

38

100283

1

1

0.8

6.77

207

Q6NUP7

Serine/threonine-protein
phosphatase 4 regulatory
subunit 4 OS=Homo
sapiens GN=PPP4R4
PE=1 SV=1

38

99389

2

1

0.7

7.96

208

Q16348

Solute carrier family 15
member 2 OS=Homo
sapiens GN=SLC15A2
PE=2 SV=2

38

81730

3

1

1.5

8.4

209

Q9P2E9

Ribosome-binding
protein 1 OS=Homo
sapiens GN=RRBP1
PE=1 SV=4

38

152381

1

1

0.4

8.69

210

P04920

Anion exchange protein
2 OS=Homo sapiens
GN=SLC4A2 PE=1
SV=4

38

136923

1

1

0.5

5.9

211

Q99819

Rho GDP-dissociation
inhibitor 3 OS=Homo
sapiens GN=ARHGDIG
PE=2 SV=2

38

25082

1

1

2.7

5.45

212

O95071_REVERSED

E3 ubiquitin-protein
ligase UBR5 OS=Homo
sapiens GN=UBR5
PE=1 SV=2 REVERSED

38

309158

2

1

0.3

5.59

213

P22352

Glutathione peroxidase 3
OS=Homo sapiens
GN=GPX3 PE=1 SV=2

37

25537

1

1

5.3

8.26

214

P29401

Transketolase OS=Homo
sapiens GN=TKT PE=1
SV=3

37

67835

1

1

2.9

7.58

215

P35443

Thrombospondin-4
OS=Homo sapiens
GN=THBS4 PE=1 SV=2

37

105802

1

1

1

4.44

216

Q14028_REVERSED

Cyclic nucleotide-gated
cation channel beta-1
OS=Homo sapiens
GN=CNGB1 PE=1
SV=2 - REVERSED

37

139590

2

1

0.6

4.76

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 37

Author Manuscript

E10
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

217

Q14573_REVERSED

Inositol 1,4,5trisphosphate receptor
type 3 OS=Homo
sapiens GN=ITPR3
PE=1 SV=2 REVERSED

37

303912

2

1

0.4

6.05

218

Q9C0B2

Uncharacterized protein
KIAA1751 OS=Homo
sapiens GN=KIAA1751
PE=2 SV=2

37

86902

2

1

1.6

5.39

219

Q6ZUT9_REVERSED

DENN domaincontaining protein 5B
OS=Homo sapiens
GN=DENND5B PE=1
SV=2 - REVERSED

37

144927

2

1

1

6.29

220

O94991

SLIT and NTRK-like
protein 5 OS=Homo
sapiens GN=SLITRK5
PE=1 SV=2

37

107418

2

1

1.4

6.48

221

O94868_REVERSED

FCH and double SH3
domains protein 2
OS=Homo sapiens
GN=FCHSD2 PE=1
SV=3 - REVERSED

37

84224

2

1

1.9

5.55

222

Q4G0X9_REVERSED

Coiled-coil domaincontaining protein 40
OS=Homo sapiens
GN=CCDC40 PE=2
SV=2 - REVERSED

37

130033

1

1

0.5

5.21

223

Q9UC07_REVERSED

Zinc finger protein 69
OS=Homo sapiens
GN=ZNF69 PE=2 SV=2
- REVERSED

37

65718

1

1

1.1

9.13

224

Q9Y496_REVERSED

Kinesin-like protein
KIF3A OS=Homo
sapiens GN=KIF3A
PE=1 SV=4 REVERSED

37

79991

1

1

0.9

6.16

225

Q14997

Proteasome activator
complex subunit 4
OS=Homo sapiens
GN=PSME4 PE=1 SV=2

37

211199

1

1

0.3

6.45

226

Q92841

Probable ATP-dependent
RNA helicase DDX17
OS=Homo sapiens
GN=DDX17 PE=1
SV=1

37

72326

1

1

0.9

8.82

227

Q8N6K7

Sterile alpha motif
domain-containing
protein 3 OS=Homo
sapiens GN=SAMD3
PE=2 SV=2

37

61197

7

1

2.1

6.67

228

Q9NU22

Midasin OS=Homo
sapiens GN=MDN1
PE=1 SV=2

36

632420

1

1

0.2

5.46

229

A8MW92_REVERSED

PHD finger protein 20like protein 1 OS=Homo
sapiens GN=PHF20L1
PE=1 SV=2 REVERSED

36

114938

1

1

1.3

6.4

230

O95613

Pericentrin OS=Homo
sapiens GN=PCNT
PE=1 SV=4

36

377806

2

1

0.6

5.4

231

P10242_REVERSED

Transcriptional activator
Myb OS=Homo sapiens
GN=MYB PE=1 SV=2 REVERSED

36

72296

3

1

1.3

6.35

232

Q7L8A9

Vasohibin-1 OS=Homo
sapiens GN=VASH1
PE=1 SV=1

36

40931

1

1

1.9

9.5

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

16183

262460

423

86

66

5.46

HDF
prot_hit

prot_acc

prot_desc

1

P02751

Fibronectin OS=Homo sapiens
GN=FN1 PE=1 SV=4

2

P07996

Thrombospondin-1 OS=Homo sapiens
GN=THBS1 PE=1 SV=2

3990

129300

115

42

49.4

4.71

3

P12111

Collagen alpha-3(VI) chain OS=Homo
sapiens GN=COL6A3 PE=1 SV=5

3014

343457

118

59

33.3

6.26

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 38

Author Manuscript

HDF
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

4

P02768

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

2557

69321

114

8

11.8

5.92

5

P02765

Alpha-2-HS-glycoprotein OS=Homo
sapiens GN=AHSG PE=1 SV=1

2385

39300

60

4

8.7

5.43

6

P04264

Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6

2277

65999

62

25

51.1

8.15

7

P13645

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10 PE=1
SV=6

2109

58792

64

27

54.8

5.13

8

P03956

Interstitial collagenase OS=Homo
sapiens GN=MMP1 PE=1 SV=3

1904

53973

57

20

60.8

6.47

9

P07093

Glia-derived nexin OS=Homo sapiens
GN=SERPINE2 PE=1 SV=1

1820

43974

53

17

59.8

9.35

10

P35908

Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

1740

65393

52

23

56.2

8.07

11

P01023

Alpha-2-macroglobulin OS=Homo
sapiens GN=A2M PE=1 SV=3

1729

163188

56

11

7.5

6.03

12

P24821

Tenascin OS=Homo sapiens GN=TNC
PE=1 SV=3

1664

240700

47

31

25.3

4.79

13

P35527

Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3

1625

62027

36

20

62.6

5.14

14

P08253

72 kDa type IV collagenase
OS=Homo sapiens GN=MMP2 PE=1
SV=2

1609

73835

50

24

60.5

5.26

15

P20742

Pregnancy zone protein OS=Homo
sapiens GN=PZP PE=1 SV=4

1393

163760

42

5

4

5.97

16

P43235

Cathepsin K OS=Homo sapiens
GN=CTSK PE=1 SV=1

1336

36942

26

9

53.5

8.72

17

P01024

Complement C3 OS=Homo sapiens
GN=C3 PE=1 SV=2

1296

187030

53

13

15.4

6.02

18

P60709

Actin, cytoplasmic 1 OS=Homo
sapiens GN=ACTB PE=1 SV=1

951

41710

31

14

47.5

5.29

19

P12109

Collagen alpha-1(VI) chain OS=Homo
sapiens GN=COL6A1 PE=1 SV=3

940

108462

21

13

19.6

5.26

20

P98160

Basement membrane-specific heparan
sulfate proteoglycan core protein
OS=Homo sapiens GN=HSPG2 PE=1
SV=4

933

468532

48

30

13.6

6.06

21

P00734

Prothrombin OS=Homo sapiens
GN=F2 PE=1 SV=2

818

69992

18

8

10.9

5.64

22

P19823

Inter-alpha-trypsin inhibitor heavy
chain H2 OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

799

106397

24

8

9.3

6.4

23

P06396

Gelsolin OS=Homo sapiens GN=GSN
PE=1 SV=1

746

85644

26

11

14.3

5.9

24

P26022

Pentraxin-related protein PTX3
OS=Homo sapiens GN=PTX3 PE=1
SV=3

727

41949

16

8

30.2

4.94

25

P36955

Pigment epithelium-derived factor
OS=Homo sapiens GN=SERPINF1
PE=1 SV=4

680

46283

23

5

12.2

5.97

26

Q08380

Galectin-3-binding protein OS=Homo
sapiens GN=LGALS3BP PE=1 SV=1

667

65289

21

12

30.3

5.13

27

Q15582

Transforming growth factor-betainduced protein ig-h3 OS=Homo
sapiens GN=TGFBI PE=1 SV=1

604

74634

17

14

28.8

7.62

28

Q99715

Collagen alpha-1(XII) chain
OS=Homo sapiens GN=COL12A1
PE=1 SV=2

550

332941

23

19

11.7

5.38

29

Q14393

Growth arrest-specific protein 6
OS=Homo sapiens GN=GAS6 PE=1
SV=2

527

79625

16

10

19.4

5.84

30

P68032

Actin, alpha cardiac muscle 1
OS=Homo sapiens GN=ACTC1 PE=1
SV=1

521

41992

19

9

26.8

5.23

31

Q07954

Prolow-density lipoprotein receptorrelated protein 1 OS=Homo sapiens
GN=LRP1 PE=1 SV=2

455

504276

16

13

4.5

5.16

32

P02771

Alpha-fetoprotein OS=Homo sapiens
GN=AFP PE=1 SV=1

433

68633

13

4

6.7

5.48

33

P12110

Collagen alpha-2(VI) chain OS=Homo
sapiens GN=COL6A2 PE=1 SV=4

430

108512

19

12

18.1

5.85

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 39

Author Manuscript

HDF
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

34

P02788

Lactotransferrin OS=Homo sapiens
GN=LTF PE=1 SV=6

429

78132

18

3

4.8

8.5

35

P0C0L4

Complement C4-A OS=Homo sapiens
GN=C4A PE=1 SV=1

405

192650

15

8

5.6

6.65

36

P08254

Stromelysin-1 OS=Homo sapiens
GN=MMP3 PE=1 SV=2

403

53943

15

9

24.9

5.77

37

P69905

Hemoglobin subunit alpha OS=Homo
sapiens GN=HBA1 PE=1 SV=2

386

15248

18

5

34.5

8.72

38

P02533

Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4

376

51529

13

9

23.5

5.09

39

P35442

Thrombospondin-2 OS=Homo sapiens
GN=THBS2 PE=1 SV=2

331

129908

13

8

9.2

4.62

40

P04406

Glyceraldehyde-3-phosphate
dehydrogenase OS=Homo sapiens
GN=GAPDH PE=1 SV=3

323

36030

9

5

26.3

8.57

41

P05121

Plasminogen activator inhibitor 1
OS=Homo sapiens GN=SERPINE1
PE=1 SV=1

323

45031

12

9

41.5

6.68

42

Q562R1

Beta-actin-like protein 2 OS=Homo
sapiens GN=ACTBL2 PE=1 SV=2

320

41976

11

4

13

5.39

43

Q8WUJ3

Protein KIAA1199 OS=Homo sapiens
GN=KIAA1199 PE=1 SV=2

308

152900

13

9

12

7.98

44

O00391

Sulfhydryl oxidase 1 OS=Homo
sapiens GN=QSOX1 PE=1 SV=3

301

82526

9

6

14.5

9.13

45

P07355

Annexin A2 OS=Homo sapiens
GN=ANXA2 PE=1 SV=2

298

38580

8

6

31

7.57

46

Q06033

Inter-alpha-trypsin inhibitor heavy
chain H3 OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

294

99787

11

4

8.8

5.49

47

P07339

Cathepsin D OS=Homo sapiens
GN=CTSD PE=1 SV=1

282

44524

13

7

25.2

6.1

48

Q08431

Lactadherin OS=Homo sapiens
GN=MFGE8 PE=1 SV=2

281

43095

12

8

26.6

8.47

49

P08123

Collagen alpha-2(I) chain OS=Homo
sapiens GN=COL1A2 PE=1 SV=7

262

129235

7

7

8.4

9.08

50

P15144

Aminopeptidase N OS=Homo sapiens
GN=ANPEP PE=1 SV=4

254

109471

12

6

13

5.31

51

P08758

Annexin A5 OS=Homo sapiens
GN=ANXA5 PE=1 SV=2

249

35914

9

5

19.1

4.94

52

P13647

Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3

246

62340

14

7

14.6

7.59

53

P02774

Vitamin D-binding protein OS=Homo
sapiens GN=GC PE=1 SV=1

244

52929

9

5

12

5.4

54

P51884

Lumican OS=Homo sapiens
GN=LUM PE=1 SV=2

239

38405

14

6

21.9

6.16

55

Q13219

Pappalysin-1 OS=Homo sapiens
GN=PAPPA PE=1 SV=3

238

180856

6

4

6.1

5.76

56

P14618

Pyruvate kinase isozymes M1/M2
OS=Homo sapiens GN=PKM2 PE=1
SV=4

238

57900

7

7

21.3

7.96

57

P11142

Heat shock cognate 71 kDa protein
OS=Homo sapiens GN=HSPA8 PE=1
SV=1

234

70854

5

5

10.2

5.37

58

P04114

Apolipoprotein B-100 OS=Homo
sapiens GN=APOB PE=1 SV=2

231

515283

15

6

2.2

6.58

59

P98095

Fibulin-2 OS=Homo sapiens
GN=FBLN2 PE=1 SV=2

221

126489

7

4

8.4

4.73

60

P04259

Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B PE=1
SV=5

216

60030

12

5

10.1

8.09

61

Q15063

Periostin OS=Homo sapiens
GN=POSTN PE=1 SV=2

215

93255

11

7

15.1

7.27

62

P00747

Plasminogen OS=Homo sapiens
GN=PLG PE=1 SV=2

212

90510

9

5

8.5

7.04

63

P12259

Coagulation factor V OS=Homo
sapiens GN=F5 PE=1 SV=4

210

251546

10

6

4.2

5.68

64

Q16363

Laminin subunit alpha-4 OS=Homo
sapiens GN=LAMA4 PE=1 SV=4

210

202397

4

3

4.1

5.89

65

P04004

Vitronectin OS=Homo sapiens
GN=VTN PE=1 SV=1

209

54271

4

1

3.1

5.55

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 40

Author Manuscript

HDF
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

66

P55268

Laminin subunit beta-2 OS=Homo
sapiens GN=LAMB2 PE=1 SV=2

207

195854

11

6

6.4

6.07

67

P02647

Apolipoprotein A-I OS=Homo sapiens
GN=APOA1 PE=1 SV=1

204

30759

4

1

6

5.56

68

P23142

Fibulin-1 OS=Homo sapiens
GN=FBLN1 PE=1 SV=4

202

77162

11

5

10.2

5.07

69

Q9Y6C2

EMILIN-1 OS=Homo sapiens
GN=EMILIN1 PE=1 SV=2

198

106601

5

4

8.8

5.07

70

Q99816

Tumor susceptibility gene 101 protein
OS=Homo sapiens GN=TSG101
PE=1 SV=2

60

43916

15

5

19.2

5.2

71

P05543

Thyroxine-binding globulin
OS=Homo sapiens GN=SERPINA7
PE=1 SV=2

197

46295

6

3

8.2

5.87

72

Q13510

Acid ceramidase OS=Homo sapiens
GN=ASAH1 PE=1 SV=5

197

44631

5

5

18.5

7.52

73

P02452

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

188

138857

8

4

5.2

5.6

74

P11047

Laminin subunit gamma-1 OS=Homo
sapiens GN=LAMC1 PE=1 SV=3

179

177489

6

4

3.8

5.01

75

P02042

Hemoglobin subunit delta OS=Homo
sapiens GN=HBD PE=1 SV=2

176

16045

11

2

12.9

7.85

76

P35443

Thrombospondin-4 OS=Homo sapiens
GN=THBS4 PE=1 SV=2

171

105802

6

5

7.3

4.44

77

P49747

Cartilage oligomeric matrix protein
OS=Homo sapiens GN=COMP PE=1
SV=2

167

82808

6

5

7.1

4.36

78

P19827

Inter-alpha-trypsin inhibitor heavy
chain H1 OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

166

101326

3

3

2.9

6.31

79

P06733

Alpha-enolase OS=Homo sapiens
GN=ENO1 PE=1 SV=2

165

47139

4

3

12

7.01

80

P13929

Beta-enolase OS=Homo sapiens
GN=ENO3 PE=1 SV=4

163

46902

2

2

7.6

7.59

81

P01031

Complement C5 OS=Homo sapiens
GN=C5 PE=1 SV=4

162

188186

7

4

3

6.11

82

P02538

Keratin, type II cytoskeletal 6A
OS=Homo sapiens GN=KRT6A PE=1
SV=3

159

60008

9

4

9.9

8.09

83

P02100

Hemoglobin subunit epsilon
OS=Homo sapiens GN=HBE1 PE=1
SV=2

159

16192

7

2

12.9

8.67

84

P07858

Cathepsin B OS=Homo sapiens
GN=CTSB PE=1 SV=3

159

37797

5

4

15

5.88

85

Q6YHK3

CD109 antigen OS=Homo sapiens
GN=CD109 PE=1 SV=2

158

161587

6

5

5.3

5.59

86

P42785

Lysosomal Pro-X carboxypeptidase
OS=Homo sapiens GN=PRCP PE=1
SV=1

155

55764

2

1

4.2

6.75

87

P02649

Apolipoprotein E OS=Homo sapiens
GN=APOE PE=1 SV=1

154

36132

6

3

9.1

5.65

88

P02794

Ferritin heavy chain OS=Homo
sapiens GN=FTH1 PE=1 SV=2

154

21212

5

4

38.3

5.3

89

P02675

Fibrinogen beta chain OS=Homo
sapiens GN=FGB PE=1 SV=2

154

55892

3

2

3.9

8.54

90

Q92626

Peroxidasin homolog OS=Homo
sapiens GN=PXDN PE=1 SV=2

153

165170

5

4

4.9

6.79

91

P08697

Alpha-2-antiplasmin OS=Homo
sapiens GN=SERPINF2 PE=1 SV=3

150

54531

2

1

2.2

5.87

92

P00736

Complement C1r subcomponent
OS=Homo sapiens GN=C1R PE=1
SV=2

150

80067

6

5

13

5.82

93

Q9Y4K0

Lysyl oxidase homolog 2 OS=Homo
sapiens GN=LOXL2 PE=1 SV=1

148

86668

3

3

5.7

5.95

94

Q13103

Secreted phosphoprotein 24
OS=Homo sapiens GN=SPP2 PE=1
SV=1

147

24322

2

1

5.7

8.59

95

P34931

Heat shock 70 kDa protein 1-like
OS=Homo sapiens GN=HSPA1L
PE=1 SV=2

145

70331

3

3

7

5.76

96

P04083

Annexin A1 OS=Homo sapiens
GN=ANXA1 PE=1 SV=2

141

38690

3

3

16.2

6.57

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 41

Author Manuscript

HDF

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

97

Q9Y490

Talin-1 OS=Homo sapiens GN=TLN1
PE=1 SV=3

140

269599

7

4

4.2

5.77

98

P68363

Tubulin alpha-1B chain OS=Homo
sapiens GN=TUBA1B PE=1 SV=1

139

50120

8

4

19.7

4.94

99

P15169

Carboxypeptidase N catalytic chain
OS=Homo sapiens GN=CPN1 PE=1
SV=1

139

52253

2

1

3.3

6.86

100

P07686

Beta-hexosaminidase subunit beta
OS=Homo sapiens GN=HEXB PE=1
SV=3

137

63071

8

3

15.8

6.29

101

P02748

Complement component C9
OS=Homo sapiens GN=C9 PE=1
SV=2

135

63133

3

2

3.8

5.43

102

P19013

Keratin, type II cytoskeletal 4
OS=Homo sapiens GN=KRT4 PE=1
SV=4

130

57250

8

4

7.3

6.25

103

P07437

Tubulin beta chain OS=Homo sapiens
GN=TUBB PE=1 SV=2

129

49639

6

4

18.5

4.78

104

Q9Y240

C-type lectin domain family 11
member A OS=Homo sapiens
GN=CLEC11A PE=1 SV=1

128

35672

3

1

8

5.06

105

P51888

Prolargin OS=Homo sapiens
GN=PRELP PE=1 SV=1

124

43782

6

4

15.2

9.47

106

Q9UBG0

C-type mannose receptor 2 OS=Homo
sapiens GN=MRC2 PE=1 SV=2

123

166568

1

1

1.1

5.54

107

P00742

Coagulation factor X OS=Homo
sapiens GN=F10 PE=1 SV=2

122

54697

5

3

7.6

5.68

108

Q86YZ3

Hornerin OS=Homo sapiens
GN=HRNR PE=1 SV=2

115

282228

1

1

0.7

10.05

109

P13646

Keratin, type I cytoskeletal 13
OS=Homo sapiens GN=KRT13 PE=1
SV=4

112

49557

5

4

6.1

4.91

110

P09871

Complement C1s subcomponent
OS=Homo sapiens GN=C1S PE=1
SV=1

111

76635

5

4

6.8

4.86

111

P10619

Lysosomal protective protein
OS=Homo sapiens GN=CTSA PE=1
SV=2

106

54431

4

3

12.5

6.16

112

P62979

Ubiquitin-40S ribosomal protein S27a
OS=Homo sapiens GN=RPS27A
PE=1 SV=2

100

17953

7

3

28.2

9.68

113

Q02809

Procollagen-lysine,2-oxoglutarate 5dioxygenase 1 OS=Homo sapiens
GN=PLOD1 PE=1 SV=2

98

83497

4

2

8.4

6.47

114

P07602

Proactivator polypeptide OS=Homo
sapiens GN=PSAP PE=1 SV=2

96

58074

4

3

7.6

5.06

115

P07900

Heat shock protein HSP 90-alpha
OS=Homo sapiens GN=HSP90AA1
PE=1 SV=5

96

84607

5

2

5.9

4.94

116

P49746

Thrombospondin-3 OS=Homo sapiens
GN=THBS3 PE=1 SV=1

94

104135

7

2

8.1

4.43

117

P08294

Extracellular superoxide dismutase
[Cu-Zn] OS=Homo sapiens
GN=SOD3 PE=1 SV=2

94

25835

1

1

5.4

6.14

118

P00450

Ceruloplasmin OS=Homo sapiens
GN=CP PE=1 SV=1

94

122128

3

1

2

5.44

119

P08473

Neprilysin OS=Homo sapiens
GN=MME PE=1 SV=2

93

85460

2

2

3.2

5.54

120

P04745

Alpha-amylase 1 OS=Homo sapiens
GN=AMY1A PE=1 SV=2

91

57731

2

2

5.5

6.47

121

P08238

Heat shock protein HSP 90-beta
OS=Homo sapiens GN=HSP90AB1
PE=1 SV=4

91

83212

3

2

4

4.97

122

P21333

Filamin-A OS=Homo sapiens
GN=FLNA PE=1 SV=4

89

280564

5

3

2.6

5.7

123

Q8NI35

InaD-like protein OS=Homo sapiens
GN=INADL PE=1 SV=3

89

196247

8

1

0.3

4.84

124

P00558

Phosphoglycerate kinase 1 OS=Homo
sapiens GN=PGK1 PE=1 SV=3

88

44586

2

1

7.9

8.3

125

P48723

Heat shock 70 kDa protein 13
OS=Homo sapiens GN=HSPA13
PE=1 SV=1

88

51895

3

3

8.1

5.52

126

Q8TEV9_REVERSED
Smith-Magenis syndrome
chromosomal region candidate gene 8
protein OS=Homo sapiens

86

104956

10

1

1.2

5.36

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 42

Author Manuscript

HDF
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

GN=SMCR8 PE=1 SV=2 REVERSED

Author Manuscript
Author Manuscript
Author Manuscript

127

P09486

SPARC OS=Homo sapiens
GN=SPARC PE=1 SV=1

85

34610

3

2

16.5

4.73

128

P68371

Tubulin beta-2C chain OS=Homo
sapiens GN=TUBB2C PE=1 SV=1

85

49799

5

3

15.7

4.79

129

P27487

Dipeptidyl peptidase 4 OS=Homo
sapiens GN=DPP4 PE=1 SV=2

85

88222

2

1

3

5.67

130

P09238

Stromelysin-2 OS=Homo sapiens
GN=MMP10 PE=1 SV=1

84

54117

4

2

6.1

5.49

131

Q8N436

Inactive carboxypeptidase-like protein
X2 OS=Homo sapiens GN=CPXM2
PE=2 SV=3

84

85816

2

2

4

6.4

132

O95497

Pantetheinase OS=Homo sapiens
GN=VNN1 PE=1 SV=2

81

56975

1

1

3.7

5.32

133

Q06828

Fibromodulin OS=Homo sapiens
GN=FMOD PE=1 SV=2

80

43152

1

1

3.5

5.66

134

O00560

Syntenin-1 OS=Homo sapiens
GN=SDCBP PE=1 SV=1

79

32424

4

2

21.1

7.05

135

P23526

Adenosylhomocysteinase OS=Homo
sapiens GN=AHCY PE=1 SV=4

79

47685

4

3

12

5.92

136

P33908

Mannosyl-oligosaccharide 1,2-alphamannosidase IA OS=Homo sapiens
GN=MAN1A1 PE=1 SV=3

78

72922

3

2

6.4

6.04

137

O14773

Tripeptidyl-peptidase 1 OS=Homo
sapiens GN=TPP1 PE=1 SV=2

77

61210

1

1

4.8

6.01

138

P01008

Antithrombin-III OS=Homo sapiens
GN=SERPINC1 PE=1 SV=1

77

52569

5

2

7.3

6.32

139

P16035

Metalloproteinase inhibitor 2
OS=Homo sapiens GN=TIMP2 PE=1
SV=2

77

24383

4

2

12.7

7.45

140

P11717

Cation-independent mannose-6phosphate receptor OS=Homo sapiens
GN=IGF2R PE=1 SV=3

77

274199

4

3

2.2

5.64

141

Q12860

Contactin-1 OS=Homo sapiens
GN=CNTN1 PE=1 SV=1

75

113249

3

2

3.4

5.62

142

Q92743

Serine protease HTRA1 OS=Homo
sapiens GN=HTRA1 PE=1 SV=1

75

51255

1

1

2.9

8.09

143

P05067

Amyloid beta A4 protein OS=Homo
sapiens GN=APP PE=1 SV=3

74

86888

2

1

2.6

4.73

144

Q8TAA3

Proteasome subunit alpha type-7-like
OS=Homo sapiens GN=PSMA8 PE=1
SV=3

74

28512

1

1

5.5

9.07

145

Q5D862

Filaggrin-2 OS=Homo sapiens
GN=FLG2 PE=1 SV=1

72

247928

2

2

1

8.45

146

O00300

Tumor necrosis factor receptor
superfamily member 11B OS=Homo
sapiens GN=TNFRSF11B PE=1
SV=3

71

45996

1

1

4.2

8.66

147

P02790

Hemopexin OS=Homo sapiens
GN=HPX PE=1 SV=2

71

51643

4

1

1.9

6.55

148

O15111_REVERSED
Inhibitor of nuclear factor kappa-B
kinase subunit alpha OS=Homo
sapiens GN=CHUK PE=1 SV=2 REVERSED

71

84585

6

1

1.6

6.28

149

P28799

Granulins OS=Homo sapiens
GN=GRN PE=1 SV=2

69

63500

4

2

6.2

6.43

150

O75508

Claudin-11 OS=Homo sapiens
GN=CLDN11 PE=1 SV=2

69

21978

1

1

6.8

8.22

151

P81605

Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

68

11277

2

2

20

6.08

152

P55058

Phospholipid transfer protein
OS=Homo sapiens GN=PLTP PE=1
SV=1

68

54705

1

1

2.2

6.53

153

P02749

Beta-2-glycoprotein 1 OS=Homo
sapiens GN=APOH PE=1 SV=3

68

38273

3

1

4.3

8.34

154

P60033

CD81 antigen OS=Homo sapiens
GN=CD81 PE=1 SV=1

67

25792

2

1

18.2

5.09

155

Q8WXE9

Stonin-2 OS=Homo sapiens
GN=STON2 PE=1 SV=1

67

101102

2

1

1

5.2

156

O95445

Apolipoprotein M OS=Homo sapiens
GN=APOM PE=1 SV=2

66

21239

5

1

6.9

5.66

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 43

Author Manuscript

HDF

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

157

Q7Z304

MAM domain-containing protein 2
OS=Homo sapiens GN=MAMDC2
PE=2 SV=3

66

77506

3

2

3.9

5.05

158

Q12931

Heat shock protein 75 kDa,
mitochondrial OS=Homo sapiens
GN=TRAP1 PE=1 SV=3

65

80060

3

1

2.8

8.3

159

P19883

Follistatin OS=Homo sapiens
GN=FST PE=1 SV=2

65

37981

2

1

7

5.53

160

P61224

Ras-related protein Rap-1b OS=Homo
sapiens GN=RAP1B PE=1 SV=1

64

20812

2

2

12.5

5.65

161

P20908

Collagen alpha-1(V) chain OS=Homo
sapiens GN=COL5A1 PE=1 SV=3

64

183447

1

1

1.2

4.94

162

P10599

Thioredoxin OS=Homo sapiens
GN=TXN PE=1 SV=3

64

11730

1

1

12.4

4.82

163

P08133

Annexin A6 OS=Homo sapiens
GN=ANXA6 PE=1 SV=3

62

75826

2

2

4.2

5.42

164

Q9NZP8

Complement C1r subcomponent-like
protein OS=Homo sapiens GN=C1RL
PE=1 SV=2

62

53464

1

1

2.5

6.75

165

Q03692

Collagen alpha-1(X) chain OS=Homo
sapiens GN=COL10A1 PE=1 SV=2

61

66117

1

1

1.9

9.68

166

P26447

Protein S100-A4 OS=Homo sapiens
GN=S100A4 PE=1 SV=1

61

11721

2

2

16.8

5.85

167

P14550

Alcohol dehydrogenase [NADP+]
OS=Homo sapiens GN=AKR1A1
PE=1 SV=3

61

36550

1

1

3.1

6.32

168

P15121

Aldose reductase OS=Homo sapiens
GN=AKR1B1 PE=1 SV=3

61

35830

1

1

3.2

6.51

169

P22105

Tenascin-X OS=Homo sapiens
GN=TNXB PE=1 SV=3

60

464034

1

1

0.3

5.19

170

Q9BYX7_REVERSED
Putative beta-actin-like protein 3
OS=Homo sapiens GN=POTEKP
PE=5 SV=1 - REVERSED

57

41989

9

1

3.5

5.92

171

P05546

Heparin cofactor 2 OS=Homo sapiens
GN=SERPIND1 PE=1 SV=3

57

57034

2

1

3.8

6.41

172

P02461

Collagen alpha-1(III) chain OS=Homo
sapiens GN=COL3A1 PE=1 SV=4

57

138479

3

1

2.9

6.21

173

P07585

Decorin OS=Homo sapiens GN=DCN
PE=1 SV=1

57

39722

2

1

9.7

8.75

174

Q03135

Caveolin-1 OS=Homo sapiens
GN=CAV1 PE=1 SV=4

56

20458

1

1

7.9

5.65

175

O43264_REVERSED
Centromere/kinetochore protein zw10
homolog OS=Homo sapiens
GN=ZW10 PE=1 SV=3 REVERSED

55

88773

2

1

0.8

5.89

176

P62937

Peptidyl-prolyl cis-trans isomerase A
OS=Homo sapiens GN=PPIA PE=1
SV=2

55

18001

2

1

13.9

7.68

177

P07737

Profilin-1 OS=Homo sapiens
GN=PFN1 PE=1 SV=2

55

15045

2

2

12.1

8.44

178

P02760

Protein AMBP OS=Homo sapiens
GN=AMBP PE=1 SV=1

55

38974

1

1

2

5.95

179

B9A064

Immunoglobulin lambda-like
polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

54

23049

1

1

3.7

9.08

180

P18206

Vinculin OS=Homo sapiens GN=VCL
PE=1 SV=4

54

123722

2

1

2

5.5

181

P10643

Complement component C7
OS=Homo sapiens GN=C7 PE=1
SV=2

54

93457

2

2

2

6.09

182

Q9UK55

Protein Z-dependent protease inhibitor
OS=Homo sapiens GN=SERPINA10
PE=1 SV=1

53

50674

4

1

4.1

8.28

183

Q8NBM4

Ubiquitin-associated domaincontaining protein 2 OS=Homo
sapiens GN=UBAC2 PE=2 SV=1

52

38938

5

1

2.3

9.21

184

Q14624

Inter-alpha-trypsin inhibitor heavy
chain H4 OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

52

103293

6

1

2.5

6.51

185

Q86VH2

Kinesin-like protein KIF27 OS=Homo
sapiens GN=KIF27 PE=2 SV=1

51

160184

1

1

0.6

6.9

186

P28300

Protein-lysine 6-oxidase OS=Homo
sapiens GN=LOX PE=1 SV=2

51

46915

1

1

3.1

8.36

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 44

Author Manuscript

HDF
prot_hit

prot_acc

prot_desc

187

P05452

Tetranectin OS=Homo sapiens
GN=CLEC3B PE=1 SV=3

Author Manuscript
Author Manuscript
Author Manuscript

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

51

22522

1

1

10.4

5.52

188

Q8NAV2_REVERSED
Uncharacterized protein C8orf58
OS=Homo sapiens GN=C8orf58
PE=2 SV=2 - REVERSED

51

39636

3

1

4.1

8.54

189

P08962

CD63 antigen OS=Homo sapiens
GN=CD63 PE=1 SV=2

51

25619

1

1

4.2

8.14

190

P61769

Beta-2-microglobulin OS=Homo
sapiens GN=B2M PE=1 SV=1

51

13706

1

1

8.4

6.06

191

P15311

Ezrin OS=Homo sapiens GN=EZR
PE=1 SV=4

50

69370

1

1

1.5

5.94

192

P04439

HLA class I histocompatibility
antigen, A-3 alpha chain OS=Homo
sapiens GN=HLA-A PE=1 SV=2

50

40815

3

2

9.3

5.66

193

Q86Y46

Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73 PE=1
SV=1

50

58887

8

3

8.5

6.93

194

P26038

Moesin OS=Homo sapiens GN=MSN
PE=1 SV=3

50

67778

2

1

3.3

6.08

195

O60312

Probable phospholipid-transporting
ATPase VA OS=Homo sapiens
GN=ATP10A PE=2 SV=2

50

167582

3

1

0.6

8.7

196

Q9HDC9

Adipocyte plasma membraneassociated protein OS=Homo sapiens
GN=APMAP PE=1 SV=2

50

46451

1

1

1.7

5.82

197

Q16394

Exostosin-1 OS=Homo sapiens
GN=EXT1 PE=1 SV=2

49

86200

3

1

8.6

9.16

198

Q15751_REVERSED
Probable E3 ubiquitin-protein ligase
HERC1 OS=Homo sapiens
GN=HERC1 PE=1 SV=2 REVERSED

48

531891

1

1

0.2

5.69

199

P02787

Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3

47

77014

2

1

1.7

6.81

200

Q13454

Tumor suppressor candidate 3
OS=Homo sapiens GN=TUSC3 PE=2
SV=1

47

39650

1

1

2

9.93

201

P00338

L-lactate dehydrogenase A chain
OS=Homo sapiens GN=LDHA PE=1
SV=2

47

36665

1

1

3

8.44

202

P60903

Protein S100-A10 OS=Homo sapiens
GN=S100A10 PE=1 SV=2

47

11196

1

1

17.5

6.82

203

P29353_REVERSED
SHC-transforming protein 1
OS=Homo sapiens GN=SHC1 PE=1
SV=4 - REVERSED

46

62782

5

1

1.4

6.01

204

P01042

Kininogen-1 OS=Homo sapiens
GN=KNG1 PE=1 SV=2

46

71912

1

1

1.4

6.34

205

Q76LX8

A disintegrin and metalloproteinase
with thrombospondin motifs 13
OS=Homo sapiens GN=ADAMTS13
PE=1 SV=1

45

153505

1

1

0.7

6.96

206

Q9UHL4

Dipeptidyl peptidase 2 OS=Homo
sapiens GN=DPP7 PE=1 SV=3

45

54307

1

1

2.4

5.91

207

P07225

Vitamin K-dependent protein S
OS=Homo sapiens GN=PROS1 PE=1
SV=1

45

75074

2

1

2.4

5.48

208

Q99456

Keratin, type I cytoskeletal 12
OS=Homo sapiens GN=KRT12 PE=1
SV=1

45

53478

3

1

3.2

4.7

209

Q96CD0_REVERSED
F-box/LRR-repeat protein 8
OS=Homo sapiens GN=FBXL8 PE=1
SV=1 - REVERSED

44

40490

6

1

1.9

7.03

210

Q6ZU45

Putative C-type lectin domaincontaining protein NCRNA00083
OS=Homo sapiens
GN=NCRNA00083 PE=5 SV=1

44

25796

1

1

3.4

6.3

211

Q3KQU3

MAP7 domain-containing protein 1
OS=Homo sapiens GN=MAP7D1
PE=1 SV=1

44

92764

1

1

0.7

10.12

212

Q5U5X0

LYR motif-containing protein 7
OS=Homo sapiens GN=LYRM7 PE=1
SV=1

44

11947

1

1

5.8

9.67

213

Q8N7B9_REVERSED
EF-hand calcium-binding domaincontaining protein 3 OS=Homo
sapiens GN=EFCAB3 PE=1 SV=1 REVERSED

44

50114

1

1

1.4

9.31

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 45

Author Manuscript

HDF
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

214

Q8NB25_REVERSED
Protein FAM184A OS=Homo sapiens
GN=FAM184A PE=2 SV=3 REVERSED

prot_acc

prot_desc

44

132883

1

1

0.5

5.59

215

P06732

44

43074

1

1

1.6

6.77

216

Q93096_REVERSED
Protein tyrosine phosphatase type IVA
1 OS=Homo sapiens GN=PTP4A1
PE=1 SV=2 - REVERSED

44

19802

1

1

3.5

9.17

217

Q8IWC1

MAP7 domain-containing protein 3
OS=Homo sapiens GN=MAP7D3
PE=1 SV=2

44

98368

1

1

0.7

9.34

218

P11137

Microtubule-associated protein 2
OS=Homo sapiens GN=MAP2 PE=1
SV=4

42

199404

2

1

1.1

4.82

219

Q16348

Solute carrier family 15 member 2
OS=Homo sapiens GN=SLC15A2
PE=2 SV=2

42

81730

3

1

1.5

8.4

220

P15531

Nucleoside diphosphate kinase A
OS=Homo sapiens GN=NME1 PE=1
SV=1

42

17138

1

1

11.2

5.83

221

Q14566_REVERSED
DNA replication licensing factor
MCM6 OS=Homo sapiens
GN=MCM6 PE=1 SV=1 REVERSED

41

92831

1

1

0.9

5.28

222

O75830

Serpin I2 OS=Homo sapiens
GN=SERPINI2 PE=2 SV=1

41

46116

1

1

3.5

5.08

223

O60568

Procollagen-lysine,2-oxoglutarate 5dioxygenase 3 OS=Homo sapiens
GN=PLOD3 PE=1 SV=1

41

84731

1

1

1.9

5.69

224

Q8NHP8

Putative phospholipase B-like 2
OS=Homo sapiens GN=PLBD2 PE=1
SV=2

41

65430

2

1

3.2

6.34

225

Q99466_REVERSED
Neurogenic locus notch homolog
protein 4 OS=Homo sapiens
GN=NOTCH4 PE=1 SV=2 REVERSED

41

209480

2

1

0.4

5.43

226

P17936

Insulin-like growth factor-binding
protein 3 OS=Homo sapiens
GN=IGFBP3 PE=1 SV=2

41

31654

1

1

3.8

9.03

227

Q14789_REVERSED
Golgin subfamily B member 1
OS=Homo sapiens GN=GOLGB1
PE=1 SV=2 - REVERSED

41

375790

1

1

0.3

4.96

228

Q9BXJ4

Complement C1q tumor necrosis
factor-related protein 3 OS=Homo
sapiens GN=C1QTNF3 PE=2 SV=1

40

26977

1

1

2.8

6.04

229

P25789

Proteasome subunit alpha type-4
OS=Homo sapiens GN=PSMA4 PE=1
SV=1

40

29465

2

2

6.5

7.57

230

Q8WZ42

Titin OS=Homo sapiens GN=TTN
PE=1 SV=2

40

3813810

5

1

0.1

6.01

231

P02750

Leucine-rich alpha-2-glycoprotein
OS=Homo sapiens GN=LRG1 PE=1
SV=2

40

38154

1

1

1.7

6.45

232

Q9GZR7

ATP-dependent RNA helicase DDX24
OS=Homo sapiens GN=DDX24 PE=1
SV=1

40

96271

1

1

0.7

9.14

233

Q92616_REVERSED
Translational activator GCN1
OS=Homo sapiens GN=GCN1L1
PE=1 SV=6 - REVERSED

40

292572

6

1

0.5

7.28

234

Q03923_REVERSED
Zinc finger protein 85 OS=Homo
sapiens GN=ZNF85 PE=2 SV=3 REVERSED

40

68691

1

1

1.5

9.45

235

Q8IVF5_REVERSED
T-lymphoma invasion and metastasisinducing protein 2 OS=Homo sapiens
GN=TIAM2 PE=2 SV=4 REVERSED

40

189985

2

1

0.4

6.8

236

A2RRP1_REVERSED
Neuroblastoma-amplified sequence
OS=Homo sapiens GN=NBAS PE=1
SV=2 - REVERSED

40

268401

1

1

0.3

5.65

237

P55083

Microfibril-associated glycoprotein 4
OS=Homo sapiens GN=MFAP4 PE=1
SV=2

39

28630

1

1

7.1

5.38

238

O14782

Kinesin-like protein KIF3C
OS=Homo sapiens GN=KIF3C PE=1
SV=3

39

89371

3

1

1.1

8.28

239

O14556

Glyceraldehyde-3-phosphate
dehydrogenase, testis-specific
OS=Homo sapiens GN=GAPDHS
PE=1 SV=2

39

44473

1

1

3.4

8.38

Creatine kinase M-type OS=Homo
sapiens GN=CKM PE=1 SV=2

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 46

Author Manuscript

HDF
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

240

P05156

Complement factor I OS=Homo
sapiens GN=CFI PE=1 SV=2

39

65707

1

1

1.2

7.72

241

Q6IWH7

Anoctamin-7 OS=Homo sapiens
GN=ANO7 PE=1 SV=1

39

105463

1

1

1

8.33

242

Q14C86_REVERSED
GTPase-activating protein and VPS9
domain-containing protein 1
OS=Homo sapiens GN=GAPVD1
PE=1 SV=2 - REVERSED

39

164876

2

1

1.1

5.09

243

P02792

Ferritin light chain OS=Homo sapiens
GN=FTL PE=1 SV=2

38

20007

2

1

19.4

5.51

244

Q15022

Polycomb protein SUZ12 OS=Homo
sapiens GN=SUZ12 PE=1 SV=3

38

83003

1

1

0.8

8.98

245

P33981

Dual specificity protein kinase TTK
OS=Homo sapiens GN=TTK PE=1
SV=2

38

97011

1

1

0.7

8.41

246

P27105

Erythrocyte band 7 integral membrane
protein OS=Homo sapiens
GN=STOM PE=1 SV=3

38

31711

1

1

4.2

7.71

247

P28066

Proteasome subunit alpha type-5
OS=Homo sapiens GN=PSMA5 PE=1
SV=3

38

26394

1

1

4.1

4.74

248

Q12968_REVERSED
Nuclear factor of activated T-cells,
cytoplasmic 3 OS=Homo sapiens
GN=NFATC3 PE=1 SV=1 REVERSED

37

115522

3

1

0.7

5.91

249

O00754

Lysosomal alpha-mannosidase
OS=Homo sapiens GN=MAN2B1
PE=1 SV=3

37

113672

1

1

1.1

6.84

250

P24347

Stromelysin-3 OS=Homo sapiens
GN=MMP11 PE=1 SV=3

36

54556

1

1

1.4

6.38

251

A6H8Y1

Transcription factor TFIIIB
component B~~ homolog OS=Homo
sapiens GN=BDP1 PE=1 SV=3

36

293705

2

1

0.3

5.06

252

O95071_REVERSED
E3 ubiquitin-protein ligase UBR5
OS=Homo sapiens GN=UBR5 PE=1
SV=2 - REVERSED

36

309158

1

1

0.3

5.59

253

Q9UDT6

36

115767

4

1

1.4

6.29

254

Q9C093_REVERSED
Sperm flagellar protein 2 OS=Homo
sapiens GN=SPEF2 PE=1 SV=2 REVERSED

36

209680

2

1

0.4

5.4

255

Q9NW08

DNA-directed RNA polymerase III
subunit RPC2 OS=Homo sapiens
GN=POLR3B PE=1 SV=2

36

127702

2

1

0.6

8.77

256

Q5VWK0

Neuroblastoma breakpoint family
member 6 OS=Homo sapiens
GN=NBPF6 PE=2 SV=2

36

72194

1

1

1.9

4.84

257

O15264

Mitogen-activated protein kinase 13
OS=Homo sapiens GN=MAPK13
PE=1 SV=1

36

42063

4

1

1.9

8.48

258

P21580_REVERSED
Tumor necrosis factor alpha-induced
protein 3 OS=Homo sapiens
GN=TNFAIP3 PE=1 SV=1 REVERSED

36

89556

1

1

0.9

8.61

259

P10242_REVERSED
Transcriptional activator Myb
OS=Homo sapiens GN=MYB PE=1
SV=2 - REVERSED

36

72296

1

1

1.3

6.35

260

Q96IF1

36

56897

2

1

1.5

6.86

261

Q96RD9_REVERSED
Fc receptor-like protein 5 OS=Homo
sapiens GN=FCRL5 PE=1 SV=3 REVERSED

36

106371

1

1

0.9

6.72

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

CAP-Gly domain-containing linker
protein 2 OS=Homo sapiens
GN=CLIP2 PE=1 SV=1

Protein ajuba OS=Homo sapiens
GN=JUB PE=1 SV=1

MCF 10A
prot_hit

prot_acc

prot_desc

1

P02751

Fibronectin OS=Homo
sapiens GN=FN1 PE=1
SV=4

3184

262460

89

44

34.2

5.46

2

P04264

Keratin, type II
cytoskeletal 1 OS=Homo
sapiens GN=KRT1 PE=1
SV=6

3099

65999

85

33

58.1

8.15

3

P13645

Keratin, type I
cytoskeletal 10

2577

58792

82

31

61.6

5.13

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 47

Author Manuscript

MCF 10A
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

OS=Homo sapiens
GN=KRT10 PE=1 SV=6

Author Manuscript
Author Manuscript
Author Manuscript

4

P12111

Collagen alpha-3(VI)
chain OS=Homo sapiens
GN=COL6A3 PE=1
SV=5

2447

343457

101

65

32.7

6.26

5

P35527

Keratin, type I
cytoskeletal 9 OS=Homo
sapiens GN=KRT9 PE=1
SV=3

2240

62027

64

25

59.9

5.14

6

P02768

Serum albumin
OS=Homo sapiens
GN=ALB PE=1 SV=2

2090

69321

94

11

11.8

5.92

7

P35908

Keratin, type II
cytoskeletal 2 epidermal
OS=Homo sapiens
GN=KRT2 PE=1 SV=2

1977

65393

59

28

58.5

8.07

8

Q99715

Collagen alpha-1(XII)
chain OS=Homo sapiens
GN=COL12A1 PE=1
SV=2

1875

332941

84

55

28.3

5.38

9

P01023

Alpha-2-macroglobulin
OS=Homo sapiens
GN=A2M PE=1 SV=3

1827

163188

60

9

7.7

6.03

10

P07996

Thrombospondin-1
OS=Homo sapiens
GN=THBS1 PE=1 SV=2

1802

129300

68

33

38.1

4.71

11

P02765

Alpha-2-HSglycoprotein OS=Homo
sapiens GN=AHSG
PE=1 SV=1

1724

39300

54

5

8.7

5.43

12

P20742

Pregnancy zone protein
OS=Homo sapiens
GN=PZP PE=1 SV=4

1283

163760

43

6

4.3

5.97

13

P01024

Complement C3
OS=Homo sapiens
GN=C3 PE=1 SV=2

756

187030

35

17

15.6

6.02

14

P12109

Collagen alpha-1(VI)
chain OS=Homo sapiens
GN=COL6A1 PE=1
SV=3

726

108462

23

10

18.9

5.26

15

P02533

Keratin, type I
cytoskeletal 14
OS=Homo sapiens
GN=KRT14 PE=1 SV=4

718

51529

32

14

32.8

5.09

16

P60709

Actin, cytoplasmic 1
OS=Homo sapiens
GN=ACTB PE=1 SV=1

676

41710

28

10

47.5

5.29

17

P00734

Prothrombin OS=Homo
sapiens GN=F2 PE=1
SV=2

607

69992

17

6

10.5

5.64

18

P08779

Keratin, type I
cytoskeletal 16
OS=Homo sapiens
GN=KRT16 PE=1 SV=4

585

51236

29

13

32.1

4.99

19

P19823

Inter-alpha-trypsin
inhibitor heavy chain H2
OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

534

106397

15

7

9.3

6.4

20

P02788

Lactotransferrin
OS=Homo sapiens
GN=LTF PE=1 SV=6

529

78132

20

3

4.8

8.5

21

Q08380

Galectin-3-binding
protein OS=Homo
sapiens GN=LGALS3BP
PE=1 SV=1

520

65289

20

13

30.4

5.13

22

P24821

Tenascin OS=Homo
sapiens GN=TNC PE=1
SV=3

429

240700

21

11

13.8

4.79

23

P04259

Keratin, type II
cytoskeletal 6B
OS=Homo sapiens
GN=KRT6B PE=1 SV=5

426

60030

21

12

21.3

8.09

24

P02538

Keratin, type II
cytoskeletal 6A
OS=Homo sapiens
GN=KRT6A PE=1
SV=3

401

60008

21

12

21.1

8.09

25

P13647

Keratin, type II
cytoskeletal 5 OS=Homo
sapiens GN=KRT5 PE=1
SV=3

387

62340

23

13

23.7

7.59

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 48

Author Manuscript

MCF 10A

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

26

P0C0L4

Complement C4-A
OS=Homo sapiens
GN=C4A PE=1 SV=1

356

192650

15

8

5.2

6.65

27

Q15582

Transforming growth
factor-beta-induced
protein ig-h3 OS=Homo
sapiens GN=TGFBI
PE=1 SV=1

344

74634

18

10

25.2

7.62

28

P68032

Actin, alpha cardiac
muscle 1 OS=Homo
sapiens GN=ACTC1
PE=1 SV=1

332

41992

16

6

26.8

5.23

29

P13646

Keratin, type I
cytoskeletal 13
OS=Homo sapiens
GN=KRT13 PE=1 SV=4

330

49557

16

6

12.9

4.91

30

P06396

Gelsolin OS=Homo
sapiens GN=GSN PE=1
SV=1

324

85644

13

5

11.4

5.9

31

P04406

Glyceraldehyde-3phosphate
dehydrogenase
OS=Homo sapiens
GN=GAPDH PE=1
SV=3

324

36030

10

5

28.4

8.57

32

P68363

Tubulin alpha-1B chain
OS=Homo sapiens
GN=TUBA1B PE=1
SV=1

318

50120

14

10

28.8

4.94

33

Q04695

Keratin, type I
cytoskeletal 17
OS=Homo sapiens
GN=KRT17 PE=1 SV=2

309

48076

19

8

22

4.97

34

P02771

Alpha-fetoprotein
OS=Homo sapiens
GN=AFP PE=1 SV=1

303

68633

10

4

6.7

5.48

35

P69905

Hemoglobin subunit
alpha OS=Homo sapiens
GN=HBA1 PE=1 SV=2

291

15248

14

4

33.1

8.72

36

P02774

Vitamin D-binding
protein OS=Homo
sapiens GN=GC PE=1
SV=1

282

52929

11

5

11.6

5.4

37

Q00610

Clathrin heavy chain 1
OS=Homo sapiens
GN=CLTC PE=1 SV=5

280

191493

7

6

6.2

5.48

38

P19012

Keratin, type I
cytoskeletal 15
OS=Homo sapiens
GN=KRT15 PE=1 SV=3

256

49181

17

6

12.1

4.71

39

P36955

Pigment epitheliumderived factor OS=Homo
sapiens GN=SERPINF1
PE=1 SV=4

254

46283

6

3

9.1

5.97

40

P02452

Collagen alpha-1(I)
chain OS=Homo sapiens
GN=COL1A1 PE=1
SV=5

243

138857

10

6

9.6

5.6

41

P04114

Apolipoprotein B-100
OS=Homo sapiens
GN=APOB PE=1 SV=2

237

515283

15

9

2.2

6.58

42

P12110

Collagen alpha-2(VI)
chain OS=Homo sapiens
GN=COL6A2 PE=1
SV=4

235

108512

15

7

15.3

5.85

43

P07355

Annexin A2 OS=Homo
sapiens GN=ANXA2
PE=1 SV=2

220

38580

7

6

23.9

7.57

44

Q562R1

Beta-actin-like protein 2
OS=Homo sapiens
GN=ACTBL2 PE=1
SV=2

213

41976

10

3

16

5.39

45

P68366

Tubulin alpha-4A chain
OS=Homo sapiens
GN=TUBA4A PE=1
SV=1

208

49892

10

7

19

4.95

46

P04004

Vitronectin OS=Homo
sapiens GN=VTN PE=1
SV=1

196

54271

6

1

4.2

5.55

47

P23142

Fibulin-1 OS=Homo
sapiens GN=FBLN1
PE=1 SV=4

180

77162

7

4

5.7

5.07

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 49

Author Manuscript

MCF 10A
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

48

P07437

Tubulin beta chain
OS=Homo sapiens
GN=TUBB PE=1 SV=2

180

49639

8

5

19.6

4.78

49

Q5XKE5

Keratin, type II
cytoskeletal 79
OS=Homo sapiens
GN=KRT79 PE=1 SV=2

179

57800

8

4

6.9

6.75

50

P62805

Histone H4 OS=Homo
sapiens GN=HIST1H4A
PE=1 SV=2

173

11360

7

5

50.5

11.36

51

P02042

Hemoglobin subunit
delta OS=Homo sapiens
GN=HBD PE=1 SV=2

171

16045

10

2

12.9

7.85

52

P05787

Keratin, type II
cytoskeletal 8 OS=Homo
sapiens GN=KRT8 PE=1
SV=7

170

53671

7

4

5.8

5.52

53

Q07954

Prolow-density
lipoprotein receptorrelated protein 1
OS=Homo sapiens
GN=LRP1 PE=1 SV=2

167

504276

9

4

2.6

5.16

54

P49747

Cartilage oligomeric
matrix protein
OS=Homo sapiens
GN=COMP PE=1 SV=2

165

82808

6

4

5.8

4.36

55

P02647

Apolipoprotein A-I
OS=Homo sapiens
GN=APOA1 PE=1
SV=1

164

30759

4

1

8.2

5.56

56

P19013

Keratin, type II
cytoskeletal 4 OS=Homo
sapiens GN=KRT4 PE=1
SV=4

163

57250

8

4

7.3

6.25

57

P08697

Alpha-2-antiplasmin
OS=Homo sapiens
GN=SERPINF2 PE=1
SV=3

145

54531

2

1

2.2

5.87

58

P01008

Antithrombin-III
OS=Homo sapiens
GN=SERPINC1 PE=1
SV=1

144

52569

11

5

10.3

6.32

59

P68371

Tubulin beta-2C chain
OS=Homo sapiens
GN=TUBB2C PE=1
SV=1

140

49799

7

4

16.2

4.79

60

Q06033

Inter-alpha-trypsin
inhibitor heavy chain H3
OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

139

99787

6

3

4.2

5.49

61

P12259

Coagulation factor V
OS=Homo sapiens
GN=F5 PE=1 SV=4

135

251546

8

4

3.2

5.68

62

P23526

Adenosylhomocysteinase
OS=Homo sapiens
GN=AHCY PE=1 SV=4

133

47685

3

2

9

5.92

63

P51884

Lumican OS=Homo
sapiens GN=LUM PE=1
SV=2

130

38405

6

2

9.8

6.16

64

Q8NI35

InaD-like protein
OS=Homo sapiens
GN=INADL PE=1 SV=3

129

196247

11

1

0.3

4.84

65

P19827

Inter-alpha-trypsin
inhibitor heavy chain H1
OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

120

101326

3

2

3.8

6.31

66

Q05707

Collagen alpha-1(XIV)
chain OS=Homo sapiens
GN=COL14A1 PE=1
SV=3

119

193394

11

4

7.6

5.16

67

P12035

Keratin, type II
cytoskeletal 3 OS=Homo
sapiens GN=KRT3 PE=1
SV=3

118

64378

6

4

5.6

6.12

68

P15169

Carboxypeptidase N
catalytic chain
OS=Homo sapiens
GN=CPN1 PE=1 SV=1

116

52253

2

1

3.3

6.86

69

P02675

Fibrinogen beta chain
OS=Homo sapiens
GN=FGB PE=1 SV=2

114

55892

5

3

5.3

8.54

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 50

Author Manuscript

MCF 10A
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

70

P02748

Complement component
C9 OS=Homo sapiens
GN=C9 PE=1 SV=2

113

63133

2

2

3.8

5.43

71

P11717

Cation-independent
mannose-6-phosphate
receptor OS=Homo
sapiens GN=IGF2R
PE=1 SV=3

111

274199

4

2

0.8

5.64

72

P00747

Plasminogen OS=Homo
sapiens GN=PLG PE=1
SV=2

110

90510

6

2

4.3

7.04

73

P81605

Dermcidin OS=Homo
sapiens GN=DCD PE=1
SV=2

110

11277

4

3

22.7

6.08

74

P05543

Thyroxine-binding
globulin OS=Homo
sapiens GN=SERPINA7
PE=1 SV=2

105

46295

4

2

4.8

5.87

75

P0C0S8

Histone H2A type 1
OS=Homo sapiens
GN=HIST1H2AG PE=1
SV=2

105

14083

3

2

21.5

10.9

76

Q86YZ3

Hornerin OS=Homo
sapiens GN=HRNR
PE=1 SV=2

102

282228

2

2

1.3

10.05

77

P02749

Beta-2-glycoprotein 1
OS=Homo sapiens
GN=APOH PE=1 SV=3

101

38273

4

1

5.2

8.34

78

Q08431

Lactadherin OS=Homo
sapiens GN=MFGE8
PE=1 SV=2

101

43095

2

1

3.9

8.47

79

P01031

Complement C5
OS=Homo sapiens
GN=C5 PE=1 SV=4

101

188186

6

2

2.6

6.11

80

Q5D862

Filaggrin-2 OS=Homo
sapiens GN=FLG2 PE=1
SV=1

100

247928

2

2

1

8.45

81

P07195

L-lactate dehydrogenase
B chain OS=Homo
sapiens GN=LDHB
PE=1 SV=2

99

36615

2

2

6

5.71

82

P01009

Alpha-1-antitrypsin
OS=Homo sapiens
GN=SERPINA1 PE=1
SV=3

98

46707

4

1

3.3

5.37

83

P55072

Transitional endoplasmic
reticulum ATPase
OS=Homo sapiens
GN=VCP PE=1 SV=4

96

89266

5

2

8.8

5.14

84

O43854

EGF-like repeat and
discoidin I-like domaincontaining protein 3
OS=Homo sapiens
GN=EDIL3 PE=1 SV=1

93

53730

4

4

7.5

7.08

85

P08238

Heat shock protein HSP
90-beta OS=Homo
sapiens GN=HSP90AB1
PE=1 SV=4

92

83212

3

2

4.1

4.97

86

O14818

Proteasome subunit
alpha type-7 OS=Homo
sapiens GN=PSMA7
PE=1 SV=1

91

27870

3

3

13.7

8.6

87

O15111_REVERSED

Inhibitor of nuclear
factor kappa-B kinase
subunit alpha OS=Homo
sapiens GN=CHUK
PE=1 SV=2 REVERSED

87

84585

7

1

1.6

6.28

88

P08107

Heat shock 70 kDa
protein 1A/1B
OS=Homo sapiens
GN=HSPA1A PE=1
SV=5

82

70009

4

3

8.3

5.48

89

Q86Y46

Keratin, type II
cytoskeletal 73
OS=Homo sapiens
GN=KRT73 PE=1 SV=1

81

58887

6

4

6.7

6.93

90

P14618

Pyruvate kinase
isozymes M1/M2
OS=Homo sapiens
GN=PKM2 PE=1 SV=4

81

57900

6

3

14.1

7.96

91

P02461

Collagen alpha-1(III)
chain OS=Homo sapiens

80

138479

3

2

2.3

6.21

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 51

Author Manuscript

MCF 10A
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

GN=COL3A1 PE=1
SV=4

Author Manuscript
Author Manuscript
Author Manuscript

92

P04075

Fructose-bisphosphate
aldolase A OS=Homo
sapiens GN=ALDOA
PE=1 SV=2

80

39395

4

2

10.7

8.3

93

P61204

ADP-ribosylation factor
3 OS=Homo sapiens
GN=ARF3 PE=1 SV=2

79

20588

1

1

8.3

6.84

94

Q14764

Major vault protein
OS=Homo sapiens
GN=MVP PE=1 SV=4

77

99266

4

3

5.6

5.34

95

P02787

Serotransferrin
OS=Homo sapiens
GN=TF PE=1 SV=3

77

77014

3

2

1.7

6.81

96

Q5QNW6

Histone H2B type 2-F
OS=Homo sapiens
GN=HIST2H2BF PE=1
SV=3

76

13912

3

2

15.9

10.31

97

P07900

Heat shock protein HSP
90-alpha OS=Homo
sapiens GN=HSP90AA1
PE=1 SV=5

76

84607

3

2

4.9

4.94

98

Q8N7M0_REVERSED

Tctex1 domaincontaining protein 1
OS=Homo sapiens
GN=TCTEX1D1 PE=2
SV=2 - REVERSED

75

20717

13

1

3.9

9.04

99

P04083

Annexin A1 OS=Homo
sapiens GN=ANXA1
PE=1 SV=2

74

38690

2

1

8.4

6.57

100

P11142

Heat shock cognate 71
kDa protein OS=Homo
sapiens GN=HSPA8
PE=1 SV=1

73

70854

4

2

8.7

5.37

101

P04180

Phosphatidylcholinesterol acyltransferase
OS=Homo sapiens
GN=LCAT PE=1 SV=1

70

49546

1

1

2.5

5.71

102

P06702

Protein S100-A9
OS=Homo sapiens
GN=S100A9 PE=1
SV=1

70

13234

3

1

24.6

5.71

103

Q9BXJ4

Complement C1q tumor
necrosis factor-related
protein 3 OS=Homo
sapiens GN=C1QTNF3
PE=2 SV=1

68

26977

2

2

8.1

6.04

104

P02753

Retinol-binding protein 4
OS=Homo sapiens
GN=RBP4 PE=1 SV=3

66

22995

2

1

16.4

5.76

105

P29353_REVERSED

SHC-transforming
protein 1 OS=Homo
sapiens GN=SHC1 PE=1
SV=4 - REVERSED

66

62782

11

1

1.4

6.01

106

Q08554

Desmocollin-1
OS=Homo sapiens
GN=DSC1 PE=1 SV=2

66

99924

1

1

1.7

5.25

107

Q16853

Membrane primary
amine oxidase
OS=Homo sapiens
GN=AOC3 PE=1 SV=3

66

84568

1

1

1.2

6.05

108

P00338

L-lactate dehydrogenase
A chain OS=Homo
sapiens GN=LDHA
PE=1 SV=2

66

36665

2

1

6

8.44

109

P00488

Coagulation factor XIII
A chain OS=Homo
sapiens GN=F13A1
PE=1 SV=4

65

83215

1

1

1.2

5.75

110

Q5VTE0

Putative elongation
factor 1-alpha-like 3
OS=Homo sapiens
GN=EEF1A1P5 PE=5
SV=1

64

50153

3

2

5.2

9.15

111

Q9H4B7

Tubulin beta-1 chain
OS=Homo sapiens
GN=TUBB1 PE=1
SV=1

64

50295

3

1

9.5

5.05

112

P62979

Ubiquitin-40S ribosomal
protein S27a OS=Homo
sapiens GN=RPS27A
PE=1 SV=2

63

17953

1

1

10.3

9.68

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 52

Author Manuscript

MCF 10A
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

113

P35443

Thrombospondin-4
OS=Homo sapiens
GN=THBS4 PE=1 SV=2

62

105802

5

2

3.9

4.44

114

P02760

Protein AMBP
OS=Homo sapiens
GN=AMBP PE=1 SV=1

61

38974

2

1

2

5.95

115

P21333

Filamin-A OS=Homo
sapiens GN=FLNA
PE=1 SV=4

60

280564

3

2

1.3

5.7

116

P35579

Myosin-9 OS=Homo
sapiens GN=MYH9
PE=1 SV=4

59

226392

2

1

1.5

5.5

117

Q15063

Periostin OS=Homo
sapiens GN=POSTN
PE=1 SV=2

59

93255

3

1

5.9

7.27

118

P02649

Apolipoprotein E
OS=Homo sapiens
GN=APOE PE=1 SV=1

59

36132

4

2

8.2

5.65

119

Q14624

Inter-alpha-trypsin
inhibitor heavy chain H4
OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

59

103293

3

1

2.5

6.51

120

P08758

Annexin A5 OS=Homo
sapiens GN=ANXA5
PE=1 SV=2

58

35914

4

2

10.6

4.94

121

P02786

Transferrin receptor
protein 1 OS=Homo
sapiens GN=TFRC PE=1
SV=2

58

84818

1

1

1.6

6.18

122

A6NIZ1

Ras-related protein
Rap-1b-like protein
OS=Homo sapiens PE=2
SV=1

57

20912

1

1

6.5

5.37

123

Q93070

Ecto-ADPribosyltransferase 4
OS=Homo sapiens
GN=ART4 PE=2 SV=2

57

35854

8

1

2.2

9.31

124

Q9Y240

C-type lectin domain
family 11 member A
OS=Homo sapiens
GN=CLEC11A PE=1
SV=1

57

35672

1

1

5.3

5.06

125

P32119

Peroxiredoxin-2
OS=Homo sapiens
GN=PRDX2 PE=1
SV=5

55

21878

1

1

9.1

5.66

126

Q99456

Keratin, type I
cytoskeletal 12
OS=Homo sapiens
GN=KRT12 PE=1 SV=1

55

53478

4

1

3.2

4.7

127

P01591

Immunoglobulin J chain
OS=Homo sapiens
GN=IGJ PE=1 SV=4

54

18087

1

1

6.3

5.12

128

Q6ZU45

Putative C-type lectin
domain-containing
protein NCRNA00083
OS=Homo sapiens
GN=NCRNA00083
PE=5 SV=1

53

25796

1

1

3.4

6.3

129

Q86TI0_REVERSED

TBC1 domain family
member 1 OS=Homo
sapiens GN=TBC1D1
PE=1 SV=2 REVERSED

53

133000

1

1

0.7

6.52

130

Q99436

Proteasome subunit beta
type-7 OS=Homo
sapiens GN=PSMB7
PE=1 SV=1

53

29946

1

1

3.6

7.57

131

P15144

Aminopeptidase N
OS=Homo sapiens
GN=ANPEP PE=1
SV=4

53

109471

3

1

3.8

5.31

132

P28066

Proteasome subunit
alpha type-5 OS=Homo
sapiens GN=PSMA5
PE=1 SV=3

52

26394

2

1

12

4.74

133

Q07092

Collagen alpha-1(XVI)
chain OS=Homo sapiens
GN=COL16A1 PE=1
SV=2

52

157653

1

1

0.7

8.14

134

Q9BYX7_REVERSED

Putative beta-actin-like
protein 3 OS=Homo
sapiens GN=POTEKP

51

41989

3

1

3.5

5.92

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 53

Author Manuscript

MCF 10A
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

PE=5 SV=1 REVERSED

Author Manuscript
Author Manuscript
Author Manuscript

135

P05452

Tetranectin OS=Homo
sapiens GN=CLEC3B
PE=1 SV=3

51

22522

1

1

5.9

5.52

136

P35125

Ubiquitin carboxylterminal hydrolase 6
OS=Homo sapiens
GN=USP6 PE=1 SV=2

50

158557

11

1

0.4

7.87

137

O95445

Apolipoprotein M
OS=Homo sapiens
GN=APOM PE=1 SV=2

50

21239

2

1

6.9

5.66

138

P02790

Hemopexin OS=Homo
sapiens GN=HPX PE=1
SV=2

50

51643

4

1

3.2

6.55

139

Q13454

Tumor suppressor
candidate 3 OS=Homo
sapiens GN=TUSC3
PE=2 SV=1

50

39650

2

1

2.3

9.93

140

Q8NA29_REVERSED

Major facilitator
superfamily domaincontaining protein 2A
OS=Homo sapiens
GN=MFSD2A PE=2
SV=1 - REVERSED

50

60131

1

1

1.3

6.55

141

Q9TNN7

HLA class I
histocompatibility
antigen, Cw-5 alpha
chain OS=Homo sapiens
GN=HLA-C PE=2 SV=1

49

40886

1

1

3.6

7.11

142

P12036

Neurofilament heavy
polypeptide OS=Homo
sapiens GN=NEFH
PE=1 SV=4

49

112411

2

1

1.6

5.99

143

Q8N1N4

Keratin, type II
cytoskeletal 78
OS=Homo sapiens
GN=KRT78 PE=1 SV=2

49

56830

2

1

2.7

5.79

144

Q9Y490

Talin-1 OS=Homo
sapiens GN=TLN1 PE=1
SV=3

49

269599

1

1

0.6

5.77

145

Q9UBR2

Cathepsin Z OS=Homo
sapiens GN=CTSZ PE=1
SV=1

49

33846

1

1

3.3

6.7

146

P49720

Proteasome subunit beta
type-3 OS=Homo
sapiens GN=PSMB3
PE=1 SV=2

48

22933

2

1

12.2

6.14

147

P05546

Heparin cofactor 2
OS=Homo sapiens
GN=SERPIND1 PE=1
SV=3

48

57034

1

1

2.4

6.41

148

P01042

Kininogen-1 OS=Homo
sapiens GN=KNG1
PE=1 SV=2

48

71912

1

1

1.4

6.34

149

Q96Q89_REVERSED

Kinesin-like protein
KIF20B OS=Homo
sapiens GN=KIF20B
PE=1 SV=3 REVERSED

48

210500

3

1

0.5

5.54

150

P03956

Interstitial collagenase
OS=Homo sapiens
GN=MMP1 PE=1 SV=3

48

53973

2

1

3

6.47

151

Q8NDM7_REVERSED

WD repeat-containing
protein 96 OS=Homo
sapiens GN=WDR96
PE=2 SV=3 REVERSED

47

191861

1

1

0.5

5.71

152

Q71DI3

Histone H3.2 OS=Homo
sapiens GN=HIST2H3A
PE=1 SV=3

46

15379

4

1

14.7

11.27

153

P13639

Elongation factor 2
OS=Homo sapiens
GN=EEF2 PE=1 SV=4

46

95277

1

1

1.2

6.41

154

Q9Y6X9_REVERSED

MORC family CW-type
zinc finger protein 2
OS=Homo sapiens
GN=MORC2 PE=1
SV=2 - REVERSED

46

117750

1

1

0.7

8.6

155

P28074

Proteasome subunit beta
type-5 OS=Homo
sapiens GN=PSMB5
PE=1 SV=3

46

28462

1

1

4.6

6.43

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 54

Author Manuscript

MCF 10A

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

156

Q9ULC6

Protein-arginine
deiminase type-1
OS=Homo sapiens
GN=PADI1 PE=1 SV=2

46

74618

1

1

1.4

6.07

157

Q8NBM4

Ubiquitin-associated
domain-containing
protein 2 OS=Homo
sapiens GN=UBAC2
PE=2 SV=1

46

38938

3

1

2.3

9.21

158

Q2VWP7

Protogenin OS=Homo
sapiens GN=PRTG PE=2
SV=1

46

126996

1

1

0.6

7.37

159

Q9NPY3_REVERSED

Complement component
C1q receptor OS=Homo
sapiens GN=CD93 PE=1
SV=3 - REVERSED

45

68515

1

1

1.1

5.27

160

Q9NRY4

Glucocorticoid receptor
DNA-binding factor 1
OS=Homo sapiens
GN=GRLF1 PE=1 SV=2

45

172121

1

1

0.5

6.33

161

Q9NU02_REVERSED

Ankyrin repeat domaincontaining protein 5
OS=Homo sapiens
GN=ANKRD5 PE=2
SV=2 - REVERSED

45

86610

5

1

1.8

8.51

162

B9A064

Immunoglobulin
lambda-like polypeptide
5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

45

23049

1

1

3.7

9.08

163

Q5T764_REVERSED

Interferon-induced
protein with
tetratricopeptide repeats
1B OS=Homo sapiens
GN=IFIT1B PE=2 SV=1
- REVERSED

45

54958

2

1

3.4

7.69

164

P07339

Cathepsin D OS=Homo
sapiens GN=CTSD
PE=1 SV=1

45

44524

1

1

1.9

6.1

165

P02794

Ferritin heavy chain
OS=Homo sapiens
GN=FTH1 PE=1 SV=2

45

21212

2

1

9.3

5.3

166

Q9UKT8_REVERSED

F-box/WD repeatcontaining protein 2
OS=Homo sapiens
GN=FBXW2 PE=1
SV=2 - REVERSED

45

51479

2

1

3.1

6.11

167

P29803_REVERSED

Pyruvate dehydrogenase
E1 component subunit
alpha, testis-specific
form, mitochondrial
OS=Homo sapiens
GN=PDHA2 PE=1
SV=1 - REVERSED

44

42906

3

1

4.1

8.76

168

Q9BY43

Charged multivesicular
body protein 4a
OS=Homo sapiens
GN=CHMP4A PE=1
SV=3

44

25083

3

1

6.3

4.65

169

Q00013

55 kDa erythrocyte
membrane protein
OS=Homo sapiens
GN=MPP1 PE=1 SV=2

44

52264

2

1

1.5

6.91

170

Q13477_REVERSED

Mucosal addressin cell
adhesion molecule 1
OS=Homo sapiens
GN=MADCAM1 PE=1
SV=2 - REVERSED

43

40130

2

1

2.6

5

171

Q8NFM7_REVERSED

Interleukin-17 receptor
D OS=Homo sapiens
GN=IL17RD PE=1
SV=3 - REVERSED

43

82358

1

1

0.9

6.81

172

Q92609

TBC1 domain family
member 5 OS=Homo
sapiens GN=TBC1D5
PE=1 SV=1

43

88949

1

1

1

6.1

173

Q96CD0_REVERSED

F-box/LRR-repeat
protein 8 OS=Homo
sapiens GN=FBXL8
PE=1 SV=1 REVERSED

43

40490

9

1

1.9

7.03

174

P04745

Alpha-amylase 1
OS=Homo sapiens
GN=AMY1A PE=1
SV=2

43

57731

1

1

2.3

6.47

175

Q9NZM4

Glioma tumor suppressor
candidate region gene 1

42

158393

2

1

0.5

6.17

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 55

Author Manuscript

MCF 10A
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

protein OS=Homo
sapiens GN=GLTSCR1
PE=1 SV=2

Author Manuscript
Author Manuscript
Author Manuscript

176

P10643

Complement component
C7 OS=Homo sapiens
GN=C7 PE=1 SV=2

42

93457

2

1

1.1

6.09

177

Q6ZUT9_REVERSED

DENN domaincontaining protein 5B
OS=Homo sapiens
GN=DENND5B PE=1
SV=2 - REVERSED

41

144927

2

1

0.5

6.29

178

Q86UQ0_REVERSED

Zinc finger protein 589
OS=Homo sapiens
GN=ZNF589 PE=1
SV=1 - REVERSED

41

41163

2

1

1.6

8.62

179

P43652

Afamin OS=Homo
sapiens GN=AFM PE=1
SV=1

41

69024

1

1

1.2

5.64

180

Q96RD9_REVERSED

Fc receptor-like protein 5
OS=Homo sapiens
GN=FCRL5 PE=1 SV=3
- REVERSED

41

106371

1

1

0.9

6.72

181

Q16563

Synaptophysin-like
protein 1 OS=Homo
sapiens GN=SYPL1
PE=1 SV=1

41

28547

1

1

4.2

8.69

182

Q58FF6

Putative heat shock
protein HSP 90-beta 4
OS=Homo sapiens
GN=HSP90AB4P PE=5
SV=1

40

58228

2

1

5

4.65

183

Q9ULT0

Tetratricopeptide repeat
protein 7A OS=Homo
sapiens GN=TTC7A
PE=1 SV=3

40

96123

3

1

1.2

6.03

184

P98160

Basement membranespecific heparan sulfate
proteoglycan core
protein OS=Homo
sapiens GN=HSPG2
PE=1 SV=4

39

468532

1

1

0.2

6.06

185

O14782

Kinesin-like protein
KIF3C OS=Homo
sapiens GN=KIF3C
PE=1 SV=3

39

89371

3

1

1.1

8.28

186

Q99816

Tumor susceptibility
gene 101 protein
OS=Homo sapiens
GN=TSG101 PE=1
SV=2

60

43916

3

1

2.4

9.4

187

P11166

Solute carrier family 2,
facilitated glucose
transporter member 1
OS=Homo sapiens
GN=SLC2A1 PE=1
SV=2

39

54049

1

1

1.6

8.93

188

Q00535_REVERSED

Cyclin-dependent kinase
5 OS=Homo sapiens
GN=CDK5 PE=1 SV=3
- REVERSED

39

33283

2

1

3.1

7.9

189

Q8N3E9

1phosphatidylinositol-4,5bisphosphate
phosphodiesterase
delta-3 OS=Homo
sapiens GN=PLCD3
PE=1 SV=3

39

89202

5

1

1.9

6.52

190

P43235

Cathepsin K OS=Homo
sapiens GN=CTSK
PE=1 SV=1

38

36942

1

1

6.1

8.72

191

P22303

Acetylcholinesterase
OS=Homo sapiens
GN=ACHE PE=1 SV=1

38

67753

1

1

2.1

5.87

192

Q9P2G4_REVERSED

Uncharacterized protein
KIAA1383 OS=Homo
sapiens GN=KIAA1383
PE=1 SV=2 REVERSED

38

100283

1

1

0.8

6.77

193

Q9BZP6

Acidic mammalian
chitinase OS=Homo
sapiens GN=CHIA PE=1
SV=1

38

52237

1

1

1.7

5.54

194

Q9ULI3_REVERSED

Protein HEG homolog 1
OS=Homo sapiens
GN=HEG1 PE=1 SV=3
- REVERSED

38

147369

5

1

0.9

5.81

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 56

Author Manuscript

MCF 10A
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

195

O43264_REVERSED

Centromere/kinetochore
protein zw10 homolog
OS=Homo sapiens
GN=ZW10 PE=1 SV=3
- REVERSED

38

88773

1

1

0.8

5.89

196

P48436_REVERSED

Transcription factor
SOX-9 OS=Homo
sapiens GN=SOX9 PE=1
SV=1 - REVERSED

38

56102

1

1

1.6

6.33

197

Q5TAH2

Sodium/hydrogen
exchanger 11 OS=Homo
sapiens GN=SLC9A11
PE=2 SV=1

38

128969

1

1

0.6

6.5

198

Q03518

Antigen peptide
transporter 1 OS=Homo
sapiens GN=TAP1 PE=1
SV=2

37

87163

10

1

1.9

8.24

199

P06746

DNA polymerase beta
OS=Homo sapiens
GN=POLB PE=1 SV=3

37

38154

1

1

1.8

9.01

200

Q7Z5M8

Abhydrolase domaincontaining protein 12B
OS=Homo sapiens
GN=ABHD12B PE=2
SV=1

37

40750

3

1

1.7

8.57

201

Q15020_REVERSED

Squamous cell
carcinoma antigen
recognized by T-cells 3
OS=Homo sapiens
GN=SART3 PE=1 SV=1
- REVERSED

37

109865

3

1

0.6

5.45

202

Q9NX14

NADH dehydrogenase
[ubiquinone] 1 beta
subcomplex subunit 11,
mitochondrial OS=Homo
sapiens GN=NDUFB11
PE=1 SV=1

37

17306

1

1

5.2

5.17

203

Q9H115_REVERSED

Beta-soluble NSF
attachment protein
OS=Homo sapiens
GN=NAPB PE=1 SV=2
- REVERSED

37

33535

1

1

4

5.32

204

Q14573_REVERSED

Inositol 1,4,5trisphosphate receptor
type 3 OS=Homo
sapiens GN=ITPR3
PE=1 SV=2 REVERSED

37

303912

3

1

0.4

6.05

205

P00742

Coagulation factor X
OS=Homo sapiens
GN=F10 PE=1 SV=2

37

54697

1

1

1.8

5.68

206

P26006

Integrin alpha-3
OS=Homo sapiens
GN=ITGA3 PE=1 SV=4

37

118680

1

1

0.9

6.51

207

Q6DHV7_REVERSED

Adenosine deaminaselike protein OS=Homo
sapiens GN=ADAL
PE=2 SV=2 REVERSED

37

40239

1

1

3.1

5.89

208

P21462_REVERSED

fMet-Leu-Phe receptor
OS=Homo sapiens
GN=FPR1 PE=1 SV=3 REVERSED

37

38420

2

1

2

9.23

209

Q9UGM3

Deleted in malignant
brain tumors 1 protein
OS=Homo sapiens
GN=DMBT1 PE=1
SV=2

36

260569

1

1

0.2

5.18

210

Q14CM0_REVERSED

FERM and PDZ domaincontaining protein 4
OS=Homo sapiens
GN=FRMPD4 PE=1
SV=1 - REVERSED

36

144289

3

1

0.6

5.12

211

O00754

Lysosomal alphamannosidase OS=Homo
sapiens GN=MAN2B1
PE=1 SV=3

36

113672

1

1

1.1

6.84

212

P05109

Protein S100-A8
OS=Homo sapiens
GN=S100A8 PE=1
SV=1

36

10828

1

1

7.5

6.51

213

O75691_REVERSED

Small subunit
processome component
20 homolog OS=Homo
sapiens GN=UTP20

36

318182

1

1

0.3

7.09

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 57

Author Manuscript

MCF 10A
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

36

83155

prot_matches

prot_sequences_sig

prot_cover

prot_pi

3

1

1.5

5.36

PE=1 SV=3 REVERSED
214

Q96ED9_REVERSED

Protein Hook homolog 2
OS=Homo sapiens
GN=HOOK2 PE=1
SV=3 - REVERSED

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

1

P04264

Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6

3363

65999

84

31

57.3

8.15

2

P13645

Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10 PE=1
SV=6

2875

58792

85

31

58.7

5.13

3

P02751

Fibronectin OS=Homo sapiens
GN=FN1 PE=1 SV=4

2436

262460

88

40

25.6

5.46

4

P02765

Alpha-2-HS-glycoprotein OS=Homo
sapiens GN=AHSG PE=1 SV=1

2048

39300

52

4

7.1

5.43

5

P35527

Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3

1994

62027

55

23

65.7

5.14

6

P35908

Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2

1865

65393

55

25

57.9

8.07

7

P02768

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

1781

69321

112

8

11.8

5.92

8

P01023

Alpha-2-macroglobulin OS=Homo
sapiens GN=A2M PE=1 SV=3

1613

163188

57

6

5.2

6.03

9

P20742

Pregnancy zone protein OS=Homo
sapiens GN=PZP PE=1 SV=4

1346

163760

41

4

3.8

5.97

10

P55072

Transitional endoplasmic reticulum
ATPase OS=Homo sapiens GN=VCP
PE=1 SV=4

906

89266

35

21

37.1

5.14

11

Q5QNW6

Histone H2B type 2-F OS=Homo
sapiens GN=HIST2H2BF PE=1
SV=3

881

13912

22

5

35.7

10.31

12

P60709

Actin, cytoplasmic 1 OS=Homo
sapiens GN=ACTB PE=1 SV=1

647

41710

25

13

47.5

5.29

13

P00734

Prothrombin OS=Homo sapiens
GN=F2 PE=1 SV=2

613

69992

15

6

9.5

5.64

14

P07996

Thrombospondin-1 OS=Homo
sapiens GN=THBS1 PE=1 SV=2

580

129300

27

13

13.2

4.71

15

P02533

Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4

575

51529

25

15

32.4

5.09

16

P01024

Complement C3 OS=Homo sapiens
GN=C3 PE=1 SV=2

509

187030

23

11

8.8

6.02

17

P19823

Inter-alpha-trypsin inhibitor heavy
chain H2 OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

468

106397

15

8

9.3

6.4

18

Q6FI13

Histone H2A type 2-A OS=Homo
sapiens GN=HIST2H2AA3 PE=1
SV=3

456

14087

14

4

49.2

10.9

19

P13647

Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3

450

62340

22

13

25.3

7.59

20

P07437

Tubulin beta chain OS=Homo
sapiens GN=TUBB PE=1 SV=2

441

49639

20

13

45

4.78

21

Q07954

Prolow-density lipoprotein receptorrelated protein 1 OS=Homo sapiens
GN=LRP1 PE=1 SV=2

439

504276

15

8

3.6

5.16

22

P98160

Basement membrane-specific
heparan sulfate proteoglycan core
protein OS=Homo sapiens
GN=HSPG2 PE=1 SV=4

439

468532

20

13

4.7

6.06

23

P08779

Keratin, type I cytoskeletal 16
OS=Homo sapiens GN=KRT16 PE=1
SV=4

394

51236

19

10

18

4.99

24

P02788

Lactotransferrin OS=Homo sapiens
GN=LTF PE=1 SV=6

380

78132

16

3

4.8

8.5

25

P0C0L4

Complement C4-A OS=Homo
sapiens GN=C4A PE=1 SV=1

367

192650

15

7

5.6

6.65

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 58

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

26

P62805

Histone H4 OS=Homo sapiens
GN=HIST1H4A PE=1 SV=2

363

11360

15

6

51.5

11.36

27

P04259

Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B
PE=1 SV=5

349

60030

15

8

14

8.09

28

P11142

Heat shock cognate 71 kDa protein
OS=Homo sapiens GN=HSPA8
PE=1 SV=1

346

70854

12

7

16.7

5.37

29

Q86YZ3

Hornerin OS=Homo sapiens
GN=HRNR PE=1 SV=2

344

282228

3

3

2.1

10.05

30

P02538

Keratin, type II cytoskeletal 6A
OS=Homo sapiens GN=KRT6A
PE=1 SV=3

339

60008

15

8

15.6

8.09

31

P68032

Actin, alpha cardiac muscle 1
OS=Homo sapiens GN=ACTC1
PE=1 SV=1

333

41992

17

9

26.8

5.23

32

P02771

Alpha-fetoprotein OS=Homo sapiens
GN=AFP PE=1 SV=1

310

68633

9

3

5.6

5.48

33

Q9BQE3

Tubulin alpha-1C chain OS=Homo
sapiens GN=TUBA1C PE=1 SV=1

285

49863

18

6

31.8

4.96

34

P02774

Vitamin D-binding protein
OS=Homo sapiens GN=GC PE=1
SV=1

277

52929

10

6

11.8

5.4

35

P04004

Vitronectin OS=Homo sapiens
GN=VTN PE=1 SV=1

277

54271

6

1

4.2

5.55

36

Q9BVA1

Tubulin beta-2B chain OS=Homo
sapiens GN=TUBB2B PE=1 SV=1

270

49921

17

10

36.9

4.78

37

Q04695

Keratin, type I cytoskeletal 17
OS=Homo sapiens GN=KRT17 PE=1
SV=2

257

48076

16

9

15

4.97

38

P68366

Tubulin alpha-4A chain OS=Homo
sapiens GN=TUBA4A PE=1 SV=1

256

49892

13

5

22.5

4.95

39

P13646

Keratin, type I cytoskeletal 13
OS=Homo sapiens GN=KRT13 PE=1
SV=4

254

49557

12

6

9.2

4.91

40

P69905

Hemoglobin subunit alpha OS=Homo
sapiens GN=HBA1 PE=1 SV=2

231

15248

8

3

33.1

8.72

41

P04114

Apolipoprotein B-100 OS=Homo
sapiens GN=APOB PE=1 SV=2

227

515283

14

7

1.9

6.58

42

P04406

Glyceraldehyde-3-phosphate
dehydrogenase OS=Homo sapiens
GN=GAPDH PE=1 SV=3

222

36030

5

2

17.6

8.57

43

Q5XKE5

Keratin, type II cytoskeletal 79
OS=Homo sapiens GN=KRT79 PE=1
SV=2

221

57800

10

4

6.9

6.75

44

P23142

Fibulin-1 OS=Homo sapiens
GN=FBLN1 PE=1 SV=4

214

77162

11

4

7.3

5.07

45

P08238

Heat shock protein HSP 90-beta
OS=Homo sapiens GN=HSP90AB1
PE=1 SV=4

193

83212

8

4

10.4

4.97

46

Q562R1

Beta-actin-like protein 2 OS=Homo
sapiens GN=ACTBL2 PE=1 SV=2

189

41976

12

4

16

5.39

47

P06396

Gelsolin OS=Homo sapiens
GN=GSN PE=1 SV=1

185

85644

6

5

9.5

5.9

48

Q96QV6

Histone H2A type 1-A OS=Homo
sapiens GN=HIST1H2AA PE=1
SV=3

183

14225

6

3

29.8

10.86

49

P36955

Pigment epithelium-derived factor
OS=Homo sapiens GN=SERPINF1
PE=1 SV=4

181

46283

6

3

8.6

5.97

50

Q5VTE0

Putative elongation factor 1-alphalike 3 OS=Homo sapiens
GN=EEF1A1P5 PE=5 SV=1

175

50153

8

6

21

9.15

51

Q06033

Inter-alpha-trypsin inhibitor heavy
chain H3 OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

168

99787

7

3

4

5.49

52

P07900

Heat shock protein HSP 90-alpha
OS=Homo sapiens GN=HSP90AA1
PE=1 SV=5

165

84607

9

4

10.7

4.94

53

P08107

Heat shock 70 kDa protein 1A/1B
OS=Homo sapiens GN=HSPA1A
PE=1 SV=5

162

70009

4

3

6.2

5.48

54

P17066

Heat shock 70 kDa protein 6
OS=Homo sapiens GN=HSPA6
PE=1 SV=2

162

70984

4

3

6.2

5.81

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 59

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

55

P14618

Pyruvate kinase isozymes M1/M2
OS=Homo sapiens GN=PKM2 PE=1
SV=4

157

57900

7

6

16

7.96

56

P19013

Keratin, type II cytoskeletal 4
OS=Homo sapiens GN=KRT4 PE=1
SV=4

155

57250

8

4

7.3

6.25

57

P05556

Integrin beta-1 OS=Homo sapiens
GN=ITGB1 PE=1 SV=2

155

88357

7

4

9.6

5.27

58

Q9UPY3

Endoribonuclease, Dicer OS=Homo
sapiens GN=DICER PE=1 SV=2

154

218682

9

4

6.6

8.38

59

P62979

Ubiquitin-40S ribosomal protein
S27a OS=Homo sapiens
GN=RPS27A PE=1 SV=2

154

17953

8

5

34

9.68

60

P02042

Hemoglobin subunit delta OS=Homo
sapiens GN=HBD PE=1 SV=2

150

16045

9

2

12.9

7.85

61

P08697

Alpha-2-antiplasmin OS=Homo
sapiens GN=SERPINF2 PE=1 SV=3

148

54531

2

1

2.2

5.87

62

P02647

Apolipoprotein A-I OS=Homo
sapiens GN=APOA1 PE=1 SV=1

146

30759

3

1

6

5.56

63

Q7Z3Y8

Keratin, type I cytoskeletal 27
OS=Homo sapiens GN=KRT27 PE=1
SV=2

142

49792

6

3

7.4

4.98

64

Q9P2B2

Prostaglandin F2 receptor negative
regulator OS=Homo sapiens
GN=PTGFRN PE=1 SV=2

140

98495

5

5

5.5

6.16

65

P13497

Bone morphogenetic protein 1
OS=Homo sapiens GN=BMP1 PE=1
SV=2

133

111178

3

2

3.1

6.48

66

P02675

Fibrinogen beta chain OS=Homo
sapiens GN=FGB PE=1 SV=2

132

55892

4

3

4.7

8.54

67

Q9Y6L7

Tolloid-like protein 2 OS=Homo
sapiens GN=TLL2 PE=1 SV=1

132

113484

2

2

2.2

5.6

68

P00747

Plasminogen OS=Homo sapiens
GN=PLG PE=1 SV=2

131

90510

6

3

4.4

7.04

69

Q8WUM4

Programmed cell death 6-interacting
protein OS=Homo sapiens
GN=PDCD6IP PE=1 SV=1

126

95963

6

3

8.3

6.13

70

Q71DI3

Histone H3.2 OS=Homo sapiens
GN=HIST2H3A PE=1 SV=3

121

15379

6

4

44.9

11.27

71

P84243

Histone H3.3 OS=Homo sapiens
GN=H3F3A PE=1 SV=2

111

15318

6

4

44.9

11.27

72

Q86Y46

Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73 PE=1
SV=1

110

58887

9

4

8

6.93

73

P12259

Coagulation factor V OS=Homo
sapiens GN=F5 PE=1 SV=4

109

251546

6

4

2.3

5.68

74

P01008

Antithrombin-III OS=Homo sapiens
GN=SERPINC1 PE=1 SV=1

108

52569

7

3

10.1

6.32

75

P06733

Alpha-enolase OS=Homo sapiens
GN=ENO1 PE=1 SV=2

108

47139

3

3

10.8

7.01

76

P19827

Inter-alpha-trypsin inhibitor heavy
chain H1 OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

106

101326

4

2

2.9

6.31

77

Q8NI35

InaD-like protein OS=Homo sapiens
GN=INADL PE=1 SV=3

106

196247

10

1

0.3

4.84

78

Q8TAA3

Proteasome subunit alpha type-7-like
OS=Homo sapiens GN=PSMA8
PE=1 SV=3

106

28512

3

2

19.5

9.07

79

P02452

Collagen alpha-1(I) chain OS=Homo
sapiens GN=COL1A1 PE=1 SV=5

104

138857

2

2

1.6

5.6

80

P68431

Histone H3.1 OS=Homo sapiens
GN=HIST1H3A PE=1 SV=2

103

15394

6

4

44.9

11.13

81

P07942

Laminin subunit beta-1 OS=Homo
sapiens GN=LAMB1 PE=1 SV=2

102

197909

3

2

1.9

4.83

82

P05787

Keratin, type II cytoskeletal 8
OS=Homo sapiens GN=KRT8 PE=1
SV=7

102

53671

5

3

7.2

5.52

83

P51884

Lumican OS=Homo sapiens
GN=LUM PE=1 SV=2

101

38405

3

2

8.3

6.16

84

Q00610

Clathrin heavy chain 1 OS=Homo
sapiens GN=CLTC PE=1 SV=5

97

191493

2

2

2.9

5.48

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 60

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

85

P00558

Phosphoglycerate kinase 1
OS=Homo sapiens GN=PGK1 PE=1
SV=3

93

44586

3

2

8.4

8.3

86

P15531

Nucleoside diphosphate kinase A
OS=Homo sapiens GN=NME1 PE=1
SV=1

92

17138

1

1

11.2

5.83

87

P04075

Fructose-bisphosphate aldolase A
OS=Homo sapiens GN=ALDOA
PE=1 SV=2

92

39395

5

2

12.4

8.3

88

P05452

Tetranectin OS=Homo sapiens
GN=CLEC3B PE=1 SV=3

91

22522

3

3

21.8

5.52

89

P02787

Serotransferrin OS=Homo sapiens
GN=TF PE=1 SV=3

91

77014

3

2

1.7

6.81

90

A6NIZ1

Ras-related protein Rap-1b-like
protein OS=Homo sapiens PE=2
SV=1

89

20912

2

1

6.5

5.37

91

Q9GZM7

Tubulointerstitial nephritis antigenlike OS=Homo sapiens
GN=TINAGL1 PE=1 SV=1

88

52353

1

1

2.8

6.54

92

P11021

78 kDa glucose-regulated protein
OS=Homo sapiens GN=HSPA5
PE=1 SV=2

87

72288

3

2

3.1

5.07

93

P16870

Carboxypeptidase E OS=Homo
sapiens GN=CPE PE=1 SV=1

87

53117

2

2

4.8

5.03

94

P81605

Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

86

11277

2

2

20

6.08

95

P15169

Carboxypeptidase N catalytic chain
OS=Homo sapiens GN=CPN1 PE=1
SV=1

84

52253

1

1

3.3

6.86

96

P11717

Cation-independent mannose-6phosphate receptor OS=Homo
sapiens GN=IGF2R PE=1 SV=3

83

274199

4

2

1.2

5.64

97

P07195

L-lactate dehydrogenase B chain
OS=Homo sapiens GN=LDHB PE=1
SV=2

81

36615

2

1

7.5

5.71

98

P06702

Protein S100-A9 OS=Homo sapiens
GN=S100A9 PE=1 SV=1

80

13234

2

1

24.6

5.71

99

Q5D862

Filaggrin-2 OS=Homo sapiens
GN=FLG2 PE=1 SV=1

79

247928

2

1

0.9

8.45

100

P28066

Proteasome subunit alpha type-5
OS=Homo sapiens GN=PSMA5
PE=1 SV=3

78

26394

1

1

7.9

4.74

101

Q92743

Serine protease HTRA1 OS=Homo
sapiens GN=HTRA1 PE=1 SV=1

78

51255

3

2

6.5

8.09

102

P23526

Adenosylhomocysteinase OS=Homo
sapiens GN=AHCY PE=1 SV=4

78

47685

2

2

6.3

5.92

103

P02760

Protein AMBP OS=Homo sapiens
GN=AMBP PE=1 SV=1

77

38974

2

1

2

5.95

104

P05543

Thyroxine-binding globulin
OS=Homo sapiens GN=SERPINA7
PE=1 SV=2

75

46295

3

1

2.4

5.87

105

P43686

26S protease regulatory subunit 6B
OS=Homo sapiens GN=PSMC4
PE=1 SV=2

74

47337

2

1

2.9

5.09

106

Q7RTS7

Keratin, type II cytoskeletal 74
OS=Homo sapiens GN=KRT74 PE=1
SV=2

74

57830

4

2

4.2

7.59

108

Q99456

Keratin, type I cytoskeletal 12
OS=Homo sapiens GN=KRT12 PE=1
SV=1

73

53478

7

2

3.6

4.7

109

P60174

Triosephosphate isomerase
OS=Homo sapiens GN=TPI1 PE=1
SV=2

72

26653

1

1

5.2

6.45

110

P05156

Complement factor I OS=Homo
sapiens GN=CFI PE=1 SV=2

71

65707

2

2

3.4

7.72

111

Q12931

Heat shock protein 75 kDa,
mitochondrial OS=Homo sapiens
GN=TRAP1 PE=1 SV=3

71

80060

1

1

2

8.3

112

P08962

CD63 OS=HOMO SAPIENS
GN=CD63 PE=4 SV=2

71

25637

3

3

16.4

5.3

113

P02749

Beta-2-glycoprotein 1 OS=Homo
sapiens GN=APOH PE=1 SV=3

67

38273

3

1

5.2

8.34

114

B9A064

Immunoglobulin lambda-like
polypeptide 5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

66

23049

2

1

3.7

9.08

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 61

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

115

P12109

Collagen alpha-1(VI) chain
OS=Homo sapiens GN=COL6A1
PE=1 SV=3

66

108462

1

1

0.9

5.26

116

P04745

Alpha-amylase 1 OS=Homo sapiens
GN=AMY1A PE=1 SV=2

66

57731

2

1

2.3

6.47

117

P35052

Glypican-1 OS=Homo sapiens
GN=GPC1 PE=1 SV=2

66

61641

4

1

10.9

7.07

118

P08133

Annexin A6 OS=Homo sapiens
GN=ANXA6 PE=1 SV=3

65

75826

4

2

5.9

5.42

119

P01031

Complement C5 OS=Homo sapiens
GN=C5 PE=1 SV=4

65

188186

4

2

1.8

6.11

120

P29353_REVERSED
SHC-transforming protein 1
OS=Homo sapiens GN=SHC1 PE=1
SV=4 - REVERSED

65

62782

10

1

1.4

6.01

121

O15111_REVERSED
Inhibitor of nuclear factor kappa-B
kinase subunit alpha OS=Homo
sapiens GN=CHUK PE=1 SV=2 REVERSED

65

84585

6

1

1.6

6.28

123

P01009

Alpha-1-antitrypsin OS=Homo
sapiens GN=SERPINA1 PE=1 SV=3

64

46707

3

2

3.3

5.37

124

P13639

Elongation factor 2 OS=Homo
sapiens GN=EEF2 PE=1 SV=4

64

95277

3

2

6.9

6.41

125

A6NMY6

Putative annexin A2-like protein
OS=Homo sapiens GN=ANXA2P2
PE=5 SV=2

63

38635

2

1

6.2

6.49

126

Q99816

Tumor susceptibility gene 101
protein OS=Homo sapiens
GN=TSG101 PE=1 SV=2

60

43916

1

1

2.6

6.06

127

P02461

Collagen alpha-1(III) chain
OS=Homo sapiens GN=COL3A1
PE=1 SV=4

59

138479

2

2

1.5

6.21

128

Q14624

Inter-alpha-trypsin inhibitor heavy
chain H4 OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

58

103293

5

2

3.3

6.51

129

P02649

Apolipoprotein E OS=Homo sapiens
GN=APOE PE=1 SV=1

57

36132

1

1

2.8

5.65

130

P26641

Elongation factor 1-gamma
OS=Homo sapiens GN=EEF1G
PE=1 SV=3

56

50087

2

1

5

6.25

131

P35125

Ubiquitin carboxyl-terminal
hydrolase 6 OS=Homo sapiens
GN=USP6 PE=1 SV=2

55

158557

13

1

0.4

7.87

132

P02790

Hemopexin OS=Homo sapiens
GN=HPX PE=1 SV=2

54

51643

6

1

5.4

6.55

133

Q9BYX7_REVERSED
Putative beta-actin-like protein 3
OS=Homo sapiens GN=POTEKP
PE=5 SV=1 - REVERSED

54

41989

6

1

3.5

5.92

135

P14923

Junction plakoglobin OS=Homo
sapiens GN=JUP PE=1 SV=3

53

81693

1

1

2.7

5.75

136

Q14764

Major vault protein OS=Homo
sapiens GN=MVP PE=1 SV=4

52

99266

1

1

1.9

5.34

138

P01042

Kininogen-1 OS=Homo sapiens
GN=KNG1 PE=1 SV=2

52

71912

1

1

1.4

6.34

139

Q8N139

ATP-binding cassette sub-family A
member 6 OS=Homo sapiens
GN=ABCA6 PE=1 SV=2

52

184167

2

1

0.4

7.05

141

Q96Q89_REVERSED
Kinesin-like protein KIF20B
OS=Homo sapiens GN=KIF20B
PE=1 SV=3 - REVERSED

51

210500

2

1

0.5

5.54

142

Q2Q1W2_REVERSED
Tripartite motif-containing protein 71
OS=Homo sapiens GN=TRIM71
PE=2 SV=1 - REVERSED

51

93326

1

1

1.2

7.62

143

Q9BY43

51

25083

2

1

3.2

4.65

144

Q8NAV2_REVERSED
Uncharacterized protein C8orf58
OS=Homo sapiens GN=C8orf58
PE=2 SV=2 - REVERSED

51

39636

1

1

1.9

8.54

145

P02748

Complement component C9
OS=Homo sapiens GN=C9 PE=1
SV=2

51

63133

1

1

1.6

5.43

146

O00754

Lysosomal alpha-mannosidase
OS=Homo sapiens GN=MAN2B1
PE=1 SV=3

51

113672

1

1

1.1

6.84

147

O14817

Tetraspanin-4 OS=Homo sapiens
GN=TSPAN4 PE=1 SV=1

50

26100

2

1

10.5

6.07

Charged multivesicular body protein
4a OS=Homo sapiens GN=CHMP4A
PE=1 SV=3

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 62

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

148

P11047

Laminin subunit gamma-1 OS=Homo
sapiens GN=LAMC1 PE=1 SV=3

50

177489

3

3

1.9

5.01

149

P21333

Filamin-A OS=Homo sapiens
GN=FLNA PE=1 SV=4

50

280564

2

1

1.6

5.7

150

A8MT19_REVERSED
Putative rhophilin-2-like protein
OS=Homo sapiens PE=5 SV=2 REVERSED

49

65903

1

1

1.2

6.53

151

P12111

Collagen alpha-3(VI) chain
OS=Homo sapiens GN=COL6A3
PE=1 SV=5

48

343457

3

1

1.2

6.26

152

Q00013

55 kDa erythrocyte membrane
protein OS=Homo sapiens
GN=MPP1 PE=1 SV=2

47

52264

2

1

1.5

6.91

153

Q8IW52

SLIT and NTRK-like protein 4
OS=Homo sapiens GN=SLITRK4
PE=2 SV=1

47

94271

1

1

0.8

7.95

154

O95445

Apolipoprotein M OS=Homo sapiens
GN=APOM PE=1 SV=2

47

21239

1

1

3.7

5.66

155

Q13162

Peroxiredoxin-4 OS=Homo sapiens
GN=PRDX4 PE=1 SV=1

46

30521

1

1

4.1

5.86

156

P00488

Coagulation factor XIII A chain
OS=Homo sapiens GN=F13A1 PE=1
SV=4

46

83215

2

2

4

5.75

157

P08572

Collagen alpha-2(IV) chain
OS=Homo sapiens GN=COL4A2
PE=1 SV=4

46

167449

1

1

0.6

8.89

158

O14782

Kinesin-like protein KIF3C
OS=Homo sapiens GN=KIF3C PE=1
SV=3

46

89371

4

1

1.1

8.28

159

P35443

Thrombospondin-4 OS=Homo
sapiens GN=THBS4 PE=1 SV=2

45

105802

2

1

2.8

4.44

161

P49747

Cartilage oligomeric matrix protein
OS=Homo sapiens GN=COMP PE=1
SV=2

44

82808

2

1

2.8

4.36

162

Q14573_REVERSED
Inositol 1,4,5-trisphosphate receptor
type 3 OS=Homo sapiens GN=ITPR3
PE=1 SV=2 - REVERSED

44

303912

1

1

0.4

6.05

163

Q8IWC1

MAP7 domain-containing protein 3
OS=Homo sapiens GN=MAP7D3
PE=1 SV=2

44

98368

2

1

2.1

9.34

164

Q3KQU3

MAP7 domain-containing protein 1
OS=Homo sapiens GN=MAP7D1
PE=1 SV=1

44

92764

1

1

0.7

10.12

165

Q5U5X0

LYR motif-containing protein 7
OS=Homo sapiens GN=LYRM7
PE=1 SV=1

44

11947

1

1

5.8

9.67

166

Q8N7B9_REVERSED
EF-hand calcium-binding domaincontaining protein 3 OS=Homo
sapiens GN=EFCAB3 PE=1 SV=1 REVERSED

44

50114

1

1

1.4

9.31

167

Q8NB25_REVERSED
Protein FAM184A OS=Homo
sapiens GN=FAM184A PE=2 SV=3 REVERSED

44

132883

1

1

0.5

5.59

168

P06732

44

43074

1

1

1.6

6.77

169

Q93096_REVERSED
Protein tyrosine phosphatase type
IVA 1 OS=Homo sapiens
GN=PTP4A1 PE=1 SV=2 REVERSED

44

19802

1

1

3.5

9.17

170

Q6YHK3

CD109 antigen OS=Homo sapiens
GN=CD109 PE=1 SV=2

44

161587

1

1

0.6

5.59

171

Q8IYT4

Katanin p60 ATPase-containing
subunit A-like 2 OS=Homo sapiens
GN=KATNAL2 PE=2 SV=3

43

61214

2

1

2.2

7.22

172

A8MPT4

Glutathione S-transferase theta-4
OS=Homo sapiens GN=GSTT4
PE=3 SV=2

43

27941

1

1

2.5

6.25

173

Q8N6V9_REVERSED
Testis-expressed sequence 9 protein
OS=Homo sapiens GN=TEX9 PE=2
SV=1 - REVERSED

43

44798

1

1

1.5

6.2

174

Q9Y2U8_REVERSED
Inner nuclear membrane protein
Man1 OS=Homo sapiens
GN=LEMD3 PE=1 SV=2 REVERSED

43

99935

1

1

0.7

7.31

175

P05154

43

45646

1

1

1.5

9.3

Creatine kinase M-type OS=Homo
sapiens GN=CKM PE=1 SV=2

Plasma serine protease inhibitor
OS=Homo sapiens GN=SERPINA5
PE=1 SV=3

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 63

Author Manuscript

MDA-MB-231

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

176

Q92609

TBC1 domain family member 5
OS=Homo sapiens GN=TBC1D5
PE=1 SV=1

42

88949

1

1

1

6.1

177

Q9H2G4

Testis-specific Y-encoded-like protein
2 OS=Homo sapiens GN=TSPYL2
PE=1 SV=1

42

79387

1

1

1

4.45

178

Q00535_REVERSED
Cyclin-dependent kinase 5
OS=Homo sapiens GN=CDK5 PE=1
SV=3 - REVERSED

42

33283

1

1

3.1

7.9

179

P06703

Protein S100-A6 OS=Homo sapiens
GN=S100A6 PE=1 SV=1

41

10173

2

1

8.9

5.33

180

Q6ZMU1

Putative protein C3P1 OS=Homo
sapiens GN=C3P1 PE=5 SV=3

41

40171

2

1

5.5

6.32

183

Q86UY8_REVERSED
5~-nucleotidase domain-containing
protein 3 OS=Homo sapiens
GN=NT5DC3 PE=2 SV=1 REVERSED

41

63379

2

1

1.5

8.47

184

O75460_REVERSED
Serine/threonine-protein kinase/
endoribonuclease IRE1 OS=Homo
sapiens GN=ERN1 PE=1 SV=2 REVERSED

41

109666

1

1

0.6

5.98

186

Q9Y6X9_REVERSED
MORC family CW-type zinc finger
protein 2 OS=Homo sapiens
GN=MORC2 PE=1 SV=2 REVERSED

40

117750

1

1

0.7

8.6

187

Q96TA0_REVERSED
Putative protocadherin beta-18
OS=Homo sapiens GN=PCDHB18
PE=5 SV=1 - REVERSED

40

80423

1

1

0.8

4.87

188

P02458

Collagen alpha-1(II) chain OS=Homo
sapiens GN=COL2A1 PE=1 SV=3

40

141698

1

1

0.7

6.58

191

Q8NBM4

Ubiquitin-associated domaincontaining protein 2 OS=Homo
sapiens GN=UBAC2 PE=2 SV=1

40

38938

1

1

2.3

9.21

193

Q7Z5M8

Abhydrolase domain-containing
protein 12B OS=Homo sapiens
GN=ABHD12B PE=2 SV=1

40

40750

5

1

1.7

8.57

194

Q15020_REVERSED
Squamous cell carcinoma antigen
recognized by T-cells 3 OS=Homo
sapiens GN=SART3 PE=1 SV=1 REVERSED

40

109865

5

1

0.6

5.45

196

O60312

39

167582

2

1

0.6

8.7

197

Q9Y6Q3_REVERSED
Zinc finger protein 37 homolog
OS=Homo sapiens GN=ZFP37 PE=2
SV=3 - REVERSED

39

71164

1

1

1.7

9.26

198

Q96RW7

39

613001

2

1

0.1

6.07

199

Q13183_REVERSED
Solute carrier family 13 member 2
OS=Homo sapiens GN=SLC13A2
PE=2 SV=1 - REVERSED

38

64368

2

1

1.4

6.61

200

Q9UK41

38

25409

2

1

6.8

5.37

201

Q14C86_REVERSED
GTPase-activating protein and VPS9
domain-containing protein 1
OS=Homo sapiens GN=GAPVD1
PE=1 SV=2 - REVERSED

38

164876

1

1

0.5

5.09

206

P26640

Valyl-tRNA synthetase OS=Homo
sapiens GN=VARS PE=1 SV=4

38

140387

1

1

1.2

7.53

207

Q96JB3

Hypermethylated in cancer 2 protein
OS=Homo sapiens GN=HIC2 PE=1
SV=2

38

66114

1

1

1.6

5.95

208

O43309

Zinc finger and SCAN domaincontaining protein 12 OS=Homo
sapiens GN=ZSCAN12 PE=2 SV=1

38

70178

1

1

2

6.28

209

Q96K21

Zinc finger FYVE domain-containing
protein 19 OS=Homo sapiens
GN=ZFYVE19 PE=1 SV=3

38

51514

2

1

1.7

5.57

210

Q8WZ42_REVERSED
Titin OS=Homo sapiens GN=TTN
PE=1 SV=2 - REVERSED

38

3813810

2

1

0.1

6.01

211

O75865_REVERSED
Trafficking protein particle complex
subunit 6A OS=Homo sapiens
GN=TRAPPC6A PE=1 SV=2 REVERSED

38

17593

1

1

3.8

5.14

213

P04083

37

38690

1

1

2.3

6.57

Probable phospholipid-transporting
ATPase VA OS=Homo sapiens
GN=ATP10A PE=2 SV=2

Hemicentin-1 OS=Homo sapiens
GN=HMCN1 PE=1 SV=2

Vacuolar protein sorting-associated
protein 28 homolog OS=Homo
sapiens GN=VPS28 PE=1 SV=1

Annexin A1 OS=Homo sapiens
GN=ANXA1 PE=1 SV=2

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 64

Author Manuscript

MDA-MB-231
prot_hit

Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

214

P28070

Proteasome subunit beta type-4
OS=Homo sapiens GN=PSMB4
PE=1 SV=4

37

29185

1

1

3.8

5.72

216

P02753

Retinol-binding protein 4 OS=Homo
sapiens GN=RBP4 PE=1 SV=3

37

22995

2

1

10

5.76

217

Q12923

Tyrosine-protein phosphatase nonreceptor type 13 OS=Homo sapiens
GN=PTPN13 PE=1 SV=2

37

276733

1

1

0.5

5.99

218

P05109

Protein S100-A8 OS=Homo sapiens
GN=S100A8 PE=1 SV=1

37

10828

1

1

11.8

6.51

220

Q5SYB0

FERM and PDZ domain-containing
protein 1 OS=Homo sapiens
GN=FRMPD1 PE=1 SV=1

37

173328

1

1

0.4

5.14

221

A6NC57_REVERSED
Ankyrin repeat domain-containing
protein 62 OS=Homo sapiens
GN=ANKRD62 PE=2 SV=4 REVERSED

37

106379

1

1

0.7

6.26

222

Q8IWZ5_REVERSED
Tripartite motif-containing protein 42
OS=Homo sapiens GN=TRIM42
PE=2 SV=2 - REVERSED

37

82690

1

1

0.8

8.31

223

Q9UKU7_REVERSED
Isobutyryl-CoA dehydrogenase,
mitochondrial OS=Homo sapiens
GN=ACAD8 PE=1 SV=1 REVERSED

37

45040

1

1

1.4

8.16

224

Q674X7_REVERSED
Kazrin OS=Homo sapiens
GN=KAZN PE=1 SV=2 REVERSED

37

86298

1

1

0.8

6.59

225

Q14534

Squalene monooxygenase OS=Homo
sapiens GN=SQLE PE=2 SV=3

37

63882

1

1

1

8.8

226

P20138

Myeloid cell surface antigen CD33
OS=Homo sapiens GN=CD33 PE=1
SV=2

37

39800

1

1

1.9

8.69

227

A2RRP1_REVERSED
Neuroblastoma-amplified sequence
OS=Homo sapiens GN=NBAS PE=1
SV=2 - REVERSED

37

268401

1

1

0.3

5.65

231

O95714_REVERSED
E3 ubiquitin-protein ligase HERC2
OS=Homo sapiens GN=HERC2
PE=1 SV=2 - REVERSED

37

526895

6

1

0.4

5.88

232

Q9UGM3

Deleted in malignant brain tumors 1
protein OS=Homo sapiens
GN=DMBT1 PE=1 SV=2

36

260569

1

1

0.2

5.18

233

P26378

ELAV-like protein 4 OS=Homo
sapiens GN=ELAVL4 PE=1 SV=2

36

41743

2

1

3.7

9.45

234

Q96A37

RING finger protein 166 OS=Homo
sapiens GN=RNF166 PE=2 SV=1

36

26105

1

1

4.2

8.42

236

P22352

Glutathione peroxidase 3 OS=Homo
sapiens GN=GPX3 PE=1 SV=2

36

25537

1

1

5.3

8.26

237

Q9Y240

C-type lectin domain family 11
member A OS=Homo sapiens
GN=CLEC11A PE=1 SV=1

36

35672

1

1

5.3

5.06

240

P25789

Proteasome subunit alpha type-4
OS=Homo sapiens GN=PSMA4
PE=1 SV=1

36

29465

1

1

3.4

7.57

241

P10242_REVERSED
Transcriptional activator Myb
OS=Homo sapiens GN=MYB PE=1
SV=2 - REVERSED

36

72296

2

1

1.3

6.35

242

P02794

35

21226

1

1

2.5

8.2

Ferritin heavy chain OS=Homo
sapiens GN=FTH1 PE=1 SV=2

NIH 3T3
prot_hit

Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

1

P04264

Keratin, type II
cytoskeletal 1 OS=Homo
sapiens GN=KRT1 PE=1
SV=6

2826

65999

70

31

55.3

8.15

2

P13645

Keratin, type I
cytoskeletal 10
OS=Homo sapiens
GN=KRT10 PE=1 SV=6

2816

58792

83

29

57.9

5.13

3

P02768

Serum albumin
OS=Homo sapiens
GN=ALB PE=1 SV=2

2011

69321

114

8

13.5

5.92

4

P01023

Alpha-2-macroglobulin
OS=Homo sapiens
GN=A2M PE=1 SV=3

1949

163188

70

8

5.7

6.03

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 65

Author Manuscript

NIH 3T3
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

5

P02765

Alpha-2-HSglycoprotein OS=Homo
sapiens GN=AHSG
PE=1 SV=1

1830

39300

50

4

8.7

5.43

6

P35527

Keratin, type I
cytoskeletal 9 OS=Homo
sapiens GN=KRT9 PE=1
SV=3

1822

62027

44

22

68.7

5.14

7

P35908

Keratin, type II
cytoskeletal 2 epidermal
OS=Homo sapiens
GN=KRT2 PE=1 SV=2

1641

65393

46

24

58.1

8.07

8

P02751

Fibronectin OS=Homo
sapiens GN=FN1 PE=1
SV=4

1564

262460

50

29

18.1

5.46

9

P20742

Pregnancy zone protein
OS=Homo sapiens
GN=PZP PE=1 SV=4

1547

163760

48

5

4.3

5.97

10

P01024

Complement C3
OS=Homo sapiens
GN=C3 PE=1 SV=2

704

187030

25

11

8.9

6.02

11

P07996

Thrombospondin-1
OS=Homo sapiens
GN=THBS1 PE=1 SV=2

622

129300

26

15

19.1

4.71

12

P19823

Inter-alpha-trypsin
inhibitor heavy chain H2
OS=Homo sapiens
GN=ITIH2 PE=1 SV=2

593

106397

18

7

9.2

6.4

13

P00734

Prothrombin OS=Homo
sapiens GN=F2 PE=1
SV=2

527

69992

11

6

8

5.64

14

P13647

Keratin, type II
cytoskeletal 5 OS=Homo
sapiens GN=KRT5 PE=1
SV=3

514

62340

23

16

28.8

7.59

15

P0C0L4

Complement C4-A
OS=Homo sapiens
GN=C4A PE=1 SV=1

467

192650

18

7

5.2

6.65

16

Q07954

Prolow-density
lipoprotein receptorrelated protein 1
OS=Homo sapiens
GN=LRP1 PE=1 SV=2

415

504276

14

11

3.5

5.16

17

P02788

Lactotransferrin
OS=Homo sapiens
GN=LTF PE=1 SV=6

406

78132

18

3

4.8

8.5

18

P04259

Keratin, type II
cytoskeletal 6B
OS=Homo sapiens
GN=KRT6B PE=1 SV=5

394

60030

17

11

23

8.09

19

P02538

Keratin, type II
cytoskeletal 6A
OS=Homo sapiens
GN=KRT6A PE=1
SV=3

388

60008

17

12

24.6

8.09

20

P06396

Gelsolin OS=Homo
sapiens GN=GSN PE=1
SV=1

360

85644

11

7

12.8

5.9

21

P02533

Keratin, type I
cytoskeletal 14
OS=Homo sapiens
GN=KRT14 PE=1 SV=4

353

51529

17

9

20.3

5.09

22

P60709

Actin, cytoplasmic 1
OS=Homo sapiens
GN=ACTB PE=1 SV=1

315

41710

12

8

33.6

5.29

23

P02771

Alpha-fetoprotein
OS=Homo sapiens
GN=AFP PE=1 SV=1

288

68633

8

3

6.7

5.48

24

P02774

Vitamin D-binding
protein OS=Homo
sapiens GN=GC PE=1
SV=1

271

52929

12

5

12

5.4

25

P69905

Hemoglobin subunit
alpha OS=Homo sapiens
GN=HBA1 PE=1 SV=2

252

15248

13

4

33.1

8.72

26

Q7Z794

Keratin, type II
cytoskeletal 1b
OS=Homo sapiens
GN=KRT77 PE=1 SV=3

248

61864

7

3

4.8

5.73

27

P36955

Pigment epitheliumderived factor OS=Homo

233

46283

10

3

12

5.97

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 66

Author Manuscript

NIH 3T3
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

sapiens GN=SERPINF1
PE=1 SV=4

Author Manuscript
Author Manuscript
Author Manuscript

28

P04004

Vitronectin OS=Homo
sapiens GN=VTN PE=1
SV=1

226

54271

6

1

4.2

5.55

29

P02647

Apolipoprotein A-I
OS=Homo sapiens
GN=APOA1 PE=1
SV=1

226

30759

4

1

6

5.56

30

P62736

Actin, aortic smooth
muscle OS=Homo
sapiens GN=ACTA2
PE=1 SV=1

220

41982

7

5

18.8

5.23

31

Q04695

Keratin, type I
cytoskeletal 17
OS=Homo sapiens
GN=KRT17 PE=1 SV=2

205

48076

12

6

14.6

4.97

32

Q5XKE5

Keratin, type II
cytoskeletal 79
OS=Homo sapiens
GN=KRT79 PE=1 SV=2

200

57800

7

4

6.9

6.75

33

P13646

Keratin, type I
cytoskeletal 13
OS=Homo sapiens
GN=KRT13 PE=1 SV=4

198

49557

8

4

6.1

4.91

34

Q06033

Inter-alpha-trypsin
inhibitor heavy chain H3
OS=Homo sapiens
GN=ITIH3 PE=1 SV=2

196

99787

9

3

6.3

5.49

35

Q86YZ3

Hornerin OS=Homo
sapiens GN=HRNR
PE=1 SV=2

193

282228

3

2

2.3

10.05

36

P02042

Hemoglobin subunit
delta OS=Homo sapiens
GN=HBD PE=1 SV=2

189

16045

10

2

12.9

7.85

37

Q15063

Periostin OS=Homo
sapiens GN=POSTN
PE=1 SV=2

174

93255

7

2

7.4

7.27

38

P23142

Fibulin-1 OS=Homo
sapiens GN=FBLN1
PE=1 SV=4

172

77162

9

4

7.3

5.07

39

P02100

Hemoglobin subunit
epsilon OS=Homo
sapiens GN=HBE1 PE=1
SV=2

160

16192

7

1

12.9

8.67

40

P08697

Alpha-2-antiplasmin
OS=Homo sapiens
GN=SERPINF2 PE=1
SV=3

143

54531

2

1

2.2

5.87

41

P00747

Plasminogen OS=Homo
sapiens GN=PLG PE=1
SV=2

139

90510

6

3

4.3

7.04

42

P02675

Fibrinogen beta chain
OS=Homo sapiens
GN=FGB PE=1 SV=2

136

55892

5

3

6.7

8.54

43

P04406

Glyceraldehyde-3phosphate
dehydrogenase
OS=Homo sapiens
GN=GAPDH PE=1
SV=3

134

36030

3

3

17.6

8.57

44

P05556

Integrin beta-1
OS=Homo sapiens
GN=ITGB1 PE=1 SV=2

131

88357

4

3

6

5.27

45

Q9BQE3

Tubulin alpha-1C chain
OS=Homo sapiens
GN=TUBA1C PE=1
SV=1

130

49863

7

4

14.9

4.96

46

P01008

Antithrombin-III
OS=Homo sapiens
GN=SERPINC1 PE=1
SV=1

130

52569

10

4

14.7

6.32

47

P02452

Collagen alpha-1(I)
chain OS=Homo sapiens
GN=COL1A1 PE=1
SV=5

124

138857

3

3

2.4

5.6

48

P01031

Complement C5
OS=Homo sapiens
GN=C5 PE=1 SV=4

122

188186

6

2

2.9

6.11

49

P11142

Heat shock cognate 71
kDa protein OS=Homo
sapiens GN=HSPA8
PE=1 SV=1

122

70854

3

3

5.3

5.37

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 67

Author Manuscript

NIH 3T3
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

50

P07437

Tubulin beta chain
OS=Homo sapiens
GN=TUBB PE=1 SV=2

121

49639

5

4

24.8

4.78

51

P19013

Keratin, type II
cytoskeletal 4 OS=Homo
sapiens GN=KRT4 PE=1
SV=4

120

57250

7

3

7.3

6.25

52

P08107

Heat shock 70 kDa
protein 1A/1B
OS=Homo sapiens
GN=HSPA1A PE=1
SV=5

119

70009

2

2

4.2

5.48

53

P17066

Heat shock 70 kDa
protein 6 OS=Homo
sapiens GN=HSPA6
PE=1 SV=2

119

70984

2

2

4.2

5.81

54

P12109

Collagen alpha-1(VI)
chain OS=Homo sapiens
GN=COL6A1 PE=1
SV=3

117

108462

2

2

2.4

5.26

55

P02748

Complement component
C9 OS=Homo sapiens
GN=C9 PE=1 SV=2

114

63133

3

2

3.8

5.43

56

P19827

Inter-alpha-trypsin
inhibitor heavy chain H1
OS=Homo sapiens
GN=ITIH1 PE=1 SV=3

113

101326

4

2

2.9

6.31

57

Q8TAA3

Proteasome subunit
alpha type-7-like
OS=Homo sapiens
GN=PSMA8 PE=1
SV=3

113

28512

2

2

10.9

9.07

58

Q7Z3Y8

Keratin, type I
cytoskeletal 27
OS=Homo sapiens
GN=KRT27 PE=1 SV=2

111

49792

6

3

7.4

4.98

59

P06702

Protein S100-A9
OS=Homo sapiens
GN=S100A9 PE=1
SV=1

109

13234

4

2

43

5.71

60

P05787

Keratin, type II
cytoskeletal 8 OS=Homo
sapiens GN=KRT8 PE=1
SV=7

109

53671

4

3

5.6

5.52

61

P05109

Protein S100-A8
OS=Homo sapiens
GN=S100A8 PE=1
SV=1

109

10828

3

3

31.2

6.51

62

P02787

Serotransferrin
OS=Homo sapiens
GN=TF PE=1 SV=3

109

77014

5

2

1.7

6.81

63

Q562R1

Beta-actin-like protein 2
OS=Homo sapiens
GN=ACTBL2 PE=1
SV=2

108

41976

5

3

13.8

5.39

64

P62979

Ubiquitin-40S ribosomal
protein S27a OS=Homo
sapiens GN=RPS27A
PE=1 SV=2

102

17953

7

3

30.1

9.68

65

P12035

Keratin, type II
cytoskeletal 3 OS=Homo
sapiens GN=KRT3 PE=1
SV=3

99

64378

5

2

4

6.12

66

Q8NI35

InaD-like protein
OS=Homo sapiens
GN=INADL PE=1 SV=3

98

196247

10

1

0.3

4.84

67

Q8TEV9_REVERSED

Smith-Magenis
syndrome chromosomal
region candidate gene 8
protein OS=Homo
sapiens GN=SMCR8
PE=1 SV=2 REVERSED

97

104956

10

1

1.2

5.36

68

Q5D862

Filaggrin-2 OS=Homo
sapiens GN=FLG2 PE=1
SV=1

96

247928

2

2

1.3

8.45

69

P12111

Collagen alpha-3(VI)
chain OS=Homo sapiens
GN=COL6A3 PE=1
SV=5

96

343457

3

3

1.1

6.26

70

P49747

Cartilage oligomeric
matrix protein
OS=Homo sapiens
GN=COMP PE=1 SV=2

94

82808

3

2

4.5

4.36

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 68

Author Manuscript

NIH 3T3

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

71

A6NIZ1

Ras-related protein
Rap-1b-like protein
OS=Homo sapiens PE=2
SV=1

91

20912

2

1

6.5

5.37

72

P12259

Coagulation factor V
OS=Homo sapiens
GN=F5 PE=1 SV=4

89

251546

5

2

2

5.68

73

Q14624

Inter-alpha-trypsin
inhibitor heavy chain H4
OS=Homo sapiens
GN=ITIH4 PE=1 SV=4

87

103293

5

2

3.3

6.51

74

Q6KB66

Keratin, type II
cytoskeletal 80
OS=Homo sapiens
GN=KRT80 PE=1 SV=2

86

50494

3

1

5.1

5.58

75

P13497

Bone morphogenetic
protein 1 OS=Homo
sapiens GN=BMP1
PE=1 SV=2

83

111178

4

3

3.1

6.48

76

Q86Y46

Keratin, type II
cytoskeletal 73
OS=Homo sapiens
GN=KRT73 PE=1 SV=1

78

58887

7

3

8

6.93

77

P04114

Apolipoprotein B-100
OS=Homo sapiens
GN=APOB PE=1 SV=2

77

515283

3

3

0.5

6.58

78

P02790

Hemopexin OS=Homo
sapiens GN=HPX PE=1
SV=2

76

51643

6

1

3.2

6.55

79

P35443

Thrombospondin-4
OS=Homo sapiens
GN=THBS4 PE=1 SV=2

75

105802

2

2

2.5

4.44

80

P08123

Collagen alpha-2(I)
chain OS=Homo sapiens
GN=COL1A2 PE=1
SV=7

75

129235

2

2

2.2

9.08

81

P15169

Carboxypeptidase N
catalytic chain
OS=Homo sapiens
GN=CPN1 PE=1 SV=1

73

52253

1

1

3.3

6.86

82

Q92743

Serine protease HTRA1
OS=Homo sapiens
GN=HTRA1 PE=1
SV=1

73

51255

2

2

4.4

8.09

83

Q9Y6L7

Tolloid-like protein 2
OS=Homo sapiens
GN=TLL2 PE=1 SV=1

72

113484

3

2

2.2

5.6

84

P05452

Tetranectin OS=Homo
sapiens GN=CLEC3B
PE=1 SV=3

69

22522

2

2

12.9

5.52

85

Q96Q89_REVERSED

Kinesin-like protein
KIF20B OS=Homo
sapiens GN=KIF20B
PE=1 SV=3 REVERSED

68

210500

2

1

0.5

5.54

86

P51884

Lumican OS=Homo
sapiens GN=LUM PE=1
SV=2

68

38405

4

1

6.8

6.16

87

P02749

Beta-2-glycoprotein 1
OS=Homo sapiens
GN=APOH PE=1 SV=3

67

38273

3

1

5.2

8.34

88

P63104

14-3-3 protein zeta/delta
OS=Homo sapiens
GN=YWHAZ PE=1
SV=1

67

27728

1

1

4.9

4.73

89

O15111_REVERSED

Inhibitor of nuclear
factor kappa-B kinase
subunit alpha OS=Homo
sapiens GN=CHUK
PE=1 SV=2 REVERSED

66

84585

7

1

1.6

6.28

90

Q03692

Collagen alpha-1(X)
chain OS=Homo sapiens
GN=COL10A1 PE=1
SV=2

64

66117

1

1

1.9

9.68

91

B9A064

Immunoglobulin
lambda-like polypeptide
5 OS=Homo sapiens
GN=IGLL5 PE=2 SV=2

63

23049

2

1

3.7

9.08

92

Q7RTS7

Keratin, type II
cytoskeletal 74
OS=Homo sapiens
GN=KRT74 PE=1 SV=2

62

57830

3

2

4.2

7.59

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 69

Author Manuscript

NIH 3T3

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

93

Q99456

Keratin, type I
cytoskeletal 12
OS=Homo sapiens
GN=KRT12 PE=1 SV=1

62

53478

5

2

3.6

4.7

94

Q9BYX7_REVERSED

Putative beta-actin-like
protein 3 OS=Homo
sapiens GN=POTEKP
PE=5 SV=1 REVERSED

61

41989

6

1

3.5

5.92

95

P00450

Ceruloplasmin
OS=Homo sapiens
GN=CP PE=1 SV=1

59

122128

3

2

2.9

5.44

96

P23526

Adenosylhomocysteinase
OS=Homo sapiens
GN=AHCY PE=1 SV=4

59

47685

2

1

6.3

5.92

97

P20618

Proteasome subunit beta
type-1 OS=Homo
sapiens GN=PSMB1
PE=1 SV=2

58

26472

1

1

5.8

8.27

98

P98160

Basement membranespecific heparan sulfate
proteoglycan core
protein OS=Homo
sapiens GN=HSPG2
PE=1 SV=4

57

468532

2

2

0.6

6.06

99

Q8WUM4

Programmed cell death
6-interacting protein
OS=Homo sapiens
GN=PDCD6IP PE=1
SV=1

57

95963

2

1

2.2

6.13

100

P35125

Ubiquitin carboxylterminal hydrolase 6
OS=Homo sapiens
GN=USP6 PE=1 SV=2

56

158557

12

1

0.4

7.87

101

P02679

Fibrinogen gamma chain
OS=Homo sapiens
GN=FGG PE=1 SV=3

56

51479

1

1

2

5.37

102

P29353_REVERSED

SHC-transforming
protein 1 OS=Homo
sapiens GN=SHC1 PE=1
SV=4 - REVERSED

56

62782

9

1

1.4

6.01

103

P05546

Heparin cofactor 2
OS=Homo sapiens
GN=SERPIND1 PE=1
SV=3

55

57034

1

1

2.4

6.41

104

P01344

Insulin-like growth
factor II OS=Homo
sapiens GN=IGF2 PE=1
SV=1

54

20127

1

1

8.9

9.5

105

P02794

Ferritin heavy chain
OS=Homo sapiens
GN=FTH1 PE=1 SV=2

54

21212

1

1

5.5

5.3

106

P01009

Alpha-1-antitrypsin
OS=Homo sapiens
GN=SERPINA1 PE=1
SV=3

52

46707

3

1

3.3

5.37

107

Q16853

Membrane primary
amine oxidase
OS=Homo sapiens
GN=AOC3 PE=1 SV=3

52

84568

1

1

1.2

6.05

108

P20930

Filaggrin OS=Homo
sapiens GN=FLG PE=1
SV=3

51

434922

1

1

0.3

9.24

109

Q13454

Tumor suppressor
candidate 3 OS=Homo
sapiens GN=TUSC3
PE=2 SV=1

49

39650

1

1

2

9.93

110

Q9BXJ4

Complement C1q tumor
necrosis factor-related
protein 3 OS=Homo
sapiens GN=C1QTNF3
PE=2 SV=1

48

26977

2

2

6.5

6.04

111

Q9HAV0

Guanine nucleotidebinding protein subunit
beta-4 OS=Homo
sapiens GN=GNB4
PE=1 SV=3

48

37543

1

1

2.9

5.6

112

Q9NWT1_REVERSED

p21-activated protein
kinase-interacting
protein 1 OS=Homo
sapiens GN=PAK1IP1
PE=1 SV=2 REVERSED

48

43936

2

1

1.8

9.07

113

Q6ZU45

Putative C-type lectin
domain-containing

48

25796

1

1

3.4

6.3

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 70

Author Manuscript

NIH 3T3
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

protein NCRNA00083
OS=Homo sapiens
GN=NCRNA00083
PE=5 SV=1

Author Manuscript
Author Manuscript
Author Manuscript

114

Q92609

TBC1 domain family
member 5 OS=Homo
sapiens GN=TBC1D5
PE=1 SV=1

47

88949

2

1

1

6.1

115

O95497

Pantetheinase OS=Homo
sapiens GN=VNN1
PE=1 SV=2

47

56975

1

1

3.7

5.32

116

O95714_REVERSED

E3 ubiquitin-protein
ligase HERC2
OS=Homo sapiens
GN=HERC2 PE=1
SV=2 - REVERSED

47

526895

4

1

0.2

5.88

117

P11717

Cation-independent
mannose-6-phosphate
receptor OS=Homo
sapiens GN=IGF2R
PE=1 SV=3

47

274199

2

1

0.8

5.64

118

Q9NPY3_REVERSED

Complement component
C1q receptor OS=Homo
sapiens GN=CD93 PE=1
SV=3 - REVERSED

46

68515

1

1

1.1

5.27

119

P31151

Protein S100-A7
OS=Homo sapiens
GN=S100A7 PE=1
SV=4

46

11464

2

1

31.7

6.28

120

P19961

Alpha-amylase 2B
OS=Homo sapiens
GN=AMY2B PE=1
SV=1

46

57673

2

1

5.1

6.64

121

P02760

Protein AMBP
OS=Homo sapiens
GN=AMBP PE=1 SV=1

46

38974

2

1

2

5.95

122

Q9H4M9

EH domain-containing
protein 1 OS=Homo
sapiens GN=EHD1
PE=1 SV=2

46

60589

2

1

4.9

6.35

123

Q96CD0_REVERSED

F-box/LRR-repeat
protein 8 OS=Homo
sapiens GN=FBXL8
PE=1 SV=1 REVERSED

45

40490

11

1

1.9

7.03

124

Q08554

Desmocollin-1
OS=Homo sapiens
GN=DSC1 PE=1 SV=2

45

99924

1

1

1.7

5.25

125

P49720

Proteasome subunit beta
type-3 OS=Homo
sapiens GN=PSMB3
PE=1 SV=2

45

22933

2

2

16.6

6.14

126

P05543

Thyroxine-binding
globulin OS=Homo
sapiens GN=SERPINA7
PE=1 SV=2

44

46295

1

1

2.4

5.87

127

Q9H2G4

Testis-specific Yencoded-like protein 2
OS=Homo sapiens
GN=TSPYL2 PE=1
SV=1

44

79387

1

1

1

4.45

128

P25787

Proteasome subunit
alpha type-2 OS=Homo
sapiens GN=PSMA2
PE=1 SV=2

44

25882

2

1

9

6.92

129

P02461

Collagen alpha-1(III)
chain OS=Homo sapiens
GN=COL3A1 PE=1
SV=4

43

138479

3

2

1.4

6.21

130

P81605

Dermcidin OS=Homo
sapiens GN=DCD PE=1
SV=2

43

11277

2

1

10

6.08

131

Q9Y6X9_REVERSED

MORC family CW-type
zinc finger protein 2
OS=Homo sapiens
GN=MORC2 PE=1
SV=2 - REVERSED

43

117750

2

1

1.6

8.6

132

Q8NBM4

Ubiquitin-associated
domain-containing
protein 2 OS=Homo
sapiens GN=UBAC2
PE=2 SV=1

43

38938

4

1

2.3

9.21

133

P10643

Complement component
C7 OS=Homo sapiens
GN=C7 PE=1 SV=2

43

93457

2

1

2

6.09

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 71

Author Manuscript

NIH 3T3
prot_hit

Author Manuscript
Author Manuscript
Author Manuscript

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

134

Q12968_REVERSED

Nuclear factor of
activated T-cells,
cytoplasmic 3 OS=Homo
sapiens GN=NFATC3
PE=1 SV=1 REVERSED

43

115522

3

1

0.7

5.91

135

P32119

Peroxiredoxin-2
OS=Homo sapiens
GN=PRDX2 PE=1
SV=5

42

21878

1

1

9.1

5.66

136

Q9UGM3

Deleted in malignant
brain tumors 1 protein
OS=Homo sapiens
GN=DMBT1 PE=1
SV=2

42

260569

1

1

0.2

5.18

137

O75460_REVERSED

Serine/threonine-protein
kinase/endoribonuclease
IRE1 OS=Homo sapiens
GN=ERN1 PE=1 SV=2 REVERSED

41

109666

1

1

0.6

5.98

138

Q9UKT8_REVERSED

F-box/WD repeatcontaining protein 2
OS=Homo sapiens
GN=FBXW2 PE=1
SV=2 - REVERSED

41

51479

2

1

3.1

6.11

139

O95445

Apolipoprotein M
OS=Homo sapiens
GN=APOM PE=1 SV=2

41

21239

2

1

6.9

5.66

140

P00558

Phosphoglycerate kinase
1 OS=Homo sapiens
GN=PGK1 PE=1 SV=3

40

44586

2

1

8.4

8.3

141

O14578_REVERSED

Citron Rho-interacting
kinase OS=Homo
sapiens GN=CIT PE=1
SV=2 - REVERSED

40

231286

2

1

0.5

6.16

142

Q7Z5M8

Abhydrolase domaincontaining protein 12B
OS=Homo sapiens
GN=ABHD12B PE=2
SV=1

40

40750

3

1

1.7

8.57

143

Q15020_REVERSED

Squamous cell
carcinoma antigen
recognized by T-cells 3
OS=Homo sapiens
GN=SART3 PE=1 SV=1
- REVERSED

40

109865

3

1

0.6

5.45

144

P29803_REVERSED

Pyruvate dehydrogenase
E1 component subunit
alpha, testis-specific
form, mitochondrial
OS=Homo sapiens
GN=PDHA2 PE=1
SV=1 - REVERSED

40

42906

2

1

1.8

8.76

145

Q14914

Prostaglandin reductase
1 OS=Homo sapiens
GN=PTGR1 PE=1 SV=2

40

35847

1

1

2.1

8.45

146

Q9NQX4

Myosin-Vc OS=Homo
sapiens GN=MYO5C
PE=1 SV=2

40

202682

1

1

0.4

7.69

147

Q13183_REVERSED

Solute carrier family 13
member 2 OS=Homo
sapiens GN=SLC13A2
PE=2 SV=1 REVERSED

40

64368

2

1

1.4

6.61

148

A8MPT4

Glutathione S-transferase
theta-4 OS=Homo
sapiens GN=GSTT4
PE=3 SV=2

39

27941

2

1

2.5

6.25

149

Q8N6V9_REVERSED

Testis-expressed
sequence 9 protein
OS=Homo sapiens
GN=TEX9 PE=2 SV=1 REVERSED

39

44798

2

1

1.5

6.2

150

Q9Y2U8_REVERSED

Inner nuclear membrane
protein Man1 OS=Homo
sapiens GN=LEMD3
PE=1 SV=2 REVERSED

39

99935

2

1

0.7

7.31

151

P05154

Plasma serine protease
inhibitor OS=Homo
sapiens GN=SERPINA5
PE=1 SV=3

39

45646

2

1

1.5

9.3

152

P11137

Microtubule-associated
protein 2 OS=Homo
sapiens GN=MAP2
PE=1 SV=4

39

199404

4

1

1.4

4.82

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 72

Author Manuscript

NIH 3T3

Author Manuscript
Author Manuscript
Author Manuscript

prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

153

Q9BY43

Charged multivesicular
body protein 4a
OS=Homo sapiens
GN=CHMP4A PE=1
SV=3

39

25083

1

1

3.2

4.65

154

P22303

Acetylcholinesterase
OS=Homo sapiens
GN=ACHE PE=1 SV=1

39

67753

1

1

2.1

5.87

155

P07864

L-lactate dehydrogenase
C chain OS=Homo
sapiens GN=LDHC
PE=2 SV=4

38

36288

3

1

6.6

7.08

156

P28066

Proteasome subunit
alpha type-5 OS=Homo
sapiens GN=PSMA5
PE=1 SV=3

38

26394

2

1

12

4.74

157

Q14C86_REVERSED

GTPase-activating
protein and VPS9
domain-containing
protein 1 OS=Homo
sapiens GN=GAPVD1
PE=1 SV=2 REVERSED

38

164876

2

1

0.5

5.09

158

O75808

Calpain-15 OS=Homo
sapiens GN=SOLH
PE=1 SV=1

38

117239

1

1

0.6

6.27

159

Q15751_REVERSED

Probable E3 ubiquitinprotein ligase HERC1
OS=Homo sapiens
GN=HERC1 PE=1
SV=2 - REVERSED

38

531891

1

1

0.2

5.69

160

Q6R2W3_REVERSED

SCAN domaincontaining protein 3
OS=Homo sapiens
GN=SCAND3 PE=2
SV=1 - REVERSED

38

151570

3

1

0.7

6.3

161

Q6ZNE9_REVERSED

RUN and FYVE
domain-containing
protein 4 OS=Homo
sapiens GN=RUFY4
PE=2 SV=2 REVERSED

37

64309

1

1

1.4

6.43

162

Q8N7B9

EF-hand calciumbinding domaincontaining protein 3
OS=Homo sapiens
GN=EFCAB3 PE=1
SV=1

37

50114

3

1

2.1

9.31

163

O60312

Probable phospholipidtransporting ATPase VA
OS=Homo sapiens
GN=ATP10A PE=2
SV=2

37

167582

1

1

0.6

8.7

164

O15264

Mitogen-activated
protein kinase 13
OS=Homo sapiens
GN=MAPK13 PE=1
SV=1

37

42063

3

1

1.9

8.48

165

Q9H2K8

Serine/threonine-protein
kinase TAO3 OS=Homo
sapiens GN=TAOK3
PE=1 SV=2

37

105340

5

1

1.9

6.83

166

P48634

Protein PRRC2A
OS=Homo sapiens
GN=PRRC2A PE=1
SV=3

37

228724

4

1

0.3

9.48

167

Q8IVF6

Ankyrin repeat domaincontaining protein 18A
OS=Homo sapiens
GN=ANKRD18A PE=1
SV=3

37

115525

4

1

0.7

7.92

168

P35580

Myosin-10 OS=Homo
sapiens GN=MYH10
PE=1 SV=3

36

228858

1

1

0.6

5.44

169

P10242_REVERSED

Transcriptional activator
Myb OS=Homo sapiens
GN=MYB PE=1 SV=2 REVERSED

36

72296

1

1

1.3

6.35

170

Q9BV38

WD repeat-containing
protein 18 OS=Homo
sapiens GN=WDR18
PE=1 SV=2

36

47375

1

1

2.1

6.21

171

Q99816

Tumor susceptibility
gene 101 protein
OS=Homo sapiens

60

43916

1

1

6.4

8.21

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 73

Author Manuscript

NIH 3T3
prot_hit

prot_acc

prot_desc

prot_score

prot_mass

prot_matches

prot_sequences_sig

prot_cover

prot_pi

GN=TSG101 PE=1
SV=2

Extended Data Table 3

Demographics of Patients and Healthy Participants
DISCOVERY COHORT

VALIDATION COHORT

No. of
participants
(n=321)

No. of
participants
(n=82)

% of participants

Pancreatic Cancer
Total

No. of
participants
(n=32)

% of participants

Pancreatic Cancer

% of participants

Breast cancer

Author Manuscript

190

59.19%

56

68.29%

32

100%

Men

104

54.74%

28

50.00%

0

0%

Women

86

45.26%

28

50.00%

32

100%

Sex

Median Age (range)

66
(37
–
86)

70
(40
–
85)

57
(30
–
85)

AJCC stage

Author Manuscript
Author Manuscript

0

n.a.

-

n.a.

-

2

6%

I

2

1.05%

2

3.57%

12

38%

II

n.a

-

n.a

-

17

53%

IIa

19

10.00%

15

26.79%

n.a.

-

IIb

117

61.58%

36

64.29%

n.a.

-

III

11

5.79%

0

0.00%

1

3%

IV

41

21.58%

3

5.36%

n.a.

-

1

1

0.53%

1

1.79%

8

25%

2

91

47.89%

35

62.5%

13

41%

3

49

25.79%

19

33.93%

10

31%

4

1

0.53%

0

0.00%

n.a.

-

Unknown

48

25.26%

1

1.79%

1

3%

Yes

152

80.00%

54

96.43%

32

100%

No

38

20.00%

2

3.57%

0

0%

10

5.26%

0

0.00%

0

0%

Tumor grade

Tumor resected

Neoadjuvant Radio- /Chemotherapy

Received

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 74

Author Manuscript

DISCOVERY COHORT

VALIDATION COHORT

No. of
participants
(n=321)

No. of
participants
(n=82)

% of participants

Pancreatic Cancer
Not received

180

% of participants

Pancreatic Cancer

94.74%

56

No. of
participants
(n=32)

100.00%

32

Benign Pancreatic disease (BPD)

Total

26

8.15%

Men

18

69.23%

3

50.00%

Women

8

30.77%

3

50.00%

Sex

Author Manuscript

Median Age (range)

58.5
(31
–
77)

49
(43
–
56)

Diagnosis

Chronic pancreatits

15

57.69%

6

100%

Autoimmune pancreatitis

3

11.54%

0

0.00%

Serous cystadenoma

8

30.77%

0

0.00%

Pancreatic cancer precursor lesion (PCPL)

Total

5

1.55%

0

0.00%

Men

2

40.00%

0

0.00%

Women

3

60.00%

0

0.00%

-

-

0

0.00%

20

24.39%

Sex

Author Manuscript

Median Age (range)

65
(59
–
74)

-

Neoplasms

* IPMN

5

100.0%

Healthy donors

Total

100

31.15%

n.a. - non applicable

Author Manuscript

Abbreviations: American Joint Committee on Cancer (AJCC), Intraductal papillary mucinous neoplasm (IPMN),
Pancreatic Intraepithelial Neoplasia (PanIN).

*
The group of IPMNs consist of 2 IPMN associated with a carcinoma in situ, 1 IPMN associated with an early
adenocarcinoma of the pancreas (pT1), an IPMN with intermediate dysplasia and an IPMN with low-grade dysplasia.

Nature. Author manuscript; available in PMC 2016 July 09.

% of participants

Breast cancer
100%

Melo et al.

Page 75

Author Manuscript

Extended Data Table 4

Histological report of patients with chronic pancreatitis
The histopathological report is listed for the 15 patients with chronic pancreatitis in the
discovery cohort.

Author Manuscript
Author Manuscript

Patient No.

PanIN described

Histopathological report

1

No

Pancreatic tissue with chronic pancreatitis and extensive fibrosis and focal necrosis
lipolytic and triptolytic areas.

0

No

Diffuse periductal lymphoplasmacytic infiltrates; severe periductal fibrosis and
duct obstruction/disappearance; severe interlobular and acinar involvement; severe
inflammatory storiform fibrosis and diffuse sclerosis; frequent venulitis and
occasional arteritis; scattered and occasionally prominent lymphoid follicles

3

No

Chronic pancreatitis with periductal, inter- and intralobular fibrosis

4

No

Chronic pancreatitis and extensive fibrosis

5

No

Chronic recurrent and acute pancreatitis with plurifocal tryptolytic and lipolytic
necrosis

6

No

Low-grade chronic pancreatitis with periductal fibrosis, in the present material no
evidence of neoplastic events, no evidence of malignancy.

7

No

Chronic recurrent pancreatitis with some more pronounced fibrosis and intraductal
calcifications. Chronic pancreatitis extends to the pancreas resection margin.

8

No

Chronic pancreatitis, cholangitis and papillitis with focally histomorphological
aspect of an autoimmune, chronic sclerosing pancreatitis.

9

PanIN 1a

10

No

Pancreatic parenchyma with perilobular fibrosis as well as dilated pancreatic ducts.
In addition, peripancreatic fat and connective tissue with fibrosis. The finding
represents a chronic pancreatitis.

11

PanIN 1a

Chronic-recurrent pancreatitis with pronounced fibrosis and dilated pancreatic
ducts with focal inflammatory reactive epithelial cells. Older areas of organized
necrosis and focal pancreatic intraepithelial neoplasia (PanIN) Grade 1A. Chronic
pancreatitis also affects the pancreas resection margin.

12

No

Pancreatitis with focally accentuated, periductal, perilobular and intralobular
fibrosis as well as smaller areas of organized fatty necrosis and presence of singel
giant cells of foreign body type.

13

No

Chronic recurrent and acute pancreatitis with plurifocal tryptolytic and lipolytic
necrosis with extensive destruction of the pancreatic parenchyma. Smaller
secretion - and obliteration of pancreatic ducts with periductal fibrosis and
localized squamous metaplasia. Peri- and interlobular fibrosis of the pancreatic
parenchyma. Pancreatitis reaches the resection margin. At present, no neoplastic
tissue, no evidence of malignancy.

14

No

Pancreatic tissue with some scarring chronic inflammation and chronic pancreatits.
In the present material, no evidence of malignancy.

15

No

Tumor -free pancreatic tissue (surgical margins) with low periductal and
interlobular fibrosis.

Pancreatic parenchyma (head of the pancreas) and peripancreatic fat and
connective tissue with chronic recurrent pancreatitis with some areas fibrosis and
abscesses. Pancreatic intraepithelial neoplasia (PanIN) Grade 1A.

Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 76

Author Manuscript

Extended Data Table 5

Histopathological findings and scoring in PKT mice in
the cross sectional study
The mouse ID, age, genotype and percent bead with GPC1+ crExos of mice in the cross
sectional study are listed. A description of the histopathological findings and associated
histological score is listed for PKT mice. Score 1: PanIN1a, Score 2: PanIN1 a/b, Score 3:
PanIN2, Score 4: PanIN3, Score 5: Ductal adenocarcinoma (DCA). P: present (lesions were
detected). 0: no lesion detected.

Author Manuscript

Mouse ID

Age (days)

Sex

Genotype

GPC1 (%)

Normal (% area)

Involved (% area)

PanIN1a

PanIN1b

PanIN2

PanIN3

DCA

T187

16

M

Healthy+control

0.6

100

0

0

0

0

0

0

Other (defined)

T188

16

M

Healthy+control

1.1

100

0

0

0

0

0

0

T157

20

M

Healthy+control

0.2

100

0

0

0

0

0

0

T158

20

M

Healthy+control

0.2

100

0

0

0

0

0

0

T163

20

M

Healthy+control

0.2

100

0

0

0

0

0

0

T164

20

M

Healthy+control

0.4

100

0

0

0

0

0

0

T183

16

M

PKT

8.4

98.6

1.4

P

0

0

0

0

T190

16

F

PKT

5.2

100.0

0.0

0

0

0

0

0

reactive+ducts

0

T191

16

F

PKT

6.4

100.0

0.0

0

0

0

0

0

reactive+ducts

0

T156

20

M

PKT

8.3

100.0

0.0

0

0

0

0

0

0

T159

20

F

PKT

10.8

95.1

4.9

P

P

P

0

0

3

T160

20

F

PKT

9.8

99.3

0.7

P

P

0

0

0

2

T165

20

F

PKT

9.2

96.1

3.9

P

P

0

0

0

2

1

P : present
0 : not detected

Author Manuscript

Acknowledgments
This work was primarily supported by the Cancer Prevention and Research Institute of Texas and UT MD Anderson
Cancer Center. RK is also supported by NIH Grants CA-155370, CA-151925, DK 081576 and Metastasis Research
Center at the MD Anderson Cancer Center (P30CA016672). VSL is supported by the NIH/NCI under the award
number P30CA016672 and the UT MDACC Khalifa Bin Zayed Al Nahya Foundation. DPW and STG are
supported by the NIH P50-CA094056. Institutional Core Grant CA16672 for High Resolution Electron Microscopy
Facility. The Flow Cytometry MDACC core facility is partially funded by NIH P30CA16672. The MDACC Small
Animal Imaging Facility is partially funded by NIH grants P30-CA016672 and 5U24-CA126577. SAM is a Human
Frontiers Science Program Fellow. CK is funded by a Research Fellowship of the Deutsche Forschungsgemeinschaf
(DFG). We thank Paul A. Kurywchak for the help with immunoblots and sucrose gradients, and Sushrut Kamerkar
for the help with the sucrose gradients. We thank Kenneth Dunner Jr. for the help with the transmission electron
microscopy and immunogold techniques.

References
Author Manuscript

1. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization
of the transferrin receptor in vesicular form in sheep reticulocytes. The Journal of cell biology.
1985; 101:942–948. [PubMed: 2993317]
2. Trajkovic K, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes.
Science. 2008; 319:1244–1247.10.1126/science.1153124 [PubMed: 18309083]
3. Skog J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth
and provide diagnostic biomarkers. Nature cell biology. 2008; 10:1470–1476.10.1038/ncb1800
[PubMed: 19011622]

Nature. Author manuscript; available in PMC 2016 July 09.

Pathological score

Melo et al.

Page 77

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

4. Al-Nedawi K, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles
derived from tumour cells. Nature cell biology. 2008; 10:619–624.10.1038/ncb1725 [PubMed:
18425114]
5. Demory Beckler M, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells
identifies intercellular transfer of mutant KRAS. Molecular & cellular proteomics : MCP. 2013;
12:343–355.10.1074/mcp.M112.022806 [PubMed: 23161513]
6. Kahlert C, et al. Identification of double-stranded genomic DNA spanning all chromosomes with
mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. The Journal
of biological chemistry. 2014; 289:3869–3875.10.1074/jbc.C113.532267 [PubMed: 24398677]
7. Ostrowski M, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway.
Nature cell biology. 2010; 12:19–30. sup pp 11–13. 10.1038/ncb2000 [PubMed: 19966785]
8. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nature
reviews. Immunology. 2009; 9:581–593.10.1038/nri2567
9. Janowska-Wieczorek A, et al. Microvesicles derived from activated platelets induce metastasis and
angiogenesis in lung cancer. International journal of cancer. Journal international du cancer. 2005;
113:752–760.10.1002/ijc.20657 [PubMed: 15499615]
10. Hergenreider E, et al. Atheroprotective communication between endothelial cells and smooth
muscle cells through miRNAs. Nature cell biology. 2012; 14:249–256.10.1038/ncb2441 [PubMed:
22327366]
11. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated
immunosuppressive microenvironments. Seminars in immunopathology. 2011; 33:441–
454.10.1007/s00281-010-0234-8 [PubMed: 21688197]
12. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic
biomarkers of ovarian cancer. Gynecologic oncology. 2008; 110:13–21.10.1016/j.ygyno.
2008.04.033 [PubMed: 18589210]
13. Silva J, et al. Analysis of exosome release and its prognostic value in human colorectal cancer.
Genes, chromosomes & cancer. 2012; 51:409–418. [PubMed: 22420032]
14. Runz S, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and
EpCAM. Gynecologic oncology. 2007; 107:563–571.10.1016/j.ygyno.2007.08.064 [PubMed:
17900673]
15. Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nature medicine. 2012; 18:883–891.10.1038/nm.2753
16. Mears R, et al. Proteomic analysis of melanoma-derived exosomes by two-dimensional
polyacrylamide gel electrophoresis and mass spectrometry. Proteomics. 2004; 4:4019–
4031.10.1002/pmic.200400876 [PubMed: 15478216]
17. Andre F, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;
360:295–305.10.1016/S0140-6736(02)09552-1 [PubMed: 12147373]
18. Adamczyk KA, et al. Characterization of soluble and exosomal forms of the EGFR released from
pancreatic cancer cells. Life sciences. 2011; 89:304–312.10.1016/j.lfs.2011.06.020 [PubMed:
21763319]
19. Baran J, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients.
Cancer immunology, immunotherapy : CII. 2010; 59:841–850.10.1007/s00262-009-0808-2
[PubMed: 20043223]
20. Ciravolo V, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumabbased therapy. Journal of cellular physiology. 2012; 227:658–667.10.1002/jcp.22773 [PubMed:
21465472]
21. Luga V, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast
cancer cell migration. Cell. 2012; 151:1542–1556.10.1016/j.cell.2012.11.024 [PubMed:
23260141]
22. Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and characterization of exosomes from
cell culture supernatants and biological fluids. In: Bonifacino, Juan S., et al., editors. Current
protocols in cell biology / editorial board. Vol. Chapter 3. 2006. p. 22
23. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature
reviews. Immunology. 2002; 2:569–579.10.1038/nri855

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 78

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

24. Wilson ID, et al. High resolution “ultra performance” liquid chromatography coupled to oa-TOF
mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic
studies. Journal of proteome research. 2005; 4:591–598.10.1021/pr049769r [PubMed: 15822939]
25. Matsuda K, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic
effects of multiple heparin-binding growth factors in breast cancer cells. Cancer research. 2001;
61:5562–5569. [PubMed: 11454708]
26. Kleeff J, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor
action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. The Journal
of clinical investigation. 1998; 102:1662–1673.10.1172/JCI4105 [PubMed: 9802880]
27. Su G, et al. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2
signaling in glioma cells. The American journal of pathology. 2006; 168:2014–2026.10.2353/
ajpath.2006.050800 [PubMed: 16723715]
28. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and
metastasis. J Mol Med (Berl). 2013; 91:431–437.10.1007/s00109-013-1020-6 [PubMed:
23519402]
29. Morris, JPt; Wang, SC.; Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental
biology of pancreatic ductal adenocarcinoma. Nature reviews. Cancer. 2010; 10:683–695.10.1038/
nrc2899 [PubMed: 20814421]
30. Chen WW, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma
Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular therapy. Nucleic acids.
2013; 2:e109.10.1038/mtna.2013.28 [PubMed: 23881452]
31. Del Villano BC, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker,
CA 19–9. Clinical chemistry. 1983; 29:549–552. [PubMed: 6825270]
32. Ozdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces
immunosuppression and accelerates pancreas cancer with reduced survival. Cancer cell. 2014;
25:719–734.10.1016/j.ccr.2014.04.005 [PubMed: 24856586]
33. Ijichi H, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific
blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
Genes & development. 2006; 20:3147–3160.10.1101/gad.1475506 [PubMed: 17114585]
34. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World journal
of gastroenterology : WJG. 2014; 20:7864–7877.10.3748/wjg.v20.i24.7864 [PubMed: 24976723]
35. Rickes S, Unkrodt K, Neye H, Ocran KW, Wermke W. Differentiation of pancreatic tumours by
conventional ultrasound, unenhanced and echo-enhanced power Doppler sonography.
Scandinavian journal of gastroenterology. 2002; 37:1313–1320. [PubMed: 12465731]
36. Murphy SJ, et al. Genetic alterations associated with progression from pancreatic intraepithelial
neoplasia to invasive pancreatic tumor. Gastroenterology. 2013; 145:1098–1109 e1091.10.1053/
j.gastro.2013.07.049 [PubMed: 23912084]
37. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature reviews. Cancer. 2002;
2:897–909.10.1038/nrc949 [PubMed: 12459728]
38. Yachida S, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
Nature. 2010; 467:1114–1117.10.1038/nature09515 [PubMed: 20981102]
39. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010; 362:1605–
1617.10.1056/NEJMra0901557 [PubMed: 20427809]
40. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and
options beyond CA 19-9. Tumour biology : the journal of the International Society for
Oncodevelopmental Biology and Medicine. 2013; 34:3279–3292.10.1007/s13277-013-1033-3
[PubMed: 23949878]
41. Jazieh KA, Foote MB, Diaz LA Jr. The clinical utility of biomarkers in the management of
pancreatic adenocarcinoma. Seminars in radiation oncology. 2014; 24:67–76.10.1016/j.semradonc.
2013.11.007 [PubMed: 24635863]
42. Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in
gastrointestinal cancer. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology. 2006; 24:5313–5327.10.1200/JCO.2006.08.2644 [PubMed: 17060676]

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 79

Author Manuscript
Author Manuscript
Author Manuscript

43. Okano K, Suzuki Y. Strategies for early detection of resectable pancreatic cancer. World journal of
gastroenterology : WJG. 2014; 20:11230–11240.10.3748/wjg.v20.i32.11230 [PubMed: 25170207]
44. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic
ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Annals of surgery. 1996;
223:273–279. [PubMed: 8604907]
45. Bilimoria KY, et al. National failure to operate on early stage pancreatic cancer. Annals of surgery.
2007; 246:173–180.10.1097/SLA.0b013e3180691579 [PubMed: 17667493]
46. Murtaza M, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of
plasma DNA. Nature. 2013; 497:108–112.10.1038/nature12065 [PubMed: 23563269]
47. Yong E. Cancer biomarkers: Written in blood. Nature. 2014; 511:524–526.10.1038/511524a
[PubMed: 25079538]
48. David G, et al. Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate
proteoglycan from human lung fibroblasts. The Journal of cell biology. 1990; 111:3165–3176.
[PubMed: 2148568]
49. Whipple CA, Young AL, Korc M. A KrasG12D-driven genetic mouse model of pancreatic cancer
requires glypican-1 for efficient proliferation and angiogenesis. Oncogene. 2012; 31:2535–
2544.10.1038/onc.2011.430 [PubMed: 21996748]
50. Aikawa T, et al. Glypican-1 modulates the angiogenic and metastatic potential of human and
mouse cancer cells. The Journal of clinical investigation. 2008; 118:89–99.10.1172/JCI32412
[PubMed: 18064304]
51. Brand RE, et al. Serum biomarker panels for the detection of pancreatic cancer. Clinical cancer
research : an official journal of the American Association for Cancer Research. 2011; 17:805–
816.10.1158/1078-0432.CCR-10-0248 [PubMed: 21325298]
52. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the
mouse. Cancer cell. 2003; 4:437–450. [PubMed: 14706336]
53. Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and
Euler diagrams in R. BMC bioinformatics. 2011; 12:35.10.1186/1471-2105-12-35 [PubMed:
21269502]
54. Rachagani S, et al. Activated KrasG(1)(2)D is associated with invasion and metastasis of
pancreatic cancer cells through inhibition of E-cadherin. British journal of cancer. 2011;
104:1038–1048.10.1038/bjc.2011.31 [PubMed: 21364589]
55. Rothstein DM, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade
and promotes long term engraftment and tolerance in stringent transplant models. J Immunol.
2001; 166:322–329. [PubMed: 11123308]
56. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative
PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001; 25:402–408.10.1006/meth.2001.1262
[PubMed: 11846609]
57. Schmid A, Braumuller H, Wehrl HF, Rocken M, Pichler BJ. Non-invasive monitoring of pancreatic
tumor progression in the RIP1-Tag2 mouse by magnetic resonance imaging. Molecular imaging
and biology : MIB : the official publication of the Academy of Molecular Imaging. 2013; 15:186–
193.10.1007/s11307-012-0548-0 [PubMed: 22752651]
58. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837–845.
[PubMed: 3203132]

Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 80

Author Manuscript
Author Manuscript
Author Manuscript
Figure 1. GPC1 is present specifically on cancer exosomes

Author Manuscript

a, Venn diagram of exosomal proteins from NIH/3T3 (blue), MCF 10A (red), HDF (green),
E10 (yellow) and MDA-MB-231 (purple) cells. 48 proteins were exclusively detected in
exosomes from MDA-MB-231 cells (n=3 protein samples, technical replicates). b,
Transmission electron micrographs (TEM; left image) and immunogold TEM (right image)
of GPC1. Upper right: digitally zoomed inset (n=2 experiments). c, Diagram of flow
cytometry experiment to detect GPC1 on the surface of exosomes bound to beads. d, TEM
of bead-bound exosomes and immunogold labeling of GPC1 (n=2 biological replicates). e,
Percent beads with GPC1+ exosomes from cancer cells (red) and non-tumorigenic cells

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 81

Author Manuscript

(black). f, Flow cytometry analyses of percent beads with GPC1+ exosomes from indicated
cell lines (n=2 biological replicates). Negative control: secondary antibody only.

Author Manuscript
Author Manuscript
Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 82

Author Manuscript
Author Manuscript
Author Manuscript
Figure 2. GPC1+ crExosomes are derived from cancer cells in tumor-bearing mice

Author Manuscript

a, Longitudinal blood collection: nude mice with orthotopic MDA-MB-231 tumors (n=4
mice). b, Percentage of beads with GPC1+ exosomes harvested from systemic circulation
(crExos) plotted against average tumor volume (n=4 mice, each sample analyzed in technical
triplicates for GPC1). ANOVA, post-hoc Tamhane T2, ** P<0.01, *** P<0.001. Data is
shown as mean ± standard deviation. c, Correlation between tumor volume and percent
beads with GPC1+ crExos (Pearson correlation test). d, NanoSight® analyses of exosomes
from cultured MDA-MB-231 CD63-GFP cells. Black: all exosomes; green: CD63-GFP+
exosomes (n=3 technical replicates). e, NanoSight® analyses of crExos from mice with
MDA-MB-231 CD63-GFP orthotopic tumor. Black: all exosomes; green: CD63-GFP+
exosomes (n=3 technical replicates). f, Flow cytometry analyses of beads with exosomes
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 83

Author Manuscript

from cultured MDA-MB-231 (upper left) and MDA-MB-231 CD63-GFP (upper middle)
cells, and from crExos of mice with MDA-MB-231 CD63-GFP orthotopic tumors (lower
left). Staining of CD63-GFP+ (cancer cell derived) and CD63-GFP− (host derived) crExos
for GPC1 (APC+, lower right; n=3 biological replicates and 3 technical replicates). Percent
positive beads are listed. Negative control: secondary antibody alone (right upper panel).

Author Manuscript
Author Manuscript
Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 84

Author Manuscript
Author Manuscript
Author Manuscript
Figure 3. GPC1+ crExos is a non-invasive biomarker for pancreas cancer

Author Manuscript

a, Percent beads with GPC1+ crExos in healthy donors (n=100), breast cancer patients
(n=32) and patients with PDAC (n=190; ANOVA, post-hoc Tamhane T2, **** P<0.0001). b,
Frequency of KRAS mutation in 47 tumor specimens and representative DNA sequencing
chromatograms. c, TEM of GPC1 immunogold of crExos from three PDAC patients
following flow cytometry isolation of GPC1+ (left column) and GPC1− (right column)
crExos (n=3, 3 technical replicates). d, Ct value for KRAS G12D/G12V, KRAS WT mRNA
and 18S rRNA expression in GPC1+ (red and blue) and GPC1− (black) crExos (after flow
cytometry isolation; n=2, 2 biological replicates and 3 technical replicates each) e, Percent
beads with GPC1+ crExos, discovery cohort (healthy donors, n=100; patients with a benign
pancreatic disease (BPD), n=26; pancreatic cancer precursor lesion (PCPL), n=5; and PDAC

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 85

Author Manuscript

patients, n=190; ANOVA, post-hoc Tamhane T2, ** P<0.01, **** P<0.0001; 3 technical
replicates. f, ROC curve of discovery cohort. g, Percent beads with GPC1+ crExos,
validation cohort (healthy donors, n=20; BPD, n=6; PDAC, n=56; ANOVA, post-hoc TukeyKramer test, **** P<0.0001; 3 technical replicates). h, ROC curve of validation cohort. Data
is shown as mean ± standard deviation.

Author Manuscript
Author Manuscript
Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 86

Author Manuscript
Author Manuscript
Author Manuscript

Figure 4. Levels of circulating GPC1+ exosomes inform pancreas cancer resection outcome

Author Manuscript

a, Longitudinal blood collection pre- (pre-op) and post-operatively (day 7). b, Percent beads
with GPC1+ crExos from patients with BPD (n=4), PCPL (n=4) or PDAC (n=29) (paired
two-tailed Student’s t-test, ** P<0.01, **** P<0.0001). Data is shown as mean ± standard
deviation. c–d, Kaplan–Meier curves (log-rank test) displaying overall (c) and diseasespecific survival (d) of patients with GPC1+ crExos drop ≥ median (blue) and GPC1+ crExos
drop < median (green) drop after resection. e–f, Kaplan–Meier curves (log-rank test)
displaying overall (e) and disease-specific survival (f) of patients with a CA 19-9 drop ≥
median (blue) and a CA 19-9 drop < median (green) drop after resection.

Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 87

Author Manuscript
Author Manuscript
Author Manuscript
Figure 5. GPC1+ circulating exosomes predict pancreas cancer in GEMM

Author Manuscript

a, Longitudinal blood collection from control and PKT mice: 4 (n=6 and n=7, respectively),
5 (n=6 and n=7), 6 (n=6 and n=6), 7 (n=6 and n=6) and 8 (n=2 and n=3) weeks of age. b,
Percent beads with GPC1+ crExos from PKT (red) and control (blue) mice; ANOVA, posthoc Tukey-Kramer test, **** P<0.0001; 3 technical replicates. c, MRI with tumor encircled
in red. d, Tumor volume and percent GPC1+ crExos in PKT mice at indicated age (ANOVA,
post-hoc Tamhane T2), *P<0.05, ** P<0.01, *** P<0.001**** P<0.0001; 3 technical
replicates) e, ROC curve analysis of 4 weeks-old control mice (n=6) and mice with acute
pancreatitis (n=4) vs. 4 weeks-old PKT mice (n=7). f, Cross sectional study: blood collected
from 16 or 20 days old control (n=6) and PKT (n=7) mice. g, Percent beads with GPC1+
crExos from control and PKT (16 – 20 days-old) mice (paired two-tailed Student’s t-test,
P<0.0001; 3 technical replicates). h–i, Correlation between histological score (h) or age (i)
and percent beads with GPC1+ crExos (Pearson correlation test). j, Relative percent PanIN
Nature. Author manuscript; available in PMC 2016 July 09.

Melo et al.

Page 88

Author Manuscript

lesions and representative staining for phosphorylated ERK. Data is shown as mean ±
standard deviation.

Author Manuscript
Author Manuscript
Author Manuscript
Nature. Author manuscript; available in PMC 2016 July 09.

